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ABSTRACT 
 
BCL6 is a zinc finger transcriptional repressor, which is highly expressed in 
germinal centre B-cells, and is essential for germinal centre formation and T-dependent 
antibody responses. Deregulated BCL6 expression is associated with certain non-
Hodgkin’s lymphomas. High expression is observed in breast cancer. Tight lineage and 
temporal regulation of BCL6 is, therefore, required for normal immunity and abnormal 
regulation occurs in cancer. Regulatory mechanisms have been analysed in two 
settings. Firstly, BCL6 is strongly induced by the tyrosine kinase inhibitor, Imatinib, in 
chronic myeloid leukaemia lymphoid blast crisis cell lines, and this effect was used in 
order to study the effects of phospho-protein signalling on BCL6 expression and a major 
finding is that p38 MAPK induced BCL6. Also, p38 is, at least in part, responsible for 
BCL6 expression in basal conditions in the germinal centre representative Burkitt’s 
lymphoma cell lines and that qualitatively different CD40 stimuli can either induce or 
repress BCL6 expression. Luciferase assays showed that p38 acts at a 300bp sequence 
immediately 5’ of exon 1, and probably also at more distal sequences. Overall it appears 
that the balance between positive and negative regulatory controls BCL6 expression 
with inhibitory signalling pathways being predominant in most circumstances. Focusing 
on BCL6 exon 1, a binding site for the multifunctional regulator CTCF was identified. 
CTCF interacts in vitro and in vivo with this sequence. Reduced expression of CTCF in 
germinal centre cells caused a moderate reduction of BCL6 expression. Finally, 
although no clear differences were observed in the methylation status of the CTCF 
binding site on exon 1, a significant enrichment of active histone modifications at this 
site was observed in BCL6 expressing cells, suggesting that CTCF may have a role in 
the epigenetic regulation of BCL6. 
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CHAPTER 1. General introduction 
 
1.1. Outline  
  
Non-Hodgkin's-Lymphomas (NHL) comprise a heterogeneous group of 
neoplasms that are derived from lymphocytes. Recent surveys and studies performed in 
Europe have reported that despite the improvements in the diagnosis and in the 
approaches to treatment, NHL are still an important cause of morbidity and mortality in 
the European Union with an increase in the mortality rate during the last two decades to 
4.4/100000 in men and 2.8/100000 in women (Bosetti et al., 2008).  
There is considerable interest in understanding the mechanisms involved in the 
process of lymphomagenesis. Non-random chromosomal translocations are frequently 
detected in lymphomas. They commonly place a proto-oncogene under the control of an 
immunoglobulin gene enhancer to produce high level and constitutive expression. Many 
important proto-oncogenes have been discovered through the analysis of translocations 
in lymphomas. For example, c-MYC translocations are characteristic of Burkitt's 
lymphomas and, cyclin D1 translocations of mantle cell lymphomas. The long arm of 
chromosome 3 band 27 is one of the most frequent targets of genetic alterations in 
lymphomas. In 1993, a potent transcriptional repressor named first BCL5 or LAZ3 and 
subsequently BCL6 was identified in the 3q27 region (Ye et al., 1993). BCL6 has been 
shown to play key roles in the development and regulation of the immune system and in 
lymphomagenesis. However, many aspects of the biology of this oncogene still remain 
unclear, especially the regulation of the gene in normal B-cells and in lymphomas 
derived from germinal centre B-cells.  
This thesis is concerned with the regulation of the BCL6 and in this introductory 
chapter, essential background information on several biological processes relevant for 
……………………………………………………………………………………………  . 
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the work presented in this thesis will be provided. Firstly, a brief overview of germinal 
centres will be presented. These are dynamic structures essential for acquired immunity. 
Next, the characteristics and functions of the BCL6 in normal conditions will be 
described, followed by its role in lymphomagenesis. Finally, the main biological functions 
of the p38 MAPK pathway and of the important regulator CTCF will be summarized, 
since this information will be useful for a better understanding of the latter chapters.  
 
1.2. Immune response and germinal centres  
 
The immune system is responsible for defending the organism from pathogenic 
agents. The immune system can be separated in three categories: the physical barriers, 
innate immunity and the adaptive response. The innate system (Delves and Roitt, 
2000a) functions to increase the protection imparted by physical barriers, by detecting 
pathogens and initiating an inflammatory response. Among the principal components of 
the innate sytem are soluble proteins such as complement proteins or cytokines, cellular 
components including leukocytes, and a group of membrane bound receptors and 
cytoplasmatic proteins, known as Pattern Recognition Receptors, which either recognize 
specific elements usually conserved and shared by many different microorganisms or, 
detect cells that have been subject of stresses or damages. Once stimulated, the innate 
immune system initiates a non-specific immflamatory response against the intruder, and 
will interact and stimulate the adaptive response (Chaplin, 2010; Turvey and Broide, 
2010).  
The unique features of the adaptive immune response are specificity and 
memory. (Bonilla and Oettgen, 2010; Delves and Roitt, 2000b). The adaptive immune 
system consists of T and B lymphocytes. The former are “cellular immune effectors” 
whereas the B lymphocytes are “antibody producing cells”. The adaptive response is 
based on the specific interaction between an antigen and a receptor expressed on T and 
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B lymphocytes. In contrast with the germline recognition molecules of the innate system, 
the B and T cell receptors generation requires a complex and sophisticated process that 
involves the rearrangement of several gene elements that encode for the different 
components of the T-cell receptor and the B cell receptor (BCR; Immonoglobulin), as 
well as the introduction of random mutations in the region responsible for the recognition 
of the antigen (the variable region)(Chaplin, 2010). 
The innate and adaptive immune systems work together, the innate system 
being responsible for the first line of defense providing a rapid but not long lasting, nor 
specific response, whereas the adaptive immune response will contribute after several 
days of clonal expansion with a very specific response, and will produce long-lived 
memory cells which will be able to recognize the pathogen and will generate a very 
specific, rapid and strong response in case of an eventual reexposition to the same 
pathogen (Chaplin, 2010; Delves and Roitt, 2000a) 
 
1.3. B-cell development 
 
The characteristic molecular feature of a mature B-cell is the presence of surface 
immunoglobulin, and the development of B-cells (Figure 1.1) bearing immunoglobulin 
with a large range of specificities is required for normal immunity. B-cells are produced 
from bone marrow haematopoietic stem cells, which have undergone several well 
characterized stages resulting in immunoglobulin gene rearrangement in order to 
generate a surface B cell receptor (Bonilla and Oettgen, 2010). Early B-cells lack 
surface or cytoplasmic immunoglobulin (Figure 1.1). Antibody (or immunoglobulin) 
genes are encoded in DNA by separate gene segments which are joined by a process 
requiring recombination activating genes (RAG1/2) to produce either a heavy (H) chain 
or light (L) chain (Figure 1.1). 
 
……………………………………………………………………………………………  . 
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Figure 1.1. Stages of B cell differentiation. (a) The development of B-lineage cells can be 
defined by the differential expression of cell-surface markers and by the rearrangement status of 
immunoglobulin genes. B cell development can be divided into two phases: the antigen 
independent and antigen dependent phases. The former takes place in the bone marrow from 
neonatal through adult life. Mature cells, which expresses IgM and IgD on its surface move into 
the periphery where they can be activated by an antigen (antigen dependent phase). (b) An
antibody is a multi-chain peptide formed with two identical heavy chains and two identical light
chains. Each chain consists of a variable region (V), responsible for the antibody specificity for a 
certain antigen, and a constant region (C). The antibodies are the result of a combination of
different V,J and C genes. This combination is essential for the diversification of the antibodies.
(This figure is based on Cambier et al, 2007; Delves et al,2000; Baron, Medical Microbiology 
1996)
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A complete antibody molecule requires 2 H chains and 2 L chains. B-cells within 
the bone marrow express a diverse primary repertoire of antibodies but they have low 
affinity for antigen and only express the µ H-chain isotype. B-cells exit the bone marrow 
and travel to lymph nodes. On encounter with a T-cell dependent antigen the B-cell 
moves to a follicle where it proliferates intensely to form a germinal centre (McHeyzer-
Williams et al., 2001). The germinal centres are therefore dynamic structures within the 
lymph nodes, and consist of two histologically well differentiated zones with distinct 
functions (Figure 1.2). The dark zone contains centroblasts, and the light zone 
centrocytes, T-cells and follicular dendritic cells. It is believed (Vinuesa et al., 2009) that 
B-cells proliferate in the dark zone and undergo a process called somatic hypermutation 
(SHM). SHM requires the enzyme activation induced deaminase, which is responsible 
for introducing mutations into the immunoglobulin genes in order to produce high affinity 
antibodies, as well as accomplishing class switch from IgM to IgG or IgA in order to 
change the effector function. The B-cells then move to the light zone and are selected 
for the production of high affinity antibodies. Those B-cells that fail selection die by 
apoptosis whereas those producing high affinity antibodies either return to the dark zone 
for a further round of SHM, or exit the germinal centre. They leave the germinal centre 
either as an antibody producing cell (plasma cell) or as a memory B-cell. 
Germinal centres, therefore, contain highly proliferating B-cells that are 
undergoing mutations and for these reasons are predisposed to the formation of 
malignancies. Indeed, a significant number of B cell lymphomas emerge from these 
areas (Kuppers et al., 1999) and, the pathogenesis of many autoimmune responses has 
been lately related to abnormal germinal centre responses (Vinuesa et al., 2009).  
Studies using mice bearing homozygous gene disruptions have demonstrated 
that several B-cell molecules e.g BCL6 (Fukuda et al., 1997) or CD19 (Barrington et al., 
2009; Fehr et al., 1998), as well as T-cell e.g. CD40 ligand (Foy et al., 1994) and 
dendritic cell e.g. lymphotoxin alpha (Matsumoto et al., 1996), are required for germinal 
centre development.  
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Figure 1.2. Germinal centre reaction. This figure illustrates biological processes of the germinal 
centres (GC). Naïve B cells, when activated by an antigen, are recruited  into the follicles within 
the lymph nodes were they start proliferating to form the germinal centre region. Two areas can 
be differentiated within the GC: the dark and the light zones. The dark zone is formed with 
hyperproliferative activated B cells, that are going through the somatic hypermutation process in 
the immunoglobulin variable genes. These cells are known as centroblasts.  The light zone, 
consists of a number of follicular dendritic cells that have the immunizing antigen on their surface. 
The B cells within this area, which are known as centrocytes, stop proliferating and are positively 
selected based on their ability to interact with the antigen presented by the Follicular Dendritic
Cells (FDC). Once selected, these cells can differentiate either into plasmatic cells or memory 
cells. Those cells not capable of interacting or that recognize self antigens undergo apoptosis. 
(This figure is based on Vinuesa et al, 2009 and Delves et al 2000)
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1.4. BCL6 is a master transcription factor in germinal centre development and the 
immune response 
 
1.4.1. Discovery of BCL6 
The observation that the 3q27 region was frequently disrupted by translocations 
in a number of patients with non-Hodgkin lymphomas, and that in isolated cases that 
abnormality was the only cytogenetic finding on the karyotypes, strongly suggested the 
possibility of a cancer gene being located in that region. Indeed, subsequent subcloning 
and sequence analysis of that region lead to the identification of the LAZ3 (now known 
as BCL6) in that region in 1993 (Kerckaert et al., 1993).  
 
1.4.2. BCL6 expression  
BCL6 protein is expressed at high levels in normal lymphoid germinal centre 
centroblast B cells, in almost all centrocytes cells (Cattoretti et al., 1995), in follicular 
helper T cells (Tfh) (Bi and Ye, 2010; Mondal et al., 2010) and, although there is less 
evidence, it seems also be expressed in other T-cells subtypes (Cattoretti et al., 1995) 
and in macrophages (Mondal et al., 2010). BCL6 protein is also detected in almost all 
lymphomas with a germinal centre origin (Cattoretti et al., 2005; Onizuka et al., 1995) 
such as a subgroup of diffuse large cell lymphoma, Burkitt’s lymphoma, follicular 
lymphoma and lymphocyte predominant Hodgkin’s lymphoma (Reljic et al., 2000). BCL6 
is tightly expressed, and although BCL6 m-RNA is detectable in naïve B cells (Allman et 
al., 1996), BCL6 protein is not found in naive B-cells or post germinal centre B cells 
including immunoblasts and normal plasma cells (Cattoretti et al., 1995).  
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1.4.3. Characteristics of BCL6 protein  
BCL6 is a 706 amino acid, 95 kDa phospho-protein (Figure 1.3) member of the 
POZ/POK family of transcription factors, which play important roles in normal 
development and in cancer (Costoya, 2007; Kawamata et al., 1994).  
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Figure 1.3. Scheme of BCL6 protein domains and protein interacting partners The human 
BCL6 protein, which belongs to the “POK family proteins”, consists of (a) a POZ (BTB) domain 
(amino acids 1 to 130) at the N-terminal region, which is essential for protein-protein interactions, 
including several corepressors such as SMRT, NcoR and BcoR (b) a central portion domain with 
a subdomain spanning from amino acids 370-380 that has been shown to be also important for 
the repression activity. The central portion has several PEST sequences, that when 
phosphorylated by the MAPK pathway triggers the BCL6 protein for degradation via the ubiquitin-
proteasome pathway. BCL6 KKYK motif (aminoacids 376-379), which is necessary for the 
acetylation by p300, is located within the PEST sequences region. (c) a C-terminus domain that 
has six zinc fingers, required for the interaction with the DNA (consensus sequence: 
TTCCTT(A/C)GAA). The BCL6 partners that interact with known BCL6 domains are shown with 
the same coloured code (Figure based on Albagli-Curiel, 2003)
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These transcription factors characteristically have a number of zinc fingers, six in BCL6, 
at the C-terminal end that recognize specific regulatory DNA sequences. At the N-
terminal end they have a POZ(BTB) domain that is required for protein/protein 
interaction (Figure 1.3). This later domain interacts with a number of co-repressors such 
as the nuclear receptor corepressor (NCoR), BCL6 corepressor (BcoR) or the silencing 
mediator of the retinoid and thyroid hormone receptors (SMRT), to recruit histone 
deacetylase and accomplish transcriptional repression (Melnick et al., 2002; Mendez et 
al., 2008; Zhang et al., 2001). BCL6 repression of genes involved in cell proliferation and 
survival, such as ATR, p53 and cyclin-dependent kinase inhibitor 1A (CDKN1A), 
depends on the BCL6 interaction with NCor, SMRT or BCoR (Mendez et al., 2008; 
Parekh et al., 2008). The POZ(BTB) domain also mediates homo-dimerization, and 
associates with other proteins such as PLZF or LRF (Ahmad et al., 2003; Albagli-Curiel, 
2003).  
BCL6 contains a central region that interacts with histone deacetylase (HDAC) 
and the co-repressor MTA3 in an acetylation-sensitive manner (Mendez et al., 2008; 
Zhang et al., 2001). In fact, BCL6-MTA3 interaction is required for inhibition of plasma 
cell differentiation (Mendez et al., 2008). The mid portion of BCL6 also has several 
PEST sequences that mediate BCL6 degradation (see section 1.4.5) (Niu et al., 1998) 
 
1.4.4. Mechanism of action of BCL6 
BCL6 knockout mice have normal early B-lymphoid development but lack 
germinal centres and do not have T-cell dependent antibody responses (Cao et al., 
1997). Experiments designed to investigate the specific function of BCL6 in B-cell 
terminal differentiation showed that BCL6 is required to differentiate follicular B cells into 
germinal centre B cells and to maintain these cells in this state (Baron et al., 2002; Cao 
et al., 1997; Reljic et al., 2000) . 
Previous work (Avantaggiati et al., 1997; Hancock et al., 2005; Harris et al., 
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1999; Reljic et al., 2000) suggested that BCL6 binds to STAT (signal transducers and 
activators of transcription) binding sites and modulates transcription driven by the STAT 
family of factors, particularly interleukins. An overview of the function of BCL6 is that it 
modulates the effects of interleukins in order to allow proliferation and prevent 
differentiation (Avantaggiati et al., 1997; Fearon et al., 2001; Reljic et al., 2000), 
although the full picture is likely to be more complicated.  
Gene expression profiling arrays (Shaffer et al., 2000), genome wide chromatin 
immunoprecipitation studies together with integrated biochemical and computational 
approaches (Basso et al., 2010) have led to the identification of a broad spectrum of 
BCL6 target genes responsible for the control of a number of pathways involved in the 
normal germinal centre reaction (Figure 1.4).  
BCL6 
Figure 1.4. Scheme of several pathways regulated by BCL6. BCL6 modulates several genes 
with a variety of functions. In this figure the more representative pathways regulated by BCL6 
gene are depicted. Repression of BCL6 by BCR and CD40 signaling pathway and by the DNA 
damage response is also illustrated. (Figure based on Basso et al, 2010)
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           These BCL6 target genes were found to be involved in cell cycle arrest, such as 
the CDKN1A7p21, in apoptosis like BCL2 and also in differentiation such as the TGF β 
receptor signalling or the WNT signalling. BCL6 also inhibitis the Positive Regulatory 
Domain 1 (PRDM1) gene, also called BLIMP1. This is a zinc finger protein that is 
essential for the terminal differentiation of B-cells to plasma cells (Crotty et al., 2010; 
Tunyaplin et al., 2004) (Tunyaplin et al., 2004). Also, BCL6 is capable of suppressing 
signalling pathways known to downregulate its own expression such as the CD40 or the 
BCR pathway. Finally, BCL6 directly represses genes required for detecting and 
responding to DNA damage like p53 (Phan and Dalla-Favera, 2004) or ATR (ataxia-
telangiectasia and Rad3 related) (Ranuncolo et al., 2007), allowing therefore the SHM 
process, required for the high affinity maturation of the antibody. Clearly, BCL6 
suppresses important cellular pathways necessary for B cell activation, differentiation 
and survival in order to protect germinal centre cells from apoptosis and from signals 
causing a premature exit from the germinal centre before they have completed the 
antibody high affinity maturation process (Basso et al., 2010).  
It has also been suggested that BCL6 might be required to maintain memory B 
cells in a self- renewing state (Fearon et al., 2001), although the opposite has also been 
reported (Crotty et al., 2010). Therefore, BCL6 and BLIMP-1 appear to form a system to 
regulate B-cell terminal differentiation (Crotty et al., 2010). BCL6 is associated with 
proliferation and BLIMP1 with differentiation.  
Mice lacking BCL6 develop a characteristic T systemic inflammatory response 
suggesting that BCL6 might have a role on T cell regulation (Cao et al., 1997). Indeed, 
recent studies have shown that BCL6 is both necessary and sufficient to induce CD4+ 
cells differentiation towards Tfh cells, which are essential for the germinal centre 
reaction (Bi and Ye, 2010). In contrast, BCL6 appears to inhibit the differentiation of T 
cells into the other CD4+ T cells subtypes (TH2, TH1 and TH17), which are not directly 
involved in the germinal centre formation (Crotty et al., 2010). Also, limited evidence 
suggests that BCL6 favours the formation of both long term memory CD4+ (Ichii et al., 
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2007) and central CD8+ memory T cells (D'Cruz et al., 2009; Yoshida et al., 2006). 
Preliminary studies indicated that apart from the germinal centre B and T cells, 
other several tissues, namely skeletal muscle, testicular germ cells and skin epithelium 
express BCL6 (Bajalica-Lagercrantz et al., 1998). Although the significance of BCL6 
expression in cells other than germinal centre B cells is yet not completely clear, it has 
been proposed that BCL6 might also be important in the terminal differentiation stage in 
many of these tissues (Bajalica-Lagercrantz et al., 1998). For instance BCL6 was 
apparently important for the maintenance of a terminally differentiated phenotype in 
myoblasts, spermatids and keratinocytes. BCL6 seems also to have a protective role 
from apoptosis due to specific stresses in myoblasts and spermatocytes (Kojima et al., 
2001; Kumagai et al., 1999; Yoshida et al., 1996). BCL6 expression was detected in the 
mammary epithelium, where it has been shown to act as an anti-apoptotic factor and 
aberrant over-expression was detected in 68% of patients with histologically high-grade 
ductal breast carcinomas (Logarajah et al., 2003).  
Therefore, the role of BCL6 in proliferation and apoptosis remains controversial. 
BCL6 has been shown to favour proliferation and block apoptosis in some cell types, 
whereas it seems to induce apoptosis in others (Baron et al., 2002; Hancock et al., 
2005; Yamochi et al., 1999). A possible explanation would be that BCL6 can either 
induce or repress apoptosis depending on the cell type (Albagli-Curiel, 2003; Fukuda et 
al., 1997; Zhang et al., 2001).  
 
1.4.5. Transcriptional and post-transcriptional regulation of BCL6 
Despite the importance of BCL6 expression for the germinal centre formation, 
little is known about BCL6 transcriptional regulation.  The BCL6 gene is composed of 10 
exons spread over 26 kb of genomic DNA (Figure 1.5). Two different mRNA splicing 
variants have been reported depending on content or not of the exon 2. The translation 
start site has been identified in exon 3 (Kawamata et al., 1994).  
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Previous studies have reported that the BCL6 promoter spans a 1.5 kb region 
(Fukuda et al., 1995) and contains different putative response elements, a TATA binding 
protein site and also BCL6 binding sites (Fukuda et al., 1995). However, the BCL6 
regulatory region has been incompletely characterized. The first intron-exon boundary 
contains BCL6 regulatory elements which have been demonstrated to play important 
roles in the transcriptional regulation of BCL6. One of these regions, named the ES 
region, located within exon 1, contains two consensus nucleotides sequence (BSA1A 
and BSA1B) for BCL6 and it has been confirmed that BCL6 binds to these regions 
repressing its own transcription (Kikuchi et al., 2000). The effect of occupancy of BCL6 
binding sites within exon 1 by BCL6, therefore, defines a negative autoregulatory circuit. 
These BCL6 binding sites are mutated in some cases of diffuse large cell lymphoma and 
the mutations disrupt the negative autoregulatory circuit thereby allowing prolonged 
BCL6 expression, which is likely to promote lymphomagenesis (Gaidano et al., 2003). 
Clearly there must be additional control mechanisms that allow sustained BCL6 
expression. 
3´UTR
109876543211
5´ 3´
Figure 1.5. BCL6 gene. This figure shows the genomic organization of the BCL6 gene. Protein 
coding exons are represented in green, whilst the non coding ones appear in blue. Two different 
mRNA isoforms, with different transcription start site, which encode for identical BCL6 protein, 
and a third variant with absence of exon 7 have been reported. The functional meaning of this 
third variant is still unknown. The major Translocation Cluster (MTC) is indicated. The Major 
Mutations Cluster, according to Migliazza et al 1995 is also illustrated. (This figure was based on 
NCBI Entrez Gene; Shen et al, 2008; Bernardin et al; 1997)
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BLIMP-1, an essential regulator of plasma cell differentiation, directly represses 
BCL6 transcription, allowing differentiation into plasmatic cells (Cimmino et al., 2008). 
BCL6 transcription is also repressed by the CD40/NF-kB/IRF4 pathway. This regulatory 
mechanism is disrupted due to chromosomal translocations and point mutations in a 
subset of Diffuse Large B cell Lymphomas (Saito et al., 2007). Additionally, our 
laboratory has recently identified a DNase I hypersensitive site located 4.4Kb upstream 
the transcriptional initiation site of the BCL6 gene, that binds a repressive complex 
formed with the ZEB1 (zinc finger E-box-binding homeobox 1) and the corepressor CtBP 
(C-terminal binding protein). As ZEB1 protein expression is relatively low in germinal 
centres cells, it is likely that ZEB1 expression is necessary for repressing BCL6 
expression in naive B-cells (Papadopoulou et al., 2010). 
Growth factors activate the STAT family of latent transcription factors. BCL6 
transcription is driven by STAT5 in tonsillar B-cells (Scheeren et al., 2005). STAT3 has 
also been shown to drive BCL6 in germinal centre cells (Arguni et al., 2006). 
A variety of post-translational modifications of BCL6 have been described. In the 
B-cell line, Ramos, activation of the B-cell receptor induces mitogen-activated protein 
(MAP) kinase mediated phosphorylation of the BCL6 PEST sequences, which in turn, 
targets BCL6 for rapid degradation by the ubiquitin-proteasome pathway (Niu et al., 
1998). Additionally, BCL6 is inhibited through p300-mediated acetylation (Bereshchenko 
et al., 2002). Finally, it has been recently reported that BCL6 can be post-
transcriptionally inhibited by the microRNA miR-127 (Saito et al., 2006). 
 
1.4.6. BCL6 deregulation and lymphomas 
BCL6 is a frequent target of chromosomal translocations with many different 
partners, the immunoglobulin (Ig) heavy chain locus being the most common. These 
translocations often cluster in a 4 kb region on the BCL6 gene known as the major 
breakpoint region (MBR) or major translocation cluster (MTC) (Figure 1.5), spanning the 
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promoter, the first non-coding exon and the 5’ part of the first intron (Albagli-Curiel, 
2003). As a result of these rearrangements transcription of the unaltered BCL6 coding 
region is controlled by the regulatory sequences of the partner gene (promoter 
substitution), leading to deregulated BCL6 expression (Akasaka et al., 2000). Despite 
repeated efforts it has not been possible to determine whether the partner involved in 
BCL6 translocations determine the clinical outcome (Ohno, 2006). However, it has been 
suggested that those lymphomas with non-IgH/BCL6 translocationas have a worse 
outcome than those with IgH/BCL6 translocations (Ohno, 2006).  
The BCL6 locus, in common with the immunoglobulin and with some other non-
immunoglobulin loci, is targeted by activation induced deaminase (AID), which is 
required for the somatic hypermutation (SHM) process. It has been proposed that the 
SHM machinery is involved in the generation of both non-IgG and IgG/BCL6 
translocations (Ohno, 2006). Also, as a result of the AID action, the BCL6 locus acquires 
point mutations (Capello et al., 2000; Chen et al., 1998; Jardin and Sahota, 2005; Mateo 
et al., 2001; Migliazza et al., 1995; Pasqualucci et al., 1998; Szereday et al., 2000; Vitolo 
et al., 2002). Mutations spanning the first non-coding exon and clustering in the 5´ 
region of the first intron have been found in about 10% of diffuse large B-cell 
lymphomas. Analysis of the region surrounding exon 1 showed a negative 
autoregulatory circuit: BCL6 bound to a high affinity site in exon 1 that caused its own 
transcription to be switched off (Pasqualucci et al., 2003; Wang et al., 2002). BCL6 gene 
mutations affecting the BCL6 binding site in exon1 have been found frequently among 
diffuse large cell lymphoma (DLBCL)-derived alleles but not in normal germinal centre 
B-cells (Pasqualucci et al., 2003). Thus, the finding of mutations within the BCL6 binding 
sites within exon 1 (BSE 1) mutations (see above) specifically restricted to DLBCL 
suggests selection of these mutations in lymphomas probably due to disruption of the 
negative autoregulatory circuit (Capello et al., 2000; Gaidano et al., 2003; Szereday et 
al., 2000; Wagner and Kaeda, 2005).  
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BCL6 expression is a prognostic marker in DLBCL. DLBCL can be classified 
attending to the cell origen in two subtypes:  the Germinal Centre B (GCB) like type, and 
the Activated B Cell like (ABC) type. The former one shows a germinal centre gene 
expression pattern showing therefore high levels of BCL6 expression, and has been 
shown to have long survival compared to the ABC ones. Moreover, patients with DLBCL 
expressing high levels of BCL6 mRNA and protein, have a favourable outcome when 
compared with those that do not express it (Lossos et al., 2004; Lossos et al., 2001; 
Ohno, 2006; Rosenwald et al., 2002), and this difference is maintained with modern 
treatments that include the anti-CD20 monoclonal antibody, Rituximab (Lenz et al., 
2008). Although the molecular mechanisms underlying the causes of the different 
behaviour of these two subtypes of lymphomas are not completely understood yet, it has 
been recently proposed that different modulation of signalling pathways and their target 
genes might exlain these differences (Sarosiek et al., 2009). 
 
This thesis analyses the regulation of BCL6. Our work led me to focus on two 
mechanisms: p38 mitogen activated protein kinase (MAPK) signalling and the DNA 
binding factor CTCF. These are very different but both centre their effects on exon 1 of 
BCL6. In the following sections scientific background of BCR-ABL, p38 MAPK and 
CTCF will be outlined. 
 
1.5. BCR-ABL involvement in BCL6 regulation 
 
The BCR-ABL oncogene is the result of a balanced translocation between 
chromosomes 9 and 22 t(9;22), that gives rise to the Philadelphia chromosome (Ph). 
Attending to the breakpoint on the BCR gene on chromosome 22, three different 
isoforms of the BCR-ABL have been identified, which encode a p190, p210 or p230 
fusion proteins. Almost all patients with chronic myeloid leukemia and around 20% of 
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patients with Ph+ acute lymphoblastic leukemia have the p210 isoform, whereas the 
p190 is detected in the rest of Ph+ ALL and may also be detected, at a low levels, in 
patients with CML (Hazlehurst et all; 2009). 
The BCR-ABL oncoprotein plays key roles in the pathogenesis of the CML, and 
most of its effects are performed through the stimulation of pre-existing signalling 
pathways such as the RAS/RAF/MEK, JAK/STAT and PI3K/AKT signaling pathways 
(Steelman et al., 2004) (Figure 1.6). Hyperactivation of these pathways by BCR-ABL, 
leads to an hyperproliferative state. 
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Figure 1.6. BCR-ABL signaling pathways. This figure shows a simplified diagram of the 
principle signaling pathways downstream BCR-ABL, including the PI3K/AKT(grey), 
JAK/STAT(pink) or the Ras/MEK/MAPK (deep red) pathways. (This figure was based on 
Steelman et al, 2004 and Deininger et al, 2000)
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           The BCR-ABL oncoprotein activity can be successfully inhibited by the signal 
transduction inhibitor Imatinib mesylate (STI571), by directly binding to the site of 
tyrosine kinase activity, and preventing its activity (O'Brien and Deininger, 2003). 
Expression profiling studies of genes transcriptionally regulated by BCR-ABL 
using differential display to compare the mRNA profile of the lymphoblastic CML cell line 
BV173 treated with Imatinib with that of untreated control cells (Deininger et al., 2000b), 
showed for the first time that BCL6 mRNA and protein were upregulated upon inhibition 
of BCR-ABL tyrosine kinase in these cells. In agreement with these results, Mattos et al 
(Fernandez de Mattos et al., 2004) have also demonstrated that BCL6 is upregulated in 
BV173 cell line on treatment with imatinib.  
There is one implication of these works for the biology of BCL6: the BV173 cell 
line cultured in the presence and absence of imatinib might be a good model system for 
analysing the regulation of BCL6. 
 
1.6. MAPK involvement in BCL6 regulation 
 
Signalling pathways are required for the co-ordination of a vast number of 
biological processes, including cellular proliferation, differentiation and death. Mitogen 
activated protein kinases (MAPK) constitute a family of complex signal transduction 
pathways that plays key roles in a number of biological systems, including the 
haematopoietic and the immune system (Geest and Coffer, 2009; Huang et al., 2009; 
Wagner and Nebreda, 2009). Deregulation of these pathways have been observed in a 
number of diseases comprising several autoimmune diseases, like rheumatoid arthritis 
(Lin et al., 2009; Mbalaviele et al., 2006), systemic lupus erythematosus (Wong et al., 
2009) and in different kinds of cancers such as breast cancer (Chen et al., 2009), 
pancreatic cancer (Adachi et al., 2010), hepatocellular carcinoma (Hsieh et al., 2007) or 
hematologic malignancies (Feng et al., 2009; Platanias, 2003).   
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1.6.1. MAPK family 
Six different subfamilies of MAPK have been identified: the extracellular signal-
regulated kinases (ERK 1 and 2), c-Jun NH2-terminal kinases (JNK 1, 2 and 3), p38 (p38 
α, β, γ and δ), ERK3, ERK5 and ERK7 (Geest and Coffer, 2009). The JNK and the p38 
pathway constitute the stress-activated pathways, since both are frequently activated by 
cellular stresses such as, ultraviolet irradiation, cytokines, heat shock proteins, or 
osmotic shock protein (Nebreda and Porras, 2000) (Figure 1.7). Parallel co-activation of 
the JNK and p38 pathway induced by the same stimuli has been reported in many 
cases.  
Four different isoforms of p38 have been identified; the p38α, p38β, p38γ and 
p38δ each encoded by different genes; MAPK14, MAPK 11, MAPK 12 and MAPK 13, 
respectively. These p38 isoforms share only 60% identity and are differently expressed 
in the body. p38α is highly and ubiquitously expressed, and most of the p38 functions 
described in the literature refer to this isoform. p38β can also be detected in a number of 
cell types, but usually at low levels, and its specific role is not well understood. In 
contrast, the γ and the δ isoforms are only expressed in certain cell types where they 
perform very specific functions (Ono and Han, 2000; Wagner and Nebreda, 2009).  
 
1.6.2. p38 functions in normal and cancer cells 
Once activated, each MAPK phosphorylates different target proteins, usually in a 
cell type and context dependent manner, including transcription factors, tyrosine kinases 
and even components of the translational machinery, leading to a complex and 
sophisticated signalling network with important functions in different biological processes 
(Figure 1.7).  
Some of the important transcription factor targets of p38 are p53, ETS like gene 
1 (ELK1), the myocyte-specific enhancer factor 2 (MEF2), STAT 1 and 3, and C/EBPβ. 
(Cuenda and Rousseau, 2007; Nebreda and Porras, 2000; Ono and Han, 2000; Wagner 
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and Nebreda, 2009; Xu et al., 2003) Many protein kinases such as the p38-
Regulated/Activated Kinase (PRAK) or certain MAPK-activated protein kinases or MAP 
kinase-interacting serine/threonine kinase 1 and 2 (MNK1 and MNK2) are also activated 
by p38 phosphorylation. In addition p38 has other targets substrates like the heat shock 
proteins (Cuenda and Rousseau, 2007; Nebreda and Porras, 2000; Ono and Han, 2000; 
Wagner and Nebreda, 2009; Xu et al., 2003) (Figures 1.7 and 1.8). 
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Figure 1.7. Stress MAPK signalling pathways. A number of different inflammatory cytokines, 
growth factors and environmental stresses, including genotoxic agents, toxins, ultraviolet 
irradiation among others, are responsible for the activation of the stress-MAPK signalling 
pathway. This figure illustrates the main MAP2K and MAP3K upstream activators of the p38 and 
JNK pathways. Also, some of the principal p38 and JNK targets are depicted. (This figure is 
based on Wagner et al, 2009 and Zhong et al, 2007)
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p38 can either induce or inhibit cell proliferation and these opposing effects are 
likely to be tissue and context specific, and may also depend on both the level of kinase 
activity and interaction with co-stimulatory pathways (Wagner and Nebreda, 2009). 
Thus, p38 antiproliferative effects were demonstrated in a number of different cell types 
such as cardiomyocytes, hepatocytes, lung cells, fibroblasts but, on the other hand a 
p38 mediated proliferative effect has been shown in certain haematopoietic and cancer 
cells (Platanias, 2003; Wagner and Nebreda, 2009). 
Interestingly, p38MAPK was shown to modulate cell cycle checkpoint controls, 
and it is therefore possible that deficient p38 function might lead to a hyperproliferative 
status (Bulavin et al., 2004). In fact, p38 was shown to inhibit cyclin D in different cell 
types (Lavoie et al., 1996). p38 is also capable of inducing apoptosis in a variety of 
models, but it can also be anti-apoptotic. The various p38 effects might, at least in some 
cases, be mediated through different p38 isoforms, since the p38β form seems to 
preferentially inhibit apoptosis whereas the p38α form has been shown to have strong 
pro-apoptotic effects in different model systems (Kaiser et al., 2004; Nemoto et al., 
1998; Silva et al., 2006).  
 
1.6.3. p38 and the immune system 
p38 plays key roles in the immune system (Huang et al., 2009). On the one 
hand, the activation of the germinal centre kinase GCK/p38-JNK pathways seems to be 
crucial for an adequate systemic inflammatory response (SIRS) (Zhong et al., 2009). 
The SIRS is a body response, frequently triggered by infections, characterized by organ 
failure and systemic immflamation, which is due to a massive release of proinflamatory 
cytokines. Pattern recognition receptors (PRR), which play a pivotal role in the innate 
immune response, are responsible for identifying invading pathogens, through their 
expression of molecular motifs called pathogen-associated molecular patterns (PAMPs). 
Stimulation of the PRR receptors initiates the SIRS response, through the activation of 
several signalling cascades.  
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Figure 1.8. p38 MAPKsignaling pathway. p38 MAPKs are implicated in a wide variety of biological 
processes including physiological responses to stress and inflammation, regulation of proliferation and 
differentiation. Studies performed in animal models have revealed that those functions are performed in a 
cell type and cell context dependent manner. A number of different inflammatory cytokines, growth factors 
and environmental stresses, including genotoxic agents, toxins, ultraviolet irradiation among others, are 
responsible for the activation of this pathway. This figure illustrates the principal p38 targets. (This figure is 
based on Wagner et al, 2009 ; Zhong et al, 2007; Cuadrado and Nebreda; 2010; Cell signaling)
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            Germinal Centre Kinase (GCK) is the best characterized member of a group of 
protein kinases, the GCKs, that has been implicated in a wide range of cellular functions 
such as proliferation, apoptosis and inflammation. GCK can be activated by certain 
PAMPs like the LPS, PGN or the bacterila flagellin. Once stiulated, the GCK recruits the 
MLK2 and MLK3, which in turn activates the JNK and p38 signaling pathway (Zhong 
and Kyriakis, 2007) (Figure 1.8), that contribute to the induction of cytokines, which play 
key roles in the systemic inflammatory response (Zhong et al., 2009)  
The JNK and the p38 pathway were implicated in the production of several 
cytokines, such as INF-γ, which is important for Th1 differentiation (Chi et al., 2004) or 
TNFα, IL-1 and IL-6, which are important mediators of the angiogenic and inflammatory 
response (Kumar et al., 2003). p38 regulation of the inflammatory response also 
involves other mechanisms, such as modulation of the NF-κB pathway (Wagner and 
Nebreda, 2009). Recently, p38 was also shown to be required for germinal centre 
formation, as mice bearing homozygous disruptions of the p38 activator MEKK1 have 
defective germinal centre formation and, as a consequence, deficient production of 
antibodies (Gallagher et al., 2007). 
 
 1.6.4. p38 and cancer 
p38 has an uncertain role in cancer pathogenesis; on the one hand it has been 
reported to act as a tumour suppressor, since it is able to induce apoptosis and stop 
proliferation in some models, but it is also involved in important oncogenic processes 
such as angiogenesis. It is becoming clear that the p38 role in cancer is completely 
depends on the tumour type (Wagner and Nebreda, 2009). 
p38 role in angiogenesis and metastasis has been widely studied. p38 seems to 
be necessary for the invasiveness of different cell cancer types, such as the human 
hepatocellular carcinoma (Hsieh et al., 2007), head and neck squamus cell carcinoma 
(Junttila et al., 2007), glioma (Demuth et al., 2007) and lung (Matsuo et al., 2006). Matrix 
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restructuration by cancer cells can be induced by p38 through induction of different 
metalloproteinases (Kumar et al., 2010; Zhou et al., 2007).  
In contrast, p38 tumour suppressor activity has been demonstrated in both mice 
models and human cell experiments. Overexpression of the p38 inhibitor protein 
phosphatase 1D (PPM1D) led to an increased sensitivity to tumourigenesis, and this 
effect was reversed by enforced expression of a constitutively active form of p38 MAPK. 
In agreement, inhibition of mammary gland proliferation is observed upon PPM1D 
genetic silencing (Bulavin et al., 2004). Another line of evidence that supports a tumour 
suppressor function for p38, is based on a decrease in apoptosis and senescence 
processes, after inhibition of Gadd45α/MEKK4, which is an upstream activator pathway 
of JNK and p38 MAPK (Tront et al., 2006). Also, loss of function studies performed in 
mice, have shown that the p38α has a protective effect against Kras-associated lung 
carcinogenesis (Ventura et al., 2007). Finally, p38 can inhibit cell growth by controlling 
the expression of cyclins (Lavoie et al., 1996), or can induce a G2/M checkpoint by 
phosphorylating p53 (Bulavin et al., 1999; Huang et al., 1999; She et al., 2000), or by 
phosphorylating and inhibiting the phosphatase Cdc25B (Bulavin et al., 2001). 
 
1.6.5. p38 and haematological malignacies 
p38MAPK has been involved in the pathogenesis of different haematological 
malignancies including leukemias myelodysplastic syndromes and several 
lymphoproliferative diseases (Feng et al., 2009). Constitutive activation of the p38 
targets, c-Jun and JunB  has been reported in Hodking lymphoma cells, and might be 
responsible for the proliferation of those cells (Mathas et al., 2002). P38 appears to be 
required for the TNFα mediated proliferation of non-Hodgkin lymphoma cells (Kotlyarov 
et al., 1999). Also, p38MAPK pathway has been shown to play key roles in the 
transformation of follicular lymphomas to the more aggressive diffuse large B cell 
lymphoma, and indeed, inhibition of this pathway led to apoptosis and inhibition of cell 
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growth in a subset of t(14;18) cell lines. Moreover, lymphoma proliferation was also 
arrested in NOD-SCID mice upon treatment with p38 inhibitors (Elenitoba-Johnson et 
al., 2003; Lin et al., 2004).  
p38 MAPK seems also to be involved in the proliferation of multiple myeloma 
cells induced by growth factors secreted by the marrow microenviroment, such as IL-6, 
IL-10, insulin-like growth factor 1 and granulocytic colony-stimulating factor (Nguyen et 
al., 2006). In fact, inhibition of p38 MAPK synergizes with the anti-myeloma effect of PS-
341 (the proteasome inhibitor also called Bortezomib) (Hideshima et al., 2004). 
p38MAPK has been shown to be inactivated in a certain lymphoma cell lines 
upon treatment with the monoclonal antibody anti-CD20 Rituximab, and in fact, inhibition 
of the p38 MAPK in those cells mimicked the Rituximab effect inducing apoptosis 
(Bonavida, 2007). On the contrary, the apoptosis induced by Rituximab in chronic 
lymphocytic leukemic cells requires activation of the p38MAPK pathway (Pedersen et 
al., 2002).  
Many p38 MAPK inhibitors have been developed and even tested in phase I 
clinical trials. Unfortunately these drugs have severe side effects (Yong et al., 2009). 
Also, as p38 has been shown to have ambivalent roles in carcinogenesis, it is still a 
matter of concern whether the use of these drugs might be beneficial for some cancer 
types, but not for others (Wagner and Nebreda, 2009).  
 
1.7. CTCF as a potential regulator of BCL6 
 
The CCCTC-binding factor (CTCF) has been implicated in various regulatory 
functions. It is a well established chromatin regulator that plays key roles in inducing and 
supporting chromatin interactions. Over the last decade a substantial amount of 
information related to the CTCF functions have been gathered together (Ohlsson et al., 
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2010b; Phillips and Corces, 2009). It is involved in epigenetic regulation, which is not 
only crucial for normal cell development but is also implicated in many cancer 
processes. The features and functions of CTCF will be summarized in the following 
sections, paying special attention to its involvement in lymphoid cell regulation, since we 
have found that CTCF is a potential regulator of the BCL6 gene. 
 
 1.7.1. CTCF structural and functional domains  
The CTCF protein consists of several domains: the N-terminal domain, a central 
DNA binding domain composed of eleven zinc fingers, and a C-terminal domain (Figure 
1.9.).  
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Figure 1.9. CTCF structural domains and interacting partners. The figure shows the N-
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The central zinc finger domain is responsible for the recognition and interaction 
with DNA. In fact, different combinations of individual zinc fingers enable CTCF to bind 
to many different DNA sequences (Filippova et al., 1996; Jothi et al., 2008). This 
particular characteristic may explain why CTCF has been implicated in a number of 
different functions such as cell proliferation, differentiation, apoptosis, transcriptional 
repression/activation, chromatin insulation, imprinting and chromosome X inactivation 
(Ohlsson et al., 2010b). The CTCF zinc finger domain interacts with DNA, but it also 
interacts with other nuclear proteins (Ohlsson et al., 2001). The zinc finger domain 
together with sequences located on both the N and C terminal domains are considered 
to be essential for CTCF transcriptional repression (Lutz et al., 2000). The N- and C- 
terminal regions do not share significant similarity to any other protein and do not form 
classical domains but unstructured regions (Martinez and Miranda, 2010).  
 
1.7.2. CTCF postranslational modifications and interacting partners  
CTCF functions are known to be modulated through several post-translational 
modifications and by the interaction with different proteins (Figure 1.9). 
The (S(604)KKEDS(609)S(610)DS(612)E (SKKEDSSDSE) motif located at the 
CTCF C-terminal domain is known to be phosphorylated at serine-residues, and this 
modification has been related to reduced transcriptional repression by CTCF (Klenova et 
al., 2001). Furthermore, mutations of these serines overcome CTCF mediated growth 
arrest. Phosphorylation of these residues has been attributed to the protein kinase CK2 
(formerly casein kinase II) (Klenova et al., 2001), and this kinase has been reported to 
be regulated by the p38 MAPK (Sayed et al., 2000). 
Another relevant CTCF modification is SUMOylation, which occurs at both the N 
and C-terminus of CTCF. This modification does not affect CTCF DNA binding ability but 
has been shown to be important for CTCF repressive function at the c-MYC promoter 
(MacPherson et al., 2009). 
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One of the most interesting modifications that the CTCF protein undergoes is 
poly(ADP-ribosyl)ation by poly(ADP-ribose) polymerase 1 (PARP1) (Farrar et al., 2010; 
Klenova and Ohlsson, 2005; Yu et al., 2004). This enzyme plays a key role in different 
cell processes such as DNA repair, cell proliferation, and genomic instability. CTCF has 
been shown to directly interact with, and possibly activate, PARP-1 (Farrar et al., 2010; 
Guastafierro et al., 2008). Poly(ADP-ribosyl)ation regulates CTCF insulator and 
chromatin barrier functions (Yu et al 2004; Witcher and Emerson 2009) (see below for 
further details). 
CTCF is known to interact with a great number of proteins involved in many 
different functions, such as transcription enzymes (RNA polymerase II large subunit), 
transcriptional regulatory factors (Oct4, YY1, etc), genome integrity mediators (PARP-1), 
nuclear architectural proteins (cohesins, nucleophosmin/B23, etc.) and chromatin 
constituents, like the variant histone H2A.Z (for review see (Ohlsson et al., 2010b; 
Zlatanova and Caiafa, 2009b). CTCF interaction partners are depicted in Figure 1.9. 
 
1.7.3. CTCF intracellular localization and expression 
CTCF is a transcriptional regulator that is highly conserved from Drosophila to 
human and ubiquitously expressed (Filippova et al., 1998; Klenova et al., 1993).  
CTCF is located in the nucleus (Klenova et al., 1993) and its distribution during 
the cell cycle is dynamic (Burke et al., 2005; Klenova et al., 1998). The different CTCF 
functions seem to depend on specific localization in different nuclear compartments, 
such as the nuclear matrix (Dunn et al., 2003), nucleolar periphery (Yusufzai and 
Felsenfeld, 2004; Yusufzai et al., 2004) , nucleolus (Torrano et al., 2006) and nuclear 
membrane (Guelen et al., 2008). 
Studies performed on hematopoietic models have shown that in the myeloid 
lineage CTCF expression progressively decreases during the differentiation process 
(Delgado et al., 1999). Work in our laboratory demonstrated the CTCF nucleolar 
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localization in several experimental model systems. In myeloid cells, localization of 
CTCF to the nucleolus was associated with cell growth inhibition and differentiation 
(Torrano et al., 2006). Expression of CTCF has also been shown to vary during normal 
murine T- cell differentiation, with the highest levels being found in immature single 
positive T cells (Heath et al., 2008). 
 
1.7.4. CTCF molecular functions 
CTCF is an important regulator that plays key roles in global chromatin structure 
and, therefore, in the organization of the entire genome (Ohlsson et al., 2010b). Over 
the past two decades progress has been made in our knowledge of precise 
mechanisms through which CTCF regulates chromatin structure and molecular 
interactions. CTCF can either function as a transcriptional repressor or activator and is 
capable of acting as an enhancer blocking protein or as a barrier element. These 
molecular functions are summarized below. 
 
a. Transcriptional repression or activation 
The first function described for CTCF was the transcriptional repression of the 
oncogene c-MYC both in humans and in chicken (Filippova et al., 1996; Klenova et al., 
1993; Lobanenkov et al., 1990) (Figure 1.10). Since then, a number of other genes with 
different functions have been also shown to be repressed by CTCF (Filippova, 2008), 
such as the chicken lysozime gene (Burcin et al., 1997), the proximal exonic region of 
the hTERT gene (Renaud et al., 2005) or a silencer region in the HLA-DRB1 gene 
(Arnold et al., 2000). However, CTCF has also been involved in the transcriptional 
upregulation of different genes like the amyloid precursor protein (APP) gene (Vostrov 
and Quitschke, 1997; Yang et al., 1999) (Figure 1.10).  
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CTCF has been found to regulate transcription of several genes implicated in the cell 
cycle control including p19ARF, the human retinoblastoma (RB) gene, PIM1, the Polo-
Kinase, p16INK4a ,p27KIP1 among others (De La Rosa-Velazquez et al., 2007; Filippova, 
2008; Klenova et al., 2002; Recillas-Targa et al., 2006) .  
 
b. Chromatin insulation 
  Chromatin insulators can be defined as DNA regulatory sequences that 
establish boundaries between genes. They control gene interactions and prevent 
inappropriate regulatory influences between neighboring genes. Insulators may act 
either as enhancer blockers or as barrier elements (Gaszner and Felsenfeld, 2006; 
Wallace and Felsenfeld, 2007). The enhancer blocking elements are usually located 
between promoters and enhancers, limiting the interactions between them and, 
therefore restricting the enhancer’s activity. The barrier elements act mainly as 
Figure 1.10. CTCF as a “classical” transcriptional factor. CTCF has been shown to mediate 
both repression and activation of transcription of a number of genes. Left panel shows some 
genes negatively regulated by CTCF including the cMYC, the Ch-lysozime and the hTERT. The 
right panel, depicts some genes activated by CTCF, such as APPβ and p19ARF
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boundaries impairing the spreading of heterochromatin into euchromatin, or sometimes 
restraining the advance of the methylation front. Insulators may harbor both properties 
(Gaszner and Felsenfeld, 2006; Recillas-Targa et al., 2006). 
Several lines of evidence have shown that CTCF is required for both enhancer 
blocking and barrier function (Figure 1.11). Studies performed on the chicken beta-
globin cluster demonstrated the enhancer blocking activity of CTCF. Other insulator 
regions at the mouse and human beta globin locus were later on identified (Bell et al., 
1999; Farrell et al., 2002; Saitoh et al., 2000). Subsequently, CTCF was found to 
mediate enhancer blocking activity at the Igf2/H19 locus. Moreover, CTCF plays key 
roles in the epigenetic modifications that are required for the genomic imprinting of that 
locus (Bell and Felsenfeld, 2000; Hark et al., 2000; Kanduri et al., 2000) reviewed in 
(Filippova, 2008). This function is regulated through DNA methylation which interferes 
with CTCF binding, eliminating CTCF-mediated enhancer blocking activity. More 
Figure 1.11. CTCF insulator activity. DNA insulators are represented by grey cylinders,. 
Nucleosomes are shown as blue circles. The enhancer blocking function is illustrated in the top 
panel. Enhancer blockers are usually located between promoters and enhancers. The bottom 
panel depicts the CTCF barrier function. The barrier elements inhibit the spreading of inactive 
chromatin (heterochromatin). CTCF is the only insulator binding protein described so far in 
vertebrates. 
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recently, genome wide studies showed a global insulation role for CTCF (reviewed in 
(Ohlsson et al., 2010a; Phillips and Corces, 2009)). 
CTCF has been shown to interact with different chromatin barrier regions, acting 
as a physical boundary and leading to a variety of effects which are mainly context-
dependent. CTCF delimits chromatin domains with opposite functions. In support for this 
notion, a comparison between the CTCF binding sites (CTS) of CD4+, HeLa and Jurkatt 
T cells showed that CTCF was preferentially bound to boundary regions between active 
and repressive chromatin domains, marked by histone H2A lysine acetylation and 
histone H3 lysine 27 trimethylation (Cuddapah et al., 2009). Also, the variant histone 
H2A.Z was shown to co-localize with CTCF genome wide (Barski et al., 2007). Thus, 
CTCF seems to be acting as a physical barrier controlling the histone modifications and 
therefore the chromatin status, and this is made in a cell-dependent manner (Barski et 
al., 2007; Bartkuhn and Renkawitz, 2008; Cuddapah et al., 2009).  Finally, CTCF was 
also shown to prevent spreading of DNA methylation (Figure 1.12) and maintain DNA 
methylation free zones. By this mechanism, CTCF protects promoters from epigenetic 
silencing (Filippova, 2008; Recillas-Targa et al., 2006). 
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Figure 1.12. CTCF regulation of CpG methylation. In some genes, CpG methylation
prevents CTCF binding (top panel). CTCF has been demonstrated to block the 
progression of  the CpG methylation front, sustaining methylation free zones (bottom 
panel). Black circles indicate methylated CpGs , whereas black bars show unmethylated
CpGs (Modified from Recillas-Targa et al, 2006 and Filippova et al, 2008) 
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The study of the CTCF functions has provided new insights on the mechanisms 
that control the genomic organization. CTCF seems to be essential in the long distance 
chromosomal interactions some times even between different chromosomes, through 
the formation and maybe stabilization of loops and hubs These structures will then 
control the access of the transcription machinery (Figure 1.13) (Kurukuti et al., 2006; 
Phillips and Corces, 2009; Splinter et al., 2006; Yoon et al., 2007; Zlatanova and Caiafa, 
2009a)  
Figure 1.13. CTCF insulation via formation of chromatin loops. This figure shows three 
examples of how CTCF intervenes in the genomic organization by the formation of loops/hubs. 
CTCF is capable of inducing loop domains that isolate genes from the effects of other close 
genes (left figure). CTCF is also able to induce the formation of a chromatin hub, where 
regulatory elements or coregulated genes are brought close together (middle figure). CTCF 
appears to mediate interchromosomal interactions by bringing nearer genes or/and regulatory 
regions located on different chromosomes (right panel) (Modified from Williams and Flavell; 
2008) 
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1.7.5. CTCF role in cell proliferation, differentiation and apoptosis 
Several lines of evidence indicate that CTCF blocks cell proliferation, probably 
through the regulation of genes involved in cell cycle control (Rasko et al., 2001). 
Indeed, in a variety of cell model systems including the Burkitt lymphoma cell line Raji, 
enforced CTCF expression lead on a substantial inhibition of the cell proliferation rate 
(Rasko et al., 2001; Torrano et al., 2005). It is interesting that CTCF effect on 
proliferation does not depend on the stage of the cell cycle, being able to arrest cells at 
any stage of cell cycle (Rasko et al., 2001). This anti-proliferative function is known to be 
dependent on the phosphorylation of CTCF at the C-terminal domains (El-Kady and 
Klenova, 2005; Klenova et al., 2001). In lymphoid cells CTCF is also involved in the 
regulation of cell cycle progression. Cell growth inhibition induced by BCR stimulation in 
the WEHI-231 mouse B-cell line was mediated through CTCF (Qi et al., 2003). In fact, 
enhanced expression on CTCF in these cells reproduced the effects of the BCR 
stimulation (Qi et al., 2003). There may also be a T-cell role for CTCF. Studies 
performed in mice have shown that CTCF is essential for the proliferation of alpha-beta 
T cells (Heath et al., 2008). Thymocytes from CTCF knockout mice were smaller than 
those of wild-type animals and blocked in the cell cycle. Thus CTCF is a crucial positive 
regulator of cell growth and proliferation in alpha-beta T cells (Heath et al., 2008). These 
data on T cells are opposite to those described in B cells which reinforce the idea that 
CTCF function is context dependent. 
Several studies have underlined the importance of CTCF on the differentiation 
processes of different cell types. Our group has demonstrated that CTCF specifically 
induce the erythroid differentiation in a pluripotent cell line (Torrano et al., 2005). CTCF 
is also essential for the T cells differentiation in the thymus (Heath et al., 2008; Ribeiro 
de Almeida et al., 2009), and in contrast enforced expression of CTCF has been 
associated to an impaired differentiation process of dendritic cells (Koesters et al., 
2007). CTCF therefore, seems able to both enhance and inhibit proliferation depending 
on the cellular context. 
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CTCF also has cell context dependent effects on apoptosis. CTCF was shown to 
cause apoptosis in the WEHI-231 B cell line (Qi et al., 2003) and also in a subset of 
dendritic cells (Koesters et al., 2007). However, decreased expression of CTCF was 
followed by apoptosis, and high levels of CTCF in breast cancer cells and tumours were 
found associated with resistance to apoptosis (Docquier et al., 2005)  
 
1.7.6. Genome wide analysis of CTCF binding sites.  
 Different approaches that included chromatin immunoprecipitation, combined 
with microarray hybridization (ChIP-chip), high throughput sequencing (ChIP-seq) and 
computational analysis have made it possible to identify between ~14,000 to ~ 40,000 
CTCF binding sites (CTS), depending on both the cell type and the organism analyzed 
(Barski et al., 2007; Boyle et al., 2008; Cuddapah et al., 2009; Chen et al., 2008; Jothi et 
al., 2008; Kim et al., 2007; Xi et al., 2007; Xie et al., 2007). Remarkably, CTCF binding 
sites are not only located promoter regions (20%) but also in introns (22%), exons (12%) 
and in intergenic regions (46%) (Kim et al., 2007) (Figure 1.14.). As a result of these 
studies, consensus motifs for the CTS have been identified in a variety of organisms 
(Figure 1.14.) (recently reviewed in (Ohlsson et al., 2010b; Phillips and Corces, 2009) 
 Over the last few decades, it has become clear that CTCF plays key roles in the 
distribution, organization and regulation of the entire genome. In agreement with this 
idea, CTS have been found across the human genome linker regions between 
nucleosomes (Fu et al., 2008). Linker regions are known to be involved in the 
positioning of the nucleosomes, suggesting a role for CTCF in nucleosome repositioning 
(reviewed in (Ohlsson et al., 2010b). The exact role of CTCF in this regard is not 
completely understood yet, but one possibility is that CTCF modulates nucleosome 
movement through its interaction with chromatin remodelers such as CHD8 (Ishihara et 
al., 2006). 
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Complexes with other proteins are required for the three dimensional organization 
of the genome mediated by CTCF (Ohlsson et al., 2010b). It is known that the location 
of each gene within chromosome territories in the nucleus is not random, and this is 
important for gene regulation and function (Takizawa et al., 2008). Various studies 
(Kurukuti et al., 2006; Splinter et al., 2006) have suggested that these interactions might 
be stabilized through CTCF-cohesin complexes. Cohesin is a multisubunit protein 
complex that mediates sister chromatid cohesion during mitosis, facilitates the repair of 
damaged DNA and has important, but not well established functions in the control of 
gene expression (Peters et al., 2008). In several independent studies cohesin proteins 
were found to co-localize extensively with CTCF (Parelho et al., 2008; Rubio et al., 
2008; Stedman et al., 2008; Wendt et al., 2008) (reviewed in (Wendt and Peters, 2009). 
About 1,800 cohesin/CTCF sites were identified in immature lymphocytes (B3 pre-B 
cells) and thymocytes (Parelho et al., 2008).  
46%
20%
12%
22% Intergenic
Promoter
Exonic
Intronic
Figure 1.14. Genome wide analysis of CTCF binding sites. (a) Illustration of a CTCF  
consensus sequence binding motif generated from ChIP on chip analysis (Kim et al, 2007). The 
size of each letter illustrates the relative frequency  of a specific nucleotide at each position. 
Other CTCF consensus sequences from ChIP seq data are reviewed in Ohlsson et al, 2010b. (b)
The pie chart shows the frequency of location of the CTCF binding sites within exons, introns, 
promoters (within 2.5 Kb of transcriptional start sites) as well as in intergenic regions. (This figure 
is based on Kim et al, 2007)
b
a
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CTCF- cohesin complexes have been proposed to play a regulatory role in CTCF-
mediated loop formation in the immunoglobulin heavy chain (Igh) locus, and this process 
is believed to be necessary for V(D)J gene recombination to produce  immunoglobulin 
H- and L-chains. CTCF in vivo binding to the 3’ regulatory region of the IgH locus was 
demonstrated in B cells at different stages of differentiation (Garrett et al., 2005). By 
ChIP-chip analysis it was found more than 50 CTCF-binding sites throughout Igh locus 
in pro-B and pre-B cells (Degner et al., 2009). In contrast, certain cohesin subunits 
colocalized with CTCF through the IgH locus preferentially in pro-B cells. Lineage and 
stage-specific cohesin subunits recruitment to CTCF sites during B lymphocyte 
development was found, suggesting that the differential binding of cohesins to CTCF 
sites may promote multiple loop formation and thus effective V(D)J recombination within 
the locus (Degner et al., 2009). 
 
 
1.7.7. CTCF in human cancer  
Over the last decade a number of mechanisms explaining the CTCF participation 
in malignant cell transformation have been considered.  
Firstly, the human CTCF gene is located on the long arm of chromosome 16 
(16q22.1), a chromosomal region frequently associated with loss of heterozygosity in 
breast and prostate cancer and Wilm´s tumor (Klenova et al., 2002). Interestingly, CTCF 
has been considered essential for the control of numerous cancer associated genes 
such as c-myc, p53, p16, RB, p19 ARF, BRCA-1, TERT, and IGF2 (De La Rosa-
Velazquez et al., 2007; Filippova, 2008; Klenova et al., 2002; Renaud et al., 2005; Soto-
Reyes and Recillas-Targa, 2010; Witcher and Emerson, 2009). Loss of CTCF binding to 
the regulatory regions of certain tumour suppressor genes such as RB or the p16 genes 
has been shown to induce an aberrant methylation and cause reduced expression of 
those genes essential for the control of the cell cycle and proliferation (De La Rosa-
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Velazquez et al., 2007; Witcher and Emerson, 2009). CTCF involvement in the 
epigenetic regulation of the human p53 gene has been recently reported. In this case 
CTCF has the ability to maintain the p53 promoter in a local chromatin conformation by 
protecting this region against suppressor histone marks (Soto-Reyes and Recillas-
Targa, 2010). There are other mechanisms altering CTCF function. Several point 
mutations at the zinc finger domain of CTCF have been identified in breast, prostate and 
Wilm´s tumours, which interfere with the recognition of specific DNA targets. For 
example, the H345R substitution was predominately found in prostate cancer whereas 
the R448Q mutation was detected in Wilm´s tumor (Filippova et al., 2002; Klenova et al., 
2002). Also, loss of imprinting due to aberrant methylation of CTS in the IGF2/H19 locus 
has been implicated in Wilm´s tumour and colorectal cancer (Filippova, 2008). Mutations 
of the target sequence can impede CTCF binding. A single mutation at one of the CTCF 
binding sites at the H19 ICR locus was sufficient for interfering with CTCF function, 
despite the presence of other CTS at the same locus (Pant et al., 2004). This mutation 
might explain why the H19ICR locus has an aberrant methylation pattern in a variety of 
cancers (Tycko, 1999). 
Abnormal CTCF localization in the cytoplasm might be another mechanism of 
tumorigenesis. Cytoplasmic CTCF was detected on an elevated percentage of patients 
with breast cancer (Rakha et al., 2004). It is not yet known how the abnormal 
localization of CTCF might be implicated in the tumor progression or development, but it 
may be associated with abnormal regulation of tumor suppressor genes (Recillas-Targa 
et al., 2006).  
Two different CTCF forms can be identified depending on the poly(ADP-
ribosyl)ation status; CTCF-180 kDa is poly(ADP-ribosyl)ated and is the predominant 
form detected in normal breast tissues (Docquier et al., 2009). In the contrary the CTCF-
130 kDa was the only form identified in breast tumor tissues. The CTCF-130 kDa form 
was predominantly detected in proliferating cells (S-Phase) and CTCF-180 kDa in non-
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proliferanting cells. In fact the poly(ADP-ribosyl)ated form of CTCF was directly 
demonstrated to be impeding cell division (Docquier et al., 2009; Farrar et al., 2010). 
……………………………………………………………………………………………  . 
68 
1.8. Aims 
The signalling pathways regulating BCL6 are not known in detail, but are very 
important because tight control of BCL6 expression is required for normal immunity. 
Deregulated expression occurs in a subgroup of lymphomas despite the presence of an 
unrearranged BCL6 locus and one cause of this is disruption of cis-acting control 
elements in exon 1. The main goal of this project was to find out how signalling 
pathways controlling BCL6 expression are integrated. For this purpose we established 
the following aims: 
 
1. To investigate BCL6 regulation in lymphoid Ph+ cell lines. Professor Melo´s 
group at the Hammersmith Hospital whilst investigating the effects of the tyrosine kinase 
inhibitor, Imatinib, in chronic myeloid leukaemia found that BCL-6 mRNA and protein 
were upregulated upon inhibition of Bcr-Abl tyrosine kinase in different lymphoid blast 
crisis cell lines. Therefore, we will use these lymphoid blast crisis cell lines cultured in 
the presence and absence of imatinib to investigate the regulation of BCL6.  
 
2. To extend our results on BCL6 regulation to Burkitt lymphoma cell.  In order to 
demonstrate relevance to the germinal centre biology, we will use human Burkitt 
lymphoma cell lines (Ramos and DG75), which are representative of the germinal centre 
stage of development, to confirm and extend our findings with the BCR-ABL expressing 
lymphoid cell lines.  
 
3. To explore the BCL6 regulation by MAPK and BCR signalling pathways. We will 
also investigate how the MAPK signalling pathways which have been shown to be 
important for the regulation of BCL6 are modulated by the CD40 and the BCR signalling 
pathways, which are known to play essential roles in the germinal centre reaction.  
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4. To determine the involvement of CTCF in BCL6 regulation. Using 
bioinformatics we discovered a CTCF binding site in BCL6 exon 1. In order to determine 
the biological relevance of CTCF in the BCL6 regulation we will investigate CTCF in vitro 
and in vivo binding to BCL6 in several BCL6 positive and negative cell lines. We will also 
characterize the pattern of expression of CTCF in human lymphoma cell lines .As CTCF 
has been implicated in the epigenetic regulation of several genes we will finally study the 
epigenetic regulation of BCL6 by CTCF. 
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CHAPTER 2. Material and methods 
 
2.1. Cell culture methods 
 
2.1.1 Cell lines culture 
Cell lines were grown in either RPMI-1640 or DMEM (Lonza) supplemented with 
10 to 20% fetal calf serum (Lonza), 2% L-glutamine and 5% penicillin/streptomycin and 
maintained at 37º C in a humidified 5% CO2 atmosphere. Cells were either purchased or 
donated by groups within the Department of Haematology. Table 2.1 provides a list of 
cell lines used in this study. Cells were maintained at the appropriate density (see table 
2.1) 
 
2.1.2 Primary cells 
Frozen mononuclear cells from a patient with lymphoid blast crisis of chronic 
myeloid leukaemia (CML) were kindly donated by Hospital Marques de Valdecilla 
(Haematology Department; Santander; Spain). Cells were thawed out using a thawing 
solution (DMEM medium with DNase I (Calbiochem) and preservative free heparin 
(Monoparin, CP Pharmaceutical Ltd)). 107 cells were cultured in 1 ml of FCS-free-
medium (Iscove’s Modified Dulbecco’s medium (Sigma, St Louis, MO), 1% penicillin-
streptomycin-l-glutamine and serum substitute (BIT:Stem Cell technologies)) and kept in 
culture overnight before performing the experiment (Hamilton et al., 2006). 
 
2.1.3. Cell counting, cell cycle and viability. 
Cell counting was performed using a haemocytometer. For ChiP assays, where 
a very accurate measure was required in order to obtain reproducible results, we used 
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the Countess® Automated Cell Counter (Invitrogen) following the manufacturer´s 
instructions.  
Cell viability was assessed by the dye exclusion test with Trypan Blue staining 
(Sigma).  
Cell cycle: Cell cycle measurement was carried out using propidium iodide 
staining. 1x106 cells were harvested, and resuspended in buffer (0,1%NP-40; 0,5mg/ml 
RNase A; PBS) and incubated at room temperature for 30 minutes. Propidium Iodide 
(0,05 x mg/ml) was added and cells were immediately analyzed by flow cytometry using 
the FACs Canto II. The analysis was performed in linear scale for cell cycle 
experiments. 
 
2.2. Purification of primary lymphoma cells using a FAC-Sorter 
 
Lymph nodes biopsies of patients with lymphomas were provided by the 
Haematology Department of the Hospital Universitario Marqués de Valdecilla after 
diagnosis was made. Informed consent was obtained from every patient and approval to 
perform this study was obtained from the local research ethics committee. Single cell 
suspensions were obtained from the lymph node by physical disruption using a 20 
gauge (0.9mm) needle attached to a sterile plastic syringe. These cells were then 
separated in the FACSAria (BD) using the FCS/SSC parameters and two to four specific 
monoclonal antibodies against surface markers specific of each type of lymphoma. The 
separated cells were then used to obtain genomic DNA.  
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Table 2.1.Phenotype, culture conditions, source and references of cell lines used in this study. 
 
CELL 
LINE 
NAME 
PHENOTYPE 
CULTURE 
MEDIUM 
SOURCE REFERENCES 
RAMOS Human Burkitt´s Lymphoma VEB  negative RPMI-10F  
Ben Bassat et al, 
1997 
DG75 Human Burkitt´s Lymphoma VEB  negative RPMI-10F  
Gasperini et al , 2005 
Martinez et al, 1993 
BJAB Human Burkitt´s Lymphoma VEB  negative RPMI-10F  Klein et al, 1975 
RAJI Human Burkitt´s Lymphoma VEB positive RPMI-10F Pr. Leon U. Cantabria 
Epstein et al, 1966; 
Epstein et al, 1965 
MUTU III Human Burkitt´s Lymphoma VEB  negative RPMI-10F 
Dr. Noémi Nagy (MTC) 
Karolinska Institute.  Nagy et al, 2000 
TOLEDO DLBCL RPMI-20F Dr.  A Piris CNIO (Madrid) Martinez et al, 1993 
LYO3 DLBCL RPMI-20F Dr.  A Piris CNIO (Madrid) Martinez et al, 1993 
K562 CML Erythroleukaemia BC (p210 BCR-ABL) RPMI-10F 
Pr. JV Melo University of 
Adelaide 
Koeffler et al, 1980; 
Klein et al, 1976 
BV173 CML Lymphoid BC (p210 BCR-ABL) RPMI-10F Pr. JV Melo U of Adelaide Pegoraro et al, 1983 
Nalm-1 CML Lymphoid BC (p210 BCR-ABL) RPMI-20F   
Z119 PRE-B-ALL Ph+ (p190 BCR-ABL) RPMI-20F Pr. JV Melo  U of Adelaide Estrov et al, 1996 
Z-33 PRE-B-ALL Ph+ (p190 BCR-ABL) RPMI-20F Pr. JV Melo U of Adelaide  
TOM-1 PRE-B-ALL Ph+(p190 BCR-ABL) RPMI-20F Pr. JV Melo U of Adelaide Blood et al, 1987 
MV(4;11) Biphenotypic B-myelomonocytic leukemia with t(4;11) RPMI-10F 
Pr. JV Melo 
U of Adelaide 
Lange et al, 1987 
HEK293T Human EmbrYonic Kidney DMEM-10F * Pear et al; 1993 
 
*These cell lines were already in the laboratory.  
Abbreviatures:  
F: Fetal Calf serum 
EVB: Epstein Barr Virus 
Burkitt´s: Lymphoma:B cell Lymphoma 
DLBCL: Diffusse Large B Cell Lymphoma 
BC CML: Blast Crisis of Chronic Myeloid Leukaemia 
ALL Ph+: Acute Lymphoblastic Leukaemia with Philadelphia chromosome (which is the result of a balanced 
translocation between chromosomes 9 and 22) 
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2.3. Fluorescence In Situ Hybridization (FISH) 
 
 
Cultured cell lines or primary cell lines were firstly washed with PBS. The pellet is 
then carefully resuspended by vortexing adding drop by drop up to 8 ml of pre-warmed 
0,075 M KCl. Samples were incubated for 30 minutes at 37ºC, centrifuged and carefully 
resuspended by vortexing and adding drop by drop up to 8 ml of cold Carnoy´s solution 
(75% methanol and 25% of glacial acetic acid(45%)). Between two and five additional 
washes with Carnoy´s were performed in order to clear all debris. Samples were then 
incubated on ice for 10 minutes and a drop of the sample was placed on a slide and 
allowed to air dry. Five µl of a prediluted- probe (LSI BCL6 (3q27) 32-191016; VYSIS) 
was put directly on the slide and covered with a cover-slide. The slide was placed in a 
block at 85°C for 3 minutes, covered with parafilm and inserted on a humid box that was 
placed on an incubator at 37ºC for 18 hours. The day after, the parafilm was removed, 
the cover slip was carefully removed by incubating it for 4 minutes in a Coplin Jar 
containing prewarmed (72ºC) hybridization solution (2XSSC (NaCl 3M y NaHC03 
0.3M)/0.3% NP-40). The slide was then placed in another Coplin Jar containing 
hybridization solution and washed for 4 minutes. Slides were then allowed to air dry 
completely. 10 µl of Vectashield (Vector Laboratories) were added and a cover slip was 
placed on top. Fluorescence signal was analyzed using a Fluorescent Microscope 
(Nikon Eclipse 50i).  
 
2.4. Drug treatments 
 
2.4.1. Signaling pathways inhibitors 
 The BCR-ABL cell lines, Z119 and BV173, and the germinal centre cell lines, 
Ramos and DG75, and primary cells were incubated with inhibitors of either the 
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MEK/MAPK or of the PI3K/AKT pathways at the concentrations and for the lengths of 
time indicated (Table 2.2). The ERK 1/2 pathway was inhibited using the MEK1/2 
inhibitors U0126 or/and PD98059 (Calbiochem). SB 202190 (Calbiochem) was used to 
inhibit the p38 MAPK pathway., LY294002 (Calbiochem) and Rapamycin (Cell Signalling 
Technology) were used to respectively inhibit the PI3K and the m-TOR pathways. 
Where indicated, Imatinib (0.5-5µM; kindly provided by Professor Junia Melo) was 
included in the cell suspension. Stock solutions of the inhibitors were prepared with 
either DMSO or PBS. The final concentration of DMSO in all the experiments was below 
0.8%. 
 
Table 2.2. Signalling pathways inhibitors and stimulators utilized in this study 
SIGNALING 
PATHWAY 
 
INHIBITOR  COMPANY DOSE REFERENCE 
MEK 1/2  
 
UO126 Calbiochem 10-100 µM Favata et al, 1998 
Promega Notes 
MEK 1/2  
 
PD98059 Calbiochem 10-100 µM Han et al,2001 
Promega Notes 
P38MAPK 
 
SB202190 Calbiochem 10-50 µM Nemoto et al ,1998 
Gauduchon et al; 2005 
JNK JNK inhibitor II Calbiochem 5-20 µM Han et al, 2001 
Bennet et al, 2001 
PI3K 
 
LY294002 Calbiochem 10-50 µM Paunescu et al, 2000 
Ireton et al, 1996 
mTOR  
 
Rapamycin Cell Signaling 5-50 nM Sin et al, 2006 
TARGET 
MOLECULE 
 
STIMULATORS  COMPANY DOSE REFERENCE 
BCR 
 
Anti-IgM Southern 
Biotech 
10 µg/ml Niu et al, 1998 
CD40 Receptor 
 
Soluble CD40 Biovision 0.1-20 ng/ml Biovision 
P38MAPK 
 
Anysomicin Sigma 50-100 ng/ml Hong et al, 2007 
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 2.4.2. CD40 and BCR stimulation 
 Ramos cells were preincubated with different inhibitors of the MEK/MAPK 
pathway and/or treated afterwards with anti-IgM (Southern Biotech; 10 µg/ml) as 
indicated.  
 For the CD40 experiments, Ramos cells were treated with CD40 ligand 
(Biovision; 0.1-20ng/ml.) or cultured on a mono-layer (80-90% confluent and 30Gy 
irradiated) of a mouse fibroblast cell line either stable transfected with human CD40 
ligand (mCD 40L), or non transfected for up to 24 hours. 
 
 2.4.3. Anisomycin and Cycloheximide 
 To assess the phospho-p38 effect on the BCL6 promoter activity, 1 µg/ml of anysomicin 
(Sigma) was added to the medium 2 hours before obtaining the lysates. To determine 
whether the p38 effect required de novo protein synthesis or was mediated by 
phosphorylation of an existing pathway, the protein synthesis inhibitor of cycloheximide 
(20µg/ml) was added 2 hours before the anisomycin. 
 
2.4.4. Demethylation treatment 
In order to study the effects of different epigenetic modifications, cells were 
treated with 5-aza-2'-deoxycytidine (5-azadC) and, in some cases with Trichostatin A 
(TSA) .Two and a half million cells were seeded on 10 ml R10F and incubated with or 
without 1µM freshly made 5-azadC (stock diluted in DMSO and stored at -80ºC; Sigma) 
for 72 hours. For 5-azadC and TSA co-treatments, cells were treated with 1µM 5-azadC 
for 72 hours after which TSA (300 nM) was added for another 72 hours. Cell pellets 
were used for RNA analysis. 
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 2.5. Construction of plasmid vectors  
 
  All constructs used in this study were verified by DNA sequencing and/or 
restriction enzyme digestion 
  2.5.1. Dominant negative STAT5. The pORSVI plasmid containing dominant 
negative Stat 5 (DN STAT5)(694F) was a kind gift from Professor Junia Melo 
 2.5.2. Luciferase Reporter Vectors 
 The pGL3 basic and the pRL null vectors were purchased from Promega. The (-
1296)BCL6pGL3 reporter vector containing a section of the BCL6 proximal promoter 
region were donated by Professor Eric Lam (Hammersmith Hospital) (Fernandez de 
Mattos et al., 2004). The BCL6(-4.9/+0.5)pGL3, BCL6(-4.9/+0.2)pGL3, BCL6(-4.3/+0.5) 
and the BCL6(-4.3/+0.2)pGL3 reporter vectors were generated by Dr. Vasiliki 
Papadopoulou (Department of Haematology, Hammersmith Hospital) (Papadopoulou et 
al., 2010). 
 The BCL6 Exon-1pGL3 and BCL6∆Exon 1pGL3, -4.9/∆+0.2pGL3 were 
generated as follows. The BCL6 gene regions spanning from -4904 to the +239 (in 
relation to the BCL6 transcription start site) were amplified using a Expand Long 
Template PCR System (Roche) in a final reaction volume of 50 µl (30 ng of genomic 
DNA, 300 nM of each primer, 200 nM of each dNTP and 0.4µl of the DNA Polymerase), 
in a thermocycler using a “Long template program” (95ºC 2min; [94º 20 s; 62ºC 30 s; 
68ºC 10min] 10 cycles; [94º 20 sec;62ºC 40 s; 68ºC 10 min-increasing 20 sec per cycle] 
25 cycles; 68ºC 9 min).  
 The BCL6 gene regions spanning from +239 to +533 were amplified using 
PhusionR High Fidelity Taq on a final volume of 50 µl containing 200 ng of genomic 
DNA, 300 nM of each primer, 200 nM ofeach dNTP and 1X Phusion Buffer and 0.06 
units of Phusion Taq. PCR conditions were 98ºC 45s followed of 40 cycles (98ºC 5s; 2-
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step 72ºC 45 s) and 72ºC 10 min. Restriction enzyme recognition sites were added to 
the primers for subsequent sub-cloning. 
The PCR products were mixed with loading buffer [0.005% (w:v) bromophenol 
blue 2% and 30% (v:v) glycerol 100%) and separated on a 1 to 1.5% agarose gels with 
0.5 µg/ml of ethidium bromide in TBE buffer for 1 hour at 100V. 1 Kb DNA ladder and 
100 bp ladder (Invitrogen) were used as weight markers. The insert fragments were then 
purified using the QIAquick Gel Extraction Kit (Qiagen) following the producer’s protocol, 
and digested overnight with an excess of restriction enzymes. Hind III and Xho I (New 
England Biolabs) were used to digest the 270 bp Exon 1 WT and mutant BCL6 
fragments and NheI and Bgl II (New England Biolabs) for the digestion of the (-
4904/+533) mutant BCL6 fragment.  
The pGL3 Basic vector was digested overnight with the same restriction 
enzymes and purified, using the QIAquick Gel Extraction Kit. In order to avoid self-
ligation, 5´phosphates of the linearized vector were removed using 10 Units of Shrimp 
Alkaline Phosphatase per µg of vector, incubating at 37ºC for 15 minutes. Then heat 
inactivation was performed for 15 additional minutes at 37ºC. In order to calculate the 
concentrations of both the insert and the vector, a small amount of both components 
were run on a 1% agarose gel. Then, vector and insert were ligated using T4 DNA 
ligase at 16ºC 0/N. Three different molar ratios were used (1:1; 1:3 and 1:5). The ligated 
material was transformed into competent E. Coli. Briefly, 1 vial of competent E.Coli cells 
(One Shot TOP10 Chemical competent E Coli cells; Invitrogen) was thawed on ice. 2 µl 
of the ligated material was added into one vial of competent bacterial cells and mixed 
gently. The vial was incubated on ice for 30 minutes, and then incubated at 42ºC for 30 
sec. After incubating the vial for two minutes on ice, 250 µl of SOC medium was added 
to the vial, and then the vial was placed on a 37º incubator with horizontal shaking for an 
hour. 100 µl of each transformation was then plated on an a pre-warmed ampicillin-agar 
plate and left on an 37ºC incubator O/N. Plasmids were then isolated from grown 
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colonies using Wizard Plus SV minipreps DNA purification system and screened by 
restriction digestion. 
Plasmids, were then purified using the PureLink™ HiPure Plasmid DNA 
Purification Ki (Invitrogen), following manufacturer’s instructions recommendations.  
 
 2.5.3. CTCF vectors 
 CTCF expression vectors used were: pCDNA-CTCF (Torrano et al., 2005), 
kindly provided by Dr Klenova (Essex University, UK) and three different pEGFP-CTCF 
constructs (pEGFP-CTCF-Full Length, pEGFP-CTCF-Zinc Finger, pEGFP-CTCF-C 
Terminal) (Burke et al., 2005; Torrano et al., 2006), kindly provided by Dr R. Renkawitz 
(Justus-Lieby University, Germany). For silencing CTCF expression the pRS-CTCF 
containing a shRNA CTCF on the pRETRO Super vector (Brummelkamp et al., 2002) 
(Figure 2.1), generated by Veronica Torrano, was used. 
Figure 2.1. Scheme depicting the pRS-CTCF vector used for silencing CTCF expression. 
CTCF target sequencing was described in Ishihara et al, 2006. 
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 2.5.4. pGMT- vector 
  For subclonning the bisulfite treated DNA sequences the pGEM-T easy vector 
(Promega) was used. For ligation 2 µl of the PCR product, 0.5 µl (25 ng) of vector, 1 µl 
of T4 DNA Ligase (3 Weiss Units/µl) and 5 µl of 2X Rapid ligation buffer, and 2.5 µl of 
distilled autoclaved water were used. Ligation reaction was performed at room 
temperature for 1:30 h. Transformation was carried out using DH5α Competent cells 
(Invitrogen). Minipreps of 10-30 colonies of each condition were carried out. The 
restriction enzyme Pvu I (Fermentas) was used to verify the insertion of the PCR 
fragment on the vector. Five to ten minipreps were then submitted for sequencing using 
the SP6 primer. 
Table 2.3. Plasmids used in this study 
   
PLASMID   NAME PLASMID TYPE REFERENCE ORIGIN 
pORSVI DN STAT5(694F) Expression Sonoyama et al, 2002 Pr. JV Melo 
Mig p210 BCR-ABL plasmid Expression Quackenbush et al, 2000 Pr. JV Melo 
Mig R1 Expression Quackenbush et al, 2000 Pr. JV Melo 
pGL3 Basic Reporter Promega Commercial 
pRL Null Reporter Promega Commercial 
-1296BCL6pGL3 Reporter Mattos et al Pr. E Lam 
BCL6(-4.9/+0.5)pGL3 Reporter Papadopoulou et al, 2010 Dr. SD Wagner 
BCL6(-4.9/+0.2)pGL3 Reporter Papadopoulou et al, 2010 Dr. SD Wagner 
BCL6(-4.3/+0.5)pGL3 Reporter Papadopoulou et al, 2010 Dr. SD Wagner 
BCL6(-4.3/+0.2)pGL3 Reporter Papadopoulou et al, 2010 Dr. SD Wagner 
BCL6(-4.3/∆+0.2)pGL3 Reporter Batlle et al , 2009  
BCL6(+5/+0.2)pGL3 Reporter Batlle et al , 2009  
BCL6(+5/∆+0.2)pGL3 Reporter Batlle et al , 2009  
pcDNA3 Expression Invitorgen Commercial 
pcDNA-hCTCF Expression Torrano et al , 2005 Dr. E Klenova 
pEGFP-C2 Expression Clontech Commercial 
pEGFP-CTCF-FL Expression Torrano et al, 2006 Dr. R.  Renkawitz 
pEGFP-CTCF-ZF Expression Torrano et al, 2006 Dr. R.  Renkawitz 
pEGFP-CTCF-CT Expression Torrano et al, 2006 Dr. R.  Renkawitz 
pGEM T-Easy vector  Promega Commercial 
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 2.6. Transfections 
 
  2.6.1. DG75, MUTU III, BV173 and Z119 cells transfections:  2 to 10×106cells 
were transfected by Nucleofection (Amaxa Gmbh, Cologne, Germany) following the 
company’s recommendations. Briefly, after centrifugation, cells were resuspended in 
100µl of specific transfection buffer (solution T for BV173; solution L for Z119; solution V 
for MUTU III and DG75). Two to ten µg of plasmid are added and then nucleofected with 
specific electrical setting (T-16 program for BV173 and Z119 cells; 0-006 program for 
DG75 and MUTU III cells). 0.5 µg of the GFP (Green fluorescent protein)-Max vector 
was cotransfected to monitor transfection efficiency. After Nucleofection, cells were 
immediately transferred into pre-warmed complete RPMI 1640 medium, left overnight 
and analyzed the day after for transfection efficiency by flow cytometry. Cells were left in 
culture up to 72 hours.  
 
   
Figure 2.2. K562 and DG75 are efficiently transfected (a,b,c and d) K562 cells and (e,f) Dg75 
48 hours after transfection with an empty vector (a,b) or a GFP-max vector (c,d,e and f). GFP 
expression was analyzed by an inverted immunofluorescence microscope . GFP expression was 
used to assess transfection efficiency
a
b
c
d
e
f
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  2.6.2. K562 cells transfections: Ten million cells were also transfected by 
nucleofection (Amaxa Gmbh, Cologne, Germany) as describe above but instead of 
using the Amaxa Nucleofector solution buffer, we used 100 µl of MIRUS Reagent 
(Ingenio Elecroporation solution). Six µg of plasmids were used per nine million cells. 
The T-16 program was used for nucleofection. Transfection efficiency was examined 
using an immunofluorescence microscope.   
 
2.6.3. 293T cells transfections: 
  For luciferase assays, 293T cells were transfected using Lipofectamine 2000 
(Invitrogen), following producer’s instructions. One day before transfection 800000 cells 
were plated on 6 well plates. Before transfection normal medium was replaced with 
medium without antibiotics.  Five µl of Lipofectamine 2000 were resuspended in 250 µl 
of RPMI without FCS or antibiotics on an eppendorf tube and on a different eppendorf 4 
µg plasmids were resupended in 250 µl RPMI. After 5 minutes at room temperature, 
diluted DNA and diluted lipofectamine were combined and incubated for 20 minutes at 
room temperature. The resultant mixture was added to the cells. Four hours later normal 
medium was added, and cells were incubated for 20 additional hours.  
  For Electrophoretic Mobility asays, 293T cells were transfected using jetPEI 
(Genycell Biotech). One day before transfection 800000 cells were plated on 6 well 
plates. Ten µl of jetPEI were resuspended in 250 µl of NaCl 150mM on an eppendorf 
tube and 5 µg of the pEGFP vector or the pEGFP-CTCF plasmid were resupended in 
250 µl of NaCl 150 mM on a different tube. Both tubes were vortexed and incubated for 
5 minutes at room temperature. Then diluted DNA and diluted lipofectamine were 
combined and incubated for 20 additional minutes at room temperature. The resultant 
mixture was added to the cells. Two hours later normal medium was added, and cells 
were incubated for 36 additional hours. Cells were then harvested and washed with cold 
PBS. Transfection efficiency was analyzed by immunofluorescence microscopy, based 
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on the GFP expression. 
 
2.7. Luciferase reporter assays  
 
 2.7.1. In DG75, Z119 and BV173 cells:  4 µg of the pGL3 basic vector 
(Promega) or equimolar concentrations of any of the different BCL6pGL3 constructs, 
were cotransfected together with 7 µg of either the dnSTAT5 plasmid, or the CTCF 
vectors and 0.6µg of the pRL reporter vector (Promega) into ten million cells using the 
Amaxa Nucleofector system as described above. pRL was used as a transfection 
control. Cells were then washed with phosphate-buffered saline (PBS), resuspended in 
50-100µl of 1X passive lysis buffer (promega) and further lysis was performed by 
several freeze-thaw cycles. Then samples were centrifuged (12000 rpm, 15 min at 4˚C) 
and 20 µl of the supernatants were assayed for luciferase activity using the Dual-Glo 
Luciferase Reporter System following the manufacturer instructions (Promega).  
 2.7.2. K562 cells:  K562 cells were co-transfected with 0.5 µg of the pRL-Null 
transfection control vector (Promega) and with either 4 µg of the pGL3 basic vector 
(Promega) or with equimolar concentrations of different BCL6pGL3 constructs, and with 
7 µg of different CTCF constructs using the nucleofector Amaxa Nucleofector system as 
described earlier. After 52 hours of transfection cells were harvested, washed using PBS 
and resupended in 120 µl of 1X passive lysis buffer and further lysis was performed by 
several freeze-thaw cycles. Five µl of the lysates were used to assess luciferase activity 
using the Dual-Glo Luciferase Reporter System in a Luminometer TD 20/20 Turner 
Designs.  
 2.7.3. 293T cells: 293T cells were transfected with 0.4 µg of PRL vector and, 
with either 3.5 µg of the PGL3 basic vector or equimolar concentrations of any of the 
different BCL6pGL3 constructs. Cells were harvested 18-24 hours later and lysed on 
120 µl of 1X passive lysis buffer and by three freeze-thaw cycles. Twenty to 50 µl of the 
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lysates were used to measure the luciferase activity as described above.  
 
 2.8. Protein analysis 
 
  2.8.1. Western blot analysis 
 Cells (2 to 10× 106) were centrifuged at 1500 rpm for 5 minutes, washed once in 
cold PBS and resuspended in RIPA lysis buffer (1% nonidet NP-40,100 mM NaCl, 20 
mM Tris-HCl (pH 7.4), 10mM NaF, 1mM orthovanadate and complete protease and 
phosphatase inhibitors cocktail (Sigma)). Lysates were then incubated on ice for 30 
minutes and centrifuged (12000rpm, 20 minutes at 4˚C). The supernatant was placed on 
a new tube and frozen at -70ºC. One to 10 µl of the lysates were used for protein 
concentration by either Bradford method or Bicinchoninic acid (BCA) kit (Sigma). 3X WB 
Loading buffer (100 mM Tris pH 6.8; 4% SDS; 30% glycerol; 200mm DTT, 0.03% bromo 
phenol blue (BPB) were mixed with 25 to 100 µg of protein in a final volume of 30µl, 
boiled for 4 minutes and separated by vertical electrophoresis (MiniProtean cubette, 
BioRad) on a 1XTGS buffer (25mM Trizma; 192 mM glycine and 1% (w:v) SDS. The 
percentages of the SDS- Polyacrylamide geles varied from 7.5 to 10%, attending to the 
weight of the protein to be analyzed. Proteins were transferred onto either a PVDF 
membrane (Immobilon-P, Millpore, Bedford, MA) or a nitrocellulose membrane 
(Schleicher and Schuell) for 1 hour at 175V using the humid Mini-Protean IITM system 
(Biorad) on transfer buffer (25mM Trizma base; 192mM glycine and 20% methanol).  
 The membrane was blocked, either in 2-5% skimmed milk or 2-5% BSA, in 
1XTBS (Tris-Borate acid-SDS) buffer pH 7.4 for an hour at RT on a shaker, and then 
incubated O/N with the primary antibody (table 2.4) diluted on either 2-5% skimmed milk 
or 2-5% BSA 1XTBS buffer. The day after, the membranes were sequentially washed 
three times for 10 minutes at RT using wash Buffer (1XTBS-T), followed by incubation 
for an additional hour at RT with the secondary antibodies (table 2.5), conjugated either 
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with HRP or with infrared dyes, on a 1XTBS-1%SDS solution. Specific bands were 
visualized either using the enhanced chemiluminescence system (ECL, GE 
Healthcare)/developer or the Odyssey imaging system (LI-COR) which detects infrared 
fluorescence. 
 In order to re-incubate with additional antibodies, membranes were washed with 
wash buffer for 5 minutes, incubated with Restore Plus Stripping buffer (Pierce) for 10-
20 minutes at 37ºC and for 5 extra minutes at RT and washed three times for 5 minutes 
with wash buffer.   
 For protein loading control, the blots were restained with either anti-GAPDH, 
anti-ABL or anti-Actin antibody. Specifications and dilutions used of the different 
antibodies included in this study are shown in table 2.5. 
 Comercial positive controls for JNK and phospho-p38 were purchased from 
Santa Cruz Biotechnology. Anti-IgM treated Ramos was used as a positive control for 
Erk1/2. 
 
  2.8.2. Immunofluorescence assays. 
  A suspension of 5x105 cells was centrifuged at 1.500 rpm, resuspended in 10 µl 
of PBS, placed on a micro-slide (Thermo-Scientific) and allowed to dry. Cells were then 
fixed with either cold methanol for 10 minutes at -20ºC or 3.7% paraformaldehyde in 
PBS for 10 minutes at RT and, in some cases, permeabilized with 0.5% triton X-100. 
Slides were washed 3 times for 5 minutes in cold 1%FCS-PBS, incubated with the 
primary antibody for 1 hour at RT, washed 3 times for 5 minutes in cold 1%FCS-PBS 
and incubated with the second antibody for 1h at room temperature. Following further 
washing slides were mounted with the anti-fading Vectashield medium (Vector 
Laboratories) with DAPI to visualize the nucleus. Cells were analyzed on 
immunoflurescence microscope (Zeiss).  
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Table 2.4. Primary antibodies used in this study 
PRIMARY ANTIBODY TYPE COMPANY Aplication CATALOG NUMBER DILUTION 
Anti-BCL6 N-3  Rabbit polyclonal Santa Cruz Biotechnology WB sc-858 1:100 
Anti-STAT5 (c-17) Rabbit polyclonal Santa Cruz Biotechnology WB sc-835 1:250 
Anti-Phospho-
STAT5(Tyr694) Rabbit polyclonal  Cell Signalling  Technology 
WB #9351 1:500 
Anti-phospho p38 MAPK 
(Tyr180/Tyr182) Rabbit Monoclonal Cell Signalling Technology 
WB #9215 1:1000 
Anti-p38 MAPK Rabbit Polyclonal Cell Signalling Technology WB #9212 1:1000 
Anti-Phospho-SAPK/JNK 
(Thr183/Tyr185) (81E11)  Rabbit Monoclonal Cell Signalling Technology 
WB #4668 1:1000 
Anti-SAPK/JNK  Rabbit Polyclonal Cell Signalling Technology WB #9252 1:1000 
Anti-Phospho-p44/42 
MAPK (Erk1/2) 
(Thr202/Tyr204) 
Rabbit Polyclonal Cell Signalling Technology 
WB 
#9101 1:1000 
anti-p42/44 MAPK 
(ERK1/2) Rabbit Polyclonal Cell Signalling  Technology 
WB #9102 1:1000 
Anti-phospho-c-Abl 
(Tyr412) (247C7) Rabbit Monoclonal Cell Signalling Technology 
WB #2865 1:1000 
Anti-c-Abl (24-11)  Mouse Monoclonal Santa Cruz Biotechnology WB Sc-23 1:100 
Anti-IRF4 Rabbit Monoclonal Cell Signalling Technology WB #4964 1:1000 
Anti-BCL-xL (54H6) Rabbit Monoclonal Cell Signalling Technology WB #2764 1:1000 
Anti-CTCF Mouse Monoclonal BD Biosciences 
WB 
EMSA 
612148 1:250 
Anti-CTCF 
 
Mixture of 9 different 
monoclonal antibodies Pugacheva et al, 2005 
CHIP 
 1:20 
anti-Actin (I-19) Mouse Polyclonal Santa Cruz Biotechnology 
WB 
EMSA 
sc-1616 1:1000 
Anti-GAPDH Rabbit Monoclonal Cell Signalling  Technology WB #2118 1:2000 
Anti-H3 AC Rabbit Polyclonal Millpore CHIP 06-599 1:20 
Anti H3K4me2 Rabitt Polyclonal Abcam CHIP 32356 1:20 
Anti H2A.Z Rabbit Polyclonal Abcam CHIP 4147 1:20 
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Table 2.5. Table of secondary antibodies used in this study 
SECONDARY ANTIBODY COMPANY CATALOG NUMBER DILUTION 
Anti mouse IgG HRP-linked 
secondary antibody Cell Signalling Technology #7076 1:2000 
Anti-Rabbit HRP-linked secondary 
antibody Cell Signalling Technology #7074 1:2000 
IRDye 800CW Goat Anti-Mouse 
Secondary Antibody LI-COR Bioscences  926-32210 1:1000 
IRDye 680CW Donkey Anti-Mouse 
Secondary Antibody LI-COR Bioscences 926-32222 1:10000 
IRDye 680 Donkey Anti-Rabbit 
Secondary Antibody LI-COR Bioscences  926-32223 1:10000 
IRDye 800 Goat Anti-Rabbit 
Secondary Antibody LI-COR Bioscences 926-32213 1:10000 
Goat Anti-Mouse IgG (H+L), 
DyLight 680 Conjugated Thermo Scientific 35518 1:10000 
Goat Anti-Mouse IgG (H+L), 
DyLight 800 Conjugated Thermo Scientific 35521 1:10000 
Goat Anti-Rabbit IgG (H+L), 
DyLight 680 Conjugated Thermo Scientific 35568 1:10000 
Goat Anti-Rabbit IgG (H+L), 
DyLight 800 Conjugated Thermo Scientific 35571 1:10000 
  
 
 2.9. RNA analysis by reverse transcription (RT) and real-time PCR  
 
 Total RNA was isolated by using the RNeasy kit (Qiagen) and DNase I treated 
(Invitrogen). 2 µg RNA were mixed with a master-mix solution containing 1XBuffer RT, 
0.5mM of each dNTPs, Oligo dT-Primer 1 µM, RNase inhibitor 10 Units/20 µl reaction, 
RNase free water and reverse transcribed by 4U/20 µl reaction of the omniscript reverse 
transcriptase (Qiagen) at 37ºC for 1h. cDNA samples were stored at -20ºC. The cDNA 
obtained was then used in real time quantitative PCR analysis using either Taqman or 
SYBR-Green approaches.  
 Taqman:  Primers (Table 2.6) and probes mixtures were purchased from 
Applied Biosystems. Amplifications were performed on an ABI Prism 7700 Sequence 
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Detector (Applied Biosystems) for 10 minutes at 95˚C, 2 minutes at 50˚C, followed by 40 
cycles of 15 seconds at 95ºC and 1 min at 60ºC. Single reactions contained 12.5 µl of 
Taqman buffer 2X; 1.25 µl of Primer-Probe mix; 4µl of cDNA and 7.25 µl of water. 
Triplicates of all conditions were performed.  
 SYBR green: Primers were designed using the primer 3 program according to 
PCR standard guidelines (length 18 to 25 bp; GC content 40 to 65%; no G at a 5´ end; 
avoiding secondary structures; Tm: 50 to 65ºC) and properly tested using a pool control 
cDNA sample. A PCR mix was prepared (44 µl final volume, used for two duplicate 
reactions) containing 22 µl of 2X SYBR® Green RT-PCR Reaction Mix, 0.3 µM of 
specific primers, 2 µl of cDNA and 17.4 µl of destilled water. Twenty µl per well were 
loaded on a 96 well plate. PCR was performed on a Bio-Rad iCycler (Bio-Rad) 
thermocycler as follows: 95ºC 10 min; [95ºC 5 min; 55-65ºC 30 s] 40 cycles; 95ºC 1 min; 
55ºC 1 min; for melting curve [55ºC 10 s decreasing by half a degree each cycle] 80 
cycles.  
Results were analyzed and expressed by comparative DeltaDeltaCt (∆∆Ct) method: 
 *deltaCT1 = CT (target condition 1) - CT (normalizer condition 1; S14 or HRTP1).  
 deltaCT2 = CT (target condition 2) - CT (normalizer condition 2; S14 or HRTP1). 
 ** delta delta CT: delta Ct1-delta Ct2 
 ***comparative expression level = 2 –∆∆CT 
 ****Standard deviation= √(SD1 2+SD2 2) 
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Table 2.6. Primers used in this study. 
Name Primers RS Aplication 
Myc N 5´-ACAAGGAGGTGGCTGGAAAC-3´ 3¨-GCGTTCAGGTTTGCGAAAG-5´  
ChIP 
 
H.1 
Gombert 
5´-CAACGCAACACAGGATATGG-3´ 
3´-TTCCCCTCCTGGCTTTTAGT-5´  
 
CHIP 
CTCF1 
5´-GGACCTGAAGCCAAAGAACA-3´ 
3´-AAGTTTCGGACTCCTCCACA-5´  
ChIP 
EMSA 
CTCF2 
5´-GGACCTGAAGCCAAAGAACA-3´ 
3´-AAGTTTCGGACTCCTCCACA-5´  RT-PCR 
BCL6 
4.9 to 
+∆0.5 
5´-GCTAGCCAGCTCCTTTCCACTCCTCTCG-3 
5´-TCAGATCTAGTGTCCGGCCTTTCCTAGAAACTTTGCGTATAGCCAC-3´ 
 
Nhe1 
BglII 
Clonning 
 luciferase vector 
 
BCL6 
+2/+0.5 
5´-GCCCCTCGAGCCTCGAACCGG-3´ 
5´-GATCAAGCTTAGTGTCCGGCCTTTCCTAGAAACTTCTTGCATCACC-3´ 
XhoI´ 
HindIII 
Clonning 
 luciferase vector 
 
BCL6 
+2/∆+0.5 
5´-GCCCCTCGAGCCTCGAACCGG-3´ 
5´-TCAAGCTTAGTGTCCGGCCTTTCCTAGAAACTTTGCGTATAGCCAC-3 
XhoI 
HindIII 
Clonning 
 luciferase vector 
 
BCL6 
(Taqman) (Hs00153368_m1)Applied Byosistems  RT-PCR 
BCL6 
(E3-E4) 
5´-AGAGCCCATAAAACGGTCCT-3´ 
3´-AGTGTCCACAACATGCTCCA-5´  RT-PCR 
HRTP-1 
(Taqman) (hs99999909_m1)Applied Byosistems  RT-PCR 
´RPS14 5´-TCACCGCCCTACACATCAAACT-3 `3´-CTGCGAGTGCTGTCAGAGG-5  RT-PCR 
NFkB  5´-AGTTGAGGGGACTTTCCCAGGC-3´ 5´-GCCTGGGAAAGTCCCCTCAACT-3´  EMSA 
PU.1 5´-GCTGCTTCTGGTCCAAACAT-3´ 3´-CCCTCCTACTCATCCCTGAA-5´   ChIP 
PU.2 5´-CTGCACTGCAATTGCCTTTA-3´ 3´-GCACTACACGCAGCACAGTC-5   ChIP 
PU.3 5´-CACTTCAGCAAAAGTCCAAGG-3´ 3´-CGTGCCTTTTCTTTCCCTATC-5´  ChIP 
PU.4 5´-AACCTCTCGCTCCCTTTTGT-3´ 3´-TGACATAAGAGGGGGAGTGC-5  ChIP 
BSP8 5`-GGAGGGAGAGTTATTTTTAGGT-3´ 5´-ACAACAACAACAATAATCACCT-3´  Bisulfite assay 
……………………………………………………………………………………………  . 
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2.10. Chromatin Immunoprecipitation (ChIP) assays  
 
ChIP assays were performed using a modified version of the Upstate 
Biotecnology protocol. Briefly, between 5 x107 to 108 cells (Niu et al., 2003) were 
harvested, resuspended in 1%formaldehide/ PBS and incubated for 10 minutes in 
agitation. Glycine was added to a final concentration of 0.125 mM and incubated for 10 
additional minutes. Cells were centrifuged, washed twice with cold PBS and resupended 
in 200 µl of lysis buffer (10mM EDTA, 50mM Tris-Cl pH 8 and 1% SDS) containing 
protease inhibitors cocktail (1:100; Roche), homogeneizated  by passing the lysate 5 
times through a blunt 20 gauge needle and incubated 10 minutes on ice.  Lysates were 
then sonicated using a Bioruptor (Diagenode) at the maximum setting for 10 minutes (30 
seconds on-30 seconds off) for three times on ice cold water, leading to fragments 
between 250-1000 bp. Lyates where then centrifuged for 10 minutes at 10000 rpm and 
supernatant was afterwards diluted 10 times with the dilution buffer (2mM EDTA, 
150mM NaCl, 20mM Tris-HCl pH 8, 1% Triton X 100, 0.01% SDS and protease 
inhibitors cocktail). Ten percent of this solution was used as INPUT control. Antibodies 
were added to the diluted lysates and incubated for 18 hours with rotation at 4ºC. A 
mixture of 9 different monoclonal antibodies (Pugacheva et al., 2005) was used to 
immunoprecipitate CTCF. Characteristics of all antibodies employed in this study are 
detailed in Table 2.4. In every experiment one sample without antibody was 
incorporated as a negative control. Seventy five µl of “Dynabeads® Protein G” were 
mixed with 35 µl of Sperm DNA salmon (Upstate), incubated 1 h at 4ºC, added to the 
antibody-chromatin mix solution and incubated for 4 additional hours at 4ºC with 
rotation. Afterwards beads were sequentially washed for 5 minutes with rotation using 1 
ml of Low salt wash Buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 1% Triton X-100, 
20 mM Tris-HCl pH 8 and 150 mM NaCl), High salt wash Buffer (0.1% SDS, 1% Triton 
X-100, 2mM EDTA, 1% Triton X-100, 20 mM Tris-HCl pH 8 and 500 mM NaCl), LiCl 
wash Buffer (0.25M LiCl, 1% NP-40,1%NaDOC, 1mM EDTA, 10mM Tris-HCl pH 8)  and 
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two washes with  1 X TE buffer. Protein-DNA complexes where then eluted using freshly 
prepared elution buffer (1% SDS and 0.1 M NaHCO3) for 30 minutes at 65º and then 
cross link was reverted by addition of 5M NaCl to the elutes and incubation at 65ºC 
overnight. Beads were removed using a magnet and lysates were treated with 
proteinase K at 45ºC for 3 hours. DNA was purified using “Wizard® SV PCR Clean-Up 
system” (Promega), using 120 µl of H2O for elution.  
Eluted DNA was then analyzed by real time-PCR. PCR was performed in 
duplicates with equal amounts of specific antibody immunoprecipitated sample, control 
(sample with no antibody) and Input. The CTCF target site oligonucleotides used were 
firstly optimized using genomic DNA as template. The primer sequences utilized are 
detailed in Table 2.6. The -5.9 Kb upstream region (H1site) on the c-myc gene (Gombert 
et al., 2003) was used as a negative control. The Myc N CTCF Binding site was used as 
a positive control (Ohlsson et al., 2001). The comparative cycle threshold approach was 
used for the data analysis as described above (Fitzpatrick et al., 2007).  The relative 
enrichment of a particular sequence was obtained using the following formula:  
2(CT Input- CT immunoprecipitated sample)  
where CT is the number of cycles needed to rise the threshold. Fluorescent levels 
obtained by amplification of the “non-antibody sample” were used to normalize the 
fluorescent levels of the rest of the samples.  
 
2.11. Electrophoretic mobility shift assay (EMSA) 
 
2.11.1. Preparation of radiollabelled probes 
T4 method: Oligonucleotides were storaged at a 100 µM stock solution. 1 µl of 
each oligonucleotide stock solution was mixed with 98 µl of annealing buffer (10mMTris; 
1mMEDTA; 50mM NaCl pH 8), and boiled for 5 minutes letting cold down at room 
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temperature for 8 hours. In order to radiolabel the probe 10 µl of the template DNA was 
mixed with 1 µl of T4 polynucleotide kinase (PNK), 2 µl of 10X T4 PNK buffer and 2 µl of 
the radio-isotope 32P, and incubated for 30 minutes at 37ºC. To eliminate labelled 
nucleotides not incorporated to the DNA probe the reaction was passed through a 
Illustra Probe Quant column (GE Healthcare) following manufacturer’s instructions. 1 µl 
of the elution was diluted with 19 µl of TE buffer, and of this 1 µl was used for a 20 µl 
final EMSA volume reaction, so the final amount used per reaction was 0.05 pmole of 
the 32P-labelled probe. 
 
PCR method: A 198 bp radioactive labelled probe was obtained by PCR from 
genomic DNA. Primers sequences are detailed on table 2.6. PCR was performed in a 
final volume of 50 µl containing 3 µl of the [α-32P]dCTP (Hartman Analytic), 200 ng of 
genomic DNA, 0.2 mM each dNTP, 0.5 µM of each primer and 1 U of DFS-Taq DNA 
Polymerase (Bioron) with the following PCR conditions: 95ºC for 2 min,40 cycles (95ºC 
30s, 65ºC 30s and 72ºC 30s) and 72ºC 1min. The efficiency and quality of the PCR was 
assesed by running on a gel the product of a PCR which didn’t contain radioisotope that 
was performed in parallel with the radioactive one.  The PCR fragments were purified 
using “Wizard® SV PCR Clean-Up system” and eluted with 50 µl of distilled water.  
 
2.11.2. Nuclear extracts: Nuclear extracts were obtained from transfected 
HEK293T cells as described earlier. Cells were resuspended with Buffer 1 (HEPES 
10mM; KCl 10mM; EDTA pH8 0.25mM, EGTA-K pH 8 0.125M, Spermidine 0.5 mM, 
NP40 0.1%, DTT 1mM and protease inhibitors 1:100) vortex and incubated 10 minutes 
on ice.  Cells were then centrifuged 5 min at 1500 rpm. Supernatant was removed and 
pellet was resupended in 50 µl of buffer 2 (HEPES 20mM; NaCl 0.4M; EDTA 0.25 mM, 
MgCl2 1.5mM, DTT 0.5 mM and proteinase inhibitors  1: 100) and incubated 1 hour with 
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rotation at 4ºC. Samples were afterwards centrifuged for 20 minutes at 15000 rpm. 
Supernatant was then placed on a clean tube and frozen at -70ºC until used. 
 
2.11.3. EMSA reaction: Binding reactions were performed by mixing 1 µl of the 
nuclear extract with EMSA buffer (1.5 µg of poli-dIdC, 20 mM HEPES pH 7.5, 50 mM 
KCL, 5% Glycerol, 0.175mM EDTA) and with either water or cold competitor or 1 µl of 
anti-CTCF antibody (Table 2.4), or 1 µl of the anti-Actin antibody (Table 2.5) and 
incubated on ice for 10 minutes. Later 1 µl of the probe was added to each condition and 
the resulting mixture was incubated for 30 additional minutes. Samples were 
electrophoresed on a vertical non-denaturing 4% poly-acrylamide gel (160V for 2 hours) 
in 0.5X Tris-borate-EDTA (TBE) buffer. Gels were fixed using 10% acetic buffer for 10 
minutes and then dried for 30 minutes (BioRad). Bands were obtained by exposing an 
X-ray film for 18-24 hours. 
 
2.11.4. Preparation of methylated probes 
Probes were methylated using the Sss I methyltransferase (New Engalnd 
Biolabs) as follows: Five µl of the purified probe were incubated with 3 µl of NEB buffer 
2, 3 µl (12U) of SssI (3 µl of H2O in the case of the control probe), 1 µl of SAM (S-
adenosylmethionine; 1 µl of H2O in the case of the control probe) 32mM and18 µl of 
distilled water for 4 hours at 37º. After this process 3 µl of NEB buffer 2, 3 µl (12U) of the 
SssI (3 µl of H2O in the case of the control probe), 1 µl of SAM 32mM (S-
adenosylmethionine; 1 µl of H2O in the case of the control probe) and 23 µl of distilled 
water were additionally added and incubated for 4 hours at 37ºC. This process was 
repeated again after 4 hours. The reaction was ended by heating at 65ºC for 20 minutes. 
Probes were afterwards purified using the Wizard® SV PCR Clean-Up system”, eluting 
with 50 µl of H2O. The New Englanb Bioloab Program (http://tools.neb.com/NEBcutter2) 
was used to find which CpG methylation sensitive enzymes were adequate to verify the 
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methylation status of both the control and Sss-I treated probe. Digestions with 1,5 U of  
SmaI or  HinP1I or (Hin6I) and PmlI (Eco71I) and 5 µl of the purified probe were left 
overnight and run on a vertical non-denaturing 8% poly-acrylamide gel for 2:30h in 0.5X 
TBE buffer.  
 
2.12. Bisulfite Genomic Sequencing  
Genomic DNA was obtained from lymphoma cell lines and samples from 
lymphoma patients (Figure 2.3) using the DNeasy Blood & Tissue Kit (Qiagen; ref: 
69506). Bisulfite conversion was performed using the commercial kit EZ DNA 
Methylation-Gold Kit Zymo Research Cat No D5005 following manufacturers instructions 
(Figure 2.3).  
Figure 2.3. Algorithm used for the bisulfite methylation analysis. 
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            Briefly 500 ng of genomic DNA were mixed on a PCR tube with 130 µl of CT 
conversion reagent. Tubes were placed on a thermal cycler and the following sequential 
steps were followed: 98ºC 10 minutes, 64ºC 2.5h. The resulting product was loaded on 
a Zymo-Spin™ IC Column containing 600 μl of M-Binding Buffer. After inversion of the 
tube samples were centrifuged for 10 minutes and then 100 μl of M-Wash Buffer were 
added to the column. After centrifuging, samples were incubated for 20 minutes at room 
temperature with 200 μl of M-Desulphonation Buffer. Columns were washed twice using 
the M-wash buffer. Ten µl of M-Elution Buffer were used to elute the bisulfite treated 
DNA. These samples were kept at -70º until used.  
BSP primers were designed using the methyl primer express software (Applied 
Byosistems). The specific oligonucleotides were optimized using bisulfite treated 
genomic DNA from K562 cell line. The sequences of the oligonucleotides are specified 
on Table 2.6. Five µl of the bisulfite modified DNA was amplified using the Expand High 
Fidelity PCR System (Roche; ref: 11 732 650 001). PCR conditions were as follows: 
95ºC for 2 min, 40 cycles (95ºC 30s, 59ºC 30s and 72ºC 30s) and 72ºC 1 min.  PCR 
products were in some cases sent for direct sequence. In other cases the PCR products 
were cloned into the pGEM-T easy vector as described earlier. 
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CHAPTER 3. CML lymphoid blast crisis cell lines as model 
systems to define the effects of BCR-ABL mediated signalling 
on BCL6 expression. 
 
3.1. INTRODUCTION 
 
The BCR-ABL oncogene is the result of a balanced translocation between 
chromosomes 9 and 22 t(9;22), that gives rise to a BCR-ABL fusion oncoprotein with 
constitutive tyrosin kinase activity  Professor Melo´s group at the Hammersmith Hospital, 
whilst investigating the effects of the BCR-ABL tyrosine kinase inhibitor, Imatinib in 
BCR-ABL positive cells have unexpectedly found a relationship between BCL6 and 
BCR-ABL. This was derived from expression profiling of genes transcriptionally 
regulated by BCR-ABL using differential display to compare the mRNA profile of the 
lymphoblastic CML cell line BV173 treated with Imatinib, with that of untreated control 
cells (Deininger et al., 2000a). As a result, BCL6 mRNA and protein were found to be 
up-regulated upon inhibition of BCR-ABL tyrosine kinase in these cells. On the basis of 
this result, they investigated whether the pattern of BCL6 mRNA up-regulation was 
restricted to BV173 cells. They tested 14 CML or Ph-positive ALL cell lines exposed or 
not to 1µM imatinib for 24 hours by northern blotting. BCL6 was found to be consistently 
upregulated in 7 out of 8 Ph-positive lymphoid lines tested upon BCR-ABL inhibition 
(Figure 3.1.). The only exception was SD1, a cell line previously shown to be resistant to 
Imatinib. In contrast, BCL6 repression by BCR-ABL was confirmed when Imatinib was 
withdrawn. Furthermore, when BCL6 expression was tested in the imatinib-resistant 
subline BV173-r8 its expression was found not to be up-regulated.  
In confirmation of these preliminary results, Walker et al, (Walker et al., 2007) 
and Mattos et al (Fernandez de Mattos et al., 2004) have also demonstrated that BCL6 
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is upregulated in BV173 cell line on treatment with Imatinib appears to be, therefore a 
suitable model system for analysing the regulation of BCL6 expression. 
 
For this reason, we used the BV173 cell line and other lymphoid BCR-ABL 
expressing cell lines, in the presence and absence of Imatinib, to investigate the 
signalling pathways involved in the regulation of BCL6 and to determine how the 
patways controlling BCL6 expression are integrated. 
Figure 3.1. BCL6 is induced in lymphoid blast crisis of CML by Imatinib. Northern showing 
BCL6 mRNA expression (upper panel) in contrast to a control gene (lower panel)  in seven BCR-
ABL positive cell lines (BV173, Nalm1, Tom1, MIK/ALL, My,SD1 and CML-T1) and two BCR-ABL 
negative (REH and 697) when treated (+) or non treated (-) with 1µM Imatinib1 for 24h. This is a 
result from the thesis of Sara de Almeida Deus Vieira.
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3.2. RESULTS 
 
3.2.1. Imatinib induces BCL6 expression in CML lymphoid blast crisis cell 
lines and primary cells 
In order to find out if the results of (Deininger et al., 2000b) and (Fernandez de 
Mattos et al., 2004) could be extended various cell lines were treated with different 
concentrations of Imatinib for different lengths of time. All BCR-ABL lymphoid blast crisis 
cell lines tested showed induction of BCL6 protein expression on treatment with 0.5 µM 
of Imatinib (Figure 3.2.a), and this was largely due to increases in BCL6 transcription 
(Figure 3.2.b). The BCR-ABL myeloid cell lines tested showed no induction of BCL6. 
Figure 3.2. Imatinib induces BCL6 expression in CML lymphoid blast crisis cell lines (a) BCL6 
expression in two lymphoid blast crisis of CML Ph+ cell lines with a p210 BCR-ABL transcript (BV173, 
Nalm-1), three acute lymphoblastic leukemia Ph+ cell lines with a p190 BCR-ABL transcript (Z-33, Z119, 
Tom-1), 1 erythroid blast crisis of CML cell line (K562) and 1 acute myelogenous leukemia Ph negative 
(MV4;11) after treatment with the indicated amounts of Imatinib for 24 hours. BCL6 expression was 
analyzed by Western blot. GAPDH was used as loading control (b) RT-qPCR analysis for the BCL6 was 
performed on BV173 cells after treatment with 1µM of Imatinib for different lengths of time as indicated. 
Values are expressed as BCL6/HPRT ratios. Triplicates of all conditions were performed.
BV173
Z119
Z-33
Nalm-1
K562
MV4;11
GAPDH
0 0.5 1 2 5
TOM-1
ba
Imatinib (µM)
BCL6
0
2,5
5
7,5
10
 O 1 2 4 8 12 24
Time(h)
B
C
L6
 m
R
N
A
re
la
tiv
e
ex
pr
es
si
on
……………………………………………………………………………………………  . 
104 
           To examine whether this phenomenon was restricted, or not, to cell lines, primary 
cells from a patient with lymphoid blast crisis of CML were investigated. These cells 
were predicted to have normal sensitivity to Imatinib because sequencing showed that 
there were no mutations on the BCR-ABL kinase domain. Sequencing was carried out 
by Natalie Rossi (Department of Haematology; Hammersmith Hospital). These cells also 
demonstrated increased BCL6 expression on treatment with Imatinib, demonstrating 
that the effects I observed were not simply a feature of transformed cell lines (See below 
Figure 3.6.c). 
BV173 and Z119 cell lines were selected to carry out further work. Both cell lines 
represent different diseases and express different BCR-ABL transcrips: BV173 derives 
from a lymphoid blast crisis of CML and expresses a p210 BCR-ABL transcript 
(Pegoraro et al., 1983) whilst Z119 is an acute lymphoblastic leukaemia cell line that 
displays a p190 transcript (Estrov et al., 1996). BV173 has low basal BCL6 expression 
but Z119 has intermediate BCL6 basal expression (Figure 3.2.a).  
 
3.2.2. BCR-ABL downstream pathways as potential regulators of BCL6 
The PI3K/Akt/FoxO3a pathway has already been implicated in BCL6 regulation 
in the BV173 cell line (Fernandez de Mattos et al., 2004). Other important targets of 
BCR-ABL such as ERK1/2 or STAT5 have been previously associated with the 
regulation of BCL6 in other cell lines (Niu et al., 1998; Scheeren et al., 2005; Walker et 
al., 2007) and, therefore, other major BCR-ABL signaling pathways might also contribute 
to the regulation of BCL6 in lymphoid blast crisis cells.  
Several downstream BCR-ABL pathways, including the Ras/Raf/MEK, the 
PI3K/AKT/mTOR and the JAK/STAT5, have been widely investigated (Steelman et al., 
2004). In order to investigate candidate molecules regulating BCL6, these major BCR-
ABL pathways were analyzed (Figure 3.3). In agreement with previous results (Parmar 
et al., 2004; Steelman et al., 2004), we found that Imatinib reduced phosphorylation of 
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STAT5 and AKT, but that p38 MAPK was relatively resistant to the effects of this drug 
(Figure 3.3). In BV173 and Z119, despite BCR-ABL, there was no detectable phosho-
ERK1/2 or phospho-JNK. This is surprising because the ERK1/2 pathway has been 
implicated in BCR-ABL mediated transformation (Cortez et al., 1997). However, there is 
also evidence that ERK1/2 is not active in primary cells from CML patients (Platanias, 
2003; Towatari et al., 1997). Therefore, the effects of STAT5, PI3K/AKT/mTOR and p38 
MAPK on BCL6 expression were investigated in more detail. 
    
 
3.2.3. STAT 5 upregulates BCL6 in CML Lymphoid blast crisis cell lines. 
 STAT5 upregulates BCL6 in primary tonsilar B-cells (Scheeren et al., 2005) but it 
appears that it downregulates BCL6 in cell lines (Walker et al., 2007). It is known that 
BCR-ABL phosphorylates STAT5 (Steelman et al., 2004) and consistent with this finding 
western analysis showed that Imatinib led to dephosphorylation of STAT5 (Figure 3.4.a).  
Figure 3.3. Inhibition of BCR-ABL signalling pathways by Imatinib. Activation of  BCR-ABL, STAT5, 
P38, ERK1/2,  JNK1/JNK2 and  AKT  on BV173 cells in basal conditions and after 6h of treatment with 1 
µM Imatinib were analyzed by western blot using specific phospho-antibodies.
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 These results raise the possibility that induction of BCL6 expression by Imatinib 
occurs through dephosphorylation of STAT5 in these cells. In order to pursue this idea, 
Z119 cells, which have detectable basal expression of BCL6, were transiently 
transfected with a mammalian expression vector encoding a dominant negative mutant 
of STAT5. Interestingly, both mRNA and protein levels of BCL6 were constantly 
downregulated by the dominant negative STAT5 (Figures 3.4.c and 3.4.b). Moreover 
reporter assays using a construct containing the BCL6 promoter region (-
Figure 3.4. STAT 5 induces BCL6 in CML lymphoid blast crisis cell lines (a) Effect of Imatinib on BCL6 and 
pSTAT5 expression in BV173 cells when exposed to 5 µM Imatinib for the indicated lengths of time (b) BCL6 
protein expression in Z119 cells after transfection of the indicated amounts of a truncated form of STAT5 
analyzed by western blot.  (c) RT-qPCR showing BCL6 mRNA expression normalised to HPRT after 
transfection of 6 µg of a dominant negative STAT5 at different time-points (Column 1: untransfected; Column 2:
transfected with GFP-max control plasmid; Columns 3,4 and 5: harvested at 4, 8 and 12 hours respectively) (d)
Reporter activity in Z119 cells after co-transfection with -1296Bcl6Pgl3 (BCL6 promoter reporter construct) and 
different amounts of a dominant negative form of STAT5 (Upper Bar :-1296Bcl6Pgl3 vector alone; The rest of 
the bars show -1296Bcl6Pgl3 vector together with 3, 6 and 9 µg of the dominant STAT5 plasmid respectively). 
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1296BCL6pGL3), which includes several STAT5 binding sites (Scheeren et al., 2005), 
showed a remarkable decrease in the promoter activity when Z119 cells transfected with 
the dominant negative STAT5 (Figure 3.4.d).   
 In conclusion, these results suggest that the BCL6 increased expression 
observed in Lymphoid Ph+ cell lines after treatement with Imatinib is not due to the 
STAT5 pathway, since STAT5 becomes dephosphorylated and therefore inactive upon 
treatment with imatinib. Also, the fact that BCL6 is not expressed in BCR-ABL cells in 
basal conditions despite the constitutive activation of STAT5, which induces BCL6 in 
basal conditions, shows that additional strong repressive pathways must be inhibiting 
BCL6 expression in these cells. 
 
3.2.4. m-Tor represses BCL6 expression in Z119 cells.  
The Phosphatidylinositol 3-kinase (PI3K) pathway is another major pathway 
downstream BCR-ABL. Aberrant activation of this pathway has been detected in several 
cancers, and has been demonstrated to be involved in cell growth and survival of cancer 
cells (Engelman, 2009). The LY294002 is a highly specific PI3K inhibitor. In order to 
investigate whether the PI3K pathway was mediating the Imatinib effect on BCL6 
expression, the LY294002 inhibitor was employed in the Z119 cell line. Western analysis 
showed a transient increase of BCL6 protein expression after 30 minutes of treatment in 
Z119 cells (Figure 3.5.a).  
The mammalian target of rapamycin (mTOR) is one of the principal targets 
downstream the PI3K/AKT pathway (Engelman, Nat reviews; 2009). For this reason we 
aimed to examine whether the Imatinib effect on BCL6 expression was performed 
through the PI3K/AKT/mTOR pathway. Z119 cells were treated with rapamycin, and 
once again these cells showed a transient upregulation of BCL6 expression after 4 
hours of treatment (Figure 3.5.b). Therefore, inhibition of mTOR can in part mimic the 
……………………………………………………………………………………………  . 
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effects of Imatinib, implying that phosphorylated mTOR contributes to inhibit BCL6 
expression. 
 
Unfortunately, such effect on BCL6 expression was not observed when the 
BV173 cell line was treated with any of the PI3K Inhibitor (Figure 3.5.c). Since the Z119 
and BV173 cell lines represent two different diseases (Ph+ Acute Lymphoblastic 
Leukemia and lymphoid blast crisis of CML respectively), further studies will be required 
to determine whether the PI3K/mTOR outcome is specific of a  the Z119 cell line, or is  
an effect  observed in other Ph+ ALL cell lines.  
 
Figure 3.5. m-Tor represses BCL6 expression in Z119 cells (a) Western displaying BCL6 expression in 
Z119 cells basal conditions (Lane 1), after treatment with 1 µM Imatinib for 4 hours (Lane 2) or with 50 µM 
LY294002 for different lengths of time (Lanes 3 to 8). GAPDH was used as loading control (b) BCL6 
expression in Z119 cells in basal conditions and after treatment with 50nM Rapamycin for the indicated 
lengths of time, were analyzed by western blot. ABL was used as a loading control (c) BCL6 expresion in 
BV173 cells in basal conditions (lane 1), after treatment with  1µM Imatinib for 4 hours (lane 2) and with 50µM 
of LY294002 at different time points. GAPDH or ABL were used as loading control 
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3.2.5. p38 MAPK induces BCL6 in CML lymphoid blast crisis cell lines 
We reasoned that, because p38 MAPK failed to be dephosphorylated by 
Imatinib, it was a candidate protein responsible for the Imatinib effect on BCL6 
expression. Utilising Z119, a cell line showing basal expression of BCL6, we found that 
a specific inhibitor of p38 MAPK, SB202190, reduced BCL6 expression (Figure 3.6.a) 
under basal conditions, supporting this idea. A prediction derived from this finding is that 
Imatinib and SB202190 will have opposing effects on BCL6 expression.  
Figure 3.6. p38 MAPK induces BCL6 in CML lymphoid blast crisis cell lines(a and b) BCL6 expression
analyzed by western blot in Z119 cells after treatment with 10 µM SB202190 for different lengths of time (a)
and after treatment with SB202190 for the same lengths of time in combination with 1 µM of Imatinib for 4 
hours (b). GAPDH was used as a loading control (c) Cells from a patient with lymphoid blast crisis of CML 
were analyzed for BCL6 expression and phospho BCR-ABL activity by western blotting in basal conditions 
after treatment with Imatinib for 8 and 16 hours, and after co-treatment with SB202190 and Imatinib for 8 
hours and 16 hours (d) RT-qPCR showing BCL6 mRNA expression normalised to HPRT in primary CML cells 
in basal conditions (Column 1), after 4 hours of Imatinib (Column 2), and after  treatment with SB202190 for 6 
hours and 1µM Imatinib for 4 hours (Column 3). Column 4 and 5 show BCL6 relative expression in the non 
BCL6 expressing cell line 293T (C-) and in the BCL6 expressing cell line Ramos (C+), respectively. 
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In addition because SB202190 acts downstream of Imatinib in the signalling 
pathway from BCR-ABL, it will reduce or abolish the Imatinib effect. When Z119 was 
treated with Imatinib and SB202190 for varying lengths of time, BCL6 expression was 
again reduced (Figure 3.6.b) and this effect was also observed in BV173 (not shown) 
and primary lymphoid blast crisis cells (Figure 3.6.c and 3.6.b) confirming the view that 
p38 acts to induce BCL6 expression under both basal conditions and in the presence of 
Imatinib. 
 
3.2.6. Ectopic expression of BCR-ABL leads to BCL6 down-regulation 
 BCL6 has important roles in normal germinal centre B-cells and the germinal 
centre derived non-Hodgkin’s lymphomas. To find out if the findings in CML lymphoid 
blast crisis cell lines could be transferred to germinal centre cells human Burkitt 
lymphoma cell lines, Ramos and DG75 were utilised. Both cell lines have been widely 
used by many researchers and have high expression of BCL6.  
   
  BCR-ABL was ectopically expressed in DG75 cells, with a Mig p210 BCR-ABL 
plasmid. Western analysis revealed that BCL6 expression was down-regulated in 
DG75/BCR-ABL cells (Figure 3.7) by p210. This result  suggests not only that BCL6 
Figure 3.7. Ectopic expression of BCR-ABL leads to BCL6 down-regulation. DG75 cells were 
transiently transfected with different amounts of Mig BCR-ABL p210 plasmid. Cells were harvested 24 hours 
after transfection and western analysis for BCR-ABL, BCL6 and GAPDH was carried out. 
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repression in Ph+ cells is a direct effect of BCR-ABL but also that the same signalling 
pathways that operate in the BCR-ABL cell lines might also be active in the germinal 
centre cells. Next the effects of manipulating STAT5 and p38 in Ramos or DG75 
lymphoma cells were investigated. 
 
3.2.7. STAT5 also regulates BCL6 in germinal centre cells.  
 To examine the STAT5 contribution to BCL6 expression in germinal centre cell 
lines we decided to inhibit STAT5 function using a dominant negative form of STAT5 in 
Ramos and DG75 cells. Transfection efficiency assessed by FACS was between 20-
30% in Ramos cells and 70-90% in DG75 cells after 8 hours of transfection (Figure 
3.8.a).  
Figure 3.8. STAT5 also regulates BCL6 in germinal centre cells (a, b) Flow cytometry analysis of GFP 
expression after 18 hours of transfection with a GPF-Max vector in DG75 and Ramos cells respectively. The 
number in the top left quadrant indicate the percentage of  cells expressing GFP (c) Plot showing GFP 
expression in untransfected DG75 cells. (d) BCL6 expression in two different Burkitt cell lines, DG75 (Left 
panel) and Ramos (Right panel) was analyzed by western after transfection co-transfection with GFP-max 
and with various doses of a truncated form of  STAT5 as indicated. 
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 Western blots showed that BCL6 downregulation could be induced by dnSTAT5 
in both DG75 and Ramos cell lines (Figure 3.8.b). All  results - in CML and B-cell lines - 
are consistent with previous reports (Scheeren et al., 2005) that STAT5 contributes to 
inducing BCL6 in germinal centre cells.  
 
  3.2.8. p38 is important for BCL6 regulation in germinal centre cells. 
   To find out the effects of manipulating p38 on basal BCL6 expression in the 
germinal centre cells the p38 inhibitor SB202190 was employed. BCL6 protein 
downregulation was observed in both DG75 and Ramos cells after treatment with this 
inhibitor (Figure 3.9), indicating that the p38MAPK pathway is also implicated in the 
BCL6 regulation in germinal center cells.  
Figure 3.9. p38 upregulates BCL6 in germinal centre cells (a) BCL6 expression in DG75 cells after 
treatment with 20 µM SB202190 for different lengths of time. (b) Western analysis for BCL6, phospho p38 
and p38 were carried out in Ramos cells after treatment for 6 hours with increasing concentrations of the the 
p38 inhibitor  SB202190 (Lane 1: untreated: Lane 2: 10 µM; Lane 3: 20 µM and Lane 4: 50 µM).
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             As previously reported SB202190 increased p38 phosphorylation (Oster et al., 
2008; Wang et al., 2000), maybe because this inhibitor inhibits p38 inhibition but 
phosphorylation by proteins in the MAPK signalling cascade continues. 
 
 
3.3. DISCUSSION 
 
Much remains to be discovered about the signalling pathways regulating BCL6, 
and they are likely to be very important in determining entry and exit from germinal 
centres and also in the causation of germinal centre derived lymphomas.  
BCL6 has been shown to be upregulated in the CML lymphoid blast crisis cell 
line BV173 when treated with the BCR-ABL tyrosine kinase inhibitor Imatinib mesylate 
(STI571). We and others have shown that BCL6 upregulation is not only observed in 
lymphoid blast crisis of CML but it is also induced in Ph+ acute leukaemia cell lines 
(Figure 3.2.a), indicating that BCL6 expression induced by Imatinib is a general 
phenomenon of BCR-ABL cells bearing a lymphoid phenotype.   
Collectively the data suggests that these different BCR-ABL lymphoid cell lines 
cultured in the presence and absence of Imatinib could be used as inducible systems for 
analysing the regulation of BCL6 transcription.  
 Among the signalling pathways downstream of BCR-ABL are MAPK, JNK/STAT 
and the PI3K pathways. The individual effects of each of these pathways can be 
analyzed by using commercial available specific inhibitors (Figure 3 10).  Dissection of 
these pathways demonstrated that in CML lymphoid blast crisis and ALL Ph + cell lines, 
BCL6 regulation is the result of the concerted action of a number of different signalling 
pathways. STAT5 was shown to be a strong BCL6 up-regulator. However, given that 
STAT5 is inhibited by Imatinib, STAT5 can not be responsible for the increase in 
expression observed as a consequence of Imatinib treatment. Here the function of the 
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p38 MAPK pathway in driving BCL6 expression in ALL and CML BCR-ABL positive cells 
upon treatment with Imatinib was shown for the first time.  
  
 Transfection of a BCR-ABL p210 vector produced a significantly decrease in the 
BCL6 protein expression in germinal centre cells. Consequently, one prediction would 
be that the same pathways running in the CML cells might be also mediating the BCL6 
regulation in the germinal centre cells. Once again, both STAT5 and p38 were shown to 
be inducers of BCL6 in the germinal representative cell line, Ramos. However, they act 
under different circumstances. The effect of STAT5 appears to be overwhelmed by 
negative pathways in CML cells, and in addition it is effectively dephosphorylated by 
Imatinib demonstrating that it cannot mediate the Imatinib effect that prompted this line 
of research. Phosphorylated p38, on the other hand, also causes induction of BCL6, but 
in distinction to other signalling molecules downstream of BCR-ABL, it is not 
dephosphorylated by Imatinib, and is thus available to induce BCL6. Our major 
conclusion is that p38 is an important and previously unrecognised inducer of BCL6. We 
will investigate mechanisms of regulation of p38 in germinal centre B-cell lines in the 
next chapter. 
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CHAPTER 4. CD40 and B-Cell receptor signalling induce MAPK 
family members that can either induce or repress BCL6 
expression 
 
4.1. INTRODUCTION 
 
 The regulation of BCL6 is still not completely understood but is of great interest, 
because disruption of normal BCL6 regulation is an important mechanism in 
lymphomagenesis. Using BCR-ABL positive lymphoid cells as model system, it was 
demonstrated in Chapter 3 that different pathways seem to be working in a co-ordinated 
way to regulate BCL6. Among these pathways, p38 MAPK was an important enhancer 
of BCL6 expression. 
  B-cell receptor (BCR) stimulation in germinal centre cells is known to induce 
BCL6 protein degradation by a mechanism involving the ERK1/2 MAPK signalling 
pathway (Niu et al., 1998). On the other hand, activation of the CD40 signalling leads to 
a decrease in BCL6 expression by activation of the NF-κB/IRF4 pathway. Therefore, 
different pathways are involved in BCL6 regulation, and in this chapter the effects of 
these stimuli on MAPK signalling and BCL6 expression was characterised.  
 
4.2. RESULTS 
4.2.1. Multiple MAPKs, including p38, are induced by anti-IgM in Ramos 
BCL6 regulation in geminal centre cells was analyzed in the Ramos cell line 
which is derived from a human Burkitt´s lymphoma, a lymphoma originated from the 
germinal centre. Ramos cell line is EBV negative, does not have rearranged the BCL6 
locus and express the IgM on its surface (Benjamin et al., 1982). Altogether, these 
……………………………………………………………………………………………  . 
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characteristics indicate that Ramos cells are representative of the GC and appropiate for 
studying the BCL6 regulation and function. 
Westerns to find out how BCR signalling alters phosphorylation of MAPK 
proteins showed increased p38 phosphorylation as well as ERK1/2 phosphorylation 
(Figure 4.1.a). It, therefore, appeared that BCR signalling activated pathways that both 
induce and repress BCL6. In order to test this in more detail I used the specific p38 
inhibitor, SB202190, together with anti-IgM antibody and found that this combination 
reduced BCL6 expression further (Figure 4.1.b).  
Figure 4.1. Multiple MAPKs, including p38, are induced by anti-IgM in Ramos (a) Ramos cells were 
exposed to 10 µg/ml of anti-IgM for different lengths of time.. (b) BCL6 expression on Ramos cells was 
analyzed by western blott in basal conditions (Lane 1), after treatment with 10 µg/ml of anti –IgM for 6 
hours (Lane 2) or after treatment with 10 µg/ml of anti –IgM for 6 hours after 30 minutes of pre-incubation 
with increasing concentrations of either the MEK1/2 inhibitor U0126 (right panel) or the p38 inhibitor, 
SB202190 (Lane 3:10 µm; Lane 4: 20 µm; Lane 5: 50 µm) (left panel).
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           Others (Niu et al., 1998) have found that MEK1/2 inhibition by PD98059 prevents 
the reduction of BCL6 protein expression caused by anti-IgM (Niu et al., 1998) but 
surprisingly U0126, which is also a MEK1/2 inhibitor and would be anticipated to have 
the same effects as PD98059, caused only a minor reversal of the effect of IgM (Figure 
4.1.b), and that increase in U0126 concentration from 10 to 75µM (whilst abolishing 
ERK1/2 phosphorylation) reduced BCL6 expression to that found with anti-IgM alone.  
In order to pursue the cause of this discrepancy we directly compared U0126 
and PD98059 (Figure 4.2). As anticipated both inhibitors abrogated ERK1/2 
phosphorylation, but they differed in their effects on p38: whereas UO126 abolished p38 
phosphorylation, PD98059 had no effect. U0126 is a potent MEK1/2 inhibitor but, at 
higher concentrations, inhibits other pathways including p38 MAPK (Duncia et al., 1998). 
A differential effect on p38 phosphorylation is, therefore, the cause of the observed 
difference in the effects of U0126 and PD98059. BCL6 expression, therefore, integrates 
positive and negative factors. ERK1/2 is a powerful negative regulator of BCL6 and, in 
this system, appears to overwhelm the positive effects of p38, which we identify as a 
positive regulator. 
Figure 4.2. Regulation of BCL6 by different MAPK. Ramos cells were either treated (+) or not (-) with 10 
µM of U0126 (Left panel) or 50 µM of PD98059 (Right panel). 30 minutes later 10 µg/ml of anti-IgM were 
added in some cases (+) to the cell culture for 6 additional hours. Whole lysates were analyzed with the 
indicated antibodies.
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 Activated ERK1/2 regulates BCL6 at a post-translational level, and the inhibitor 
PD98059 has been shown not to affect BCL6 transcription (Niu et al., 1998). We 
measured changes in BCL6 mRNA in order to investigate the mechanism of action of 
p38 MAPK (Figure 4.3). SB202190 and U0126 reduced BCL6 mRNA expression in the 
absence of anti-IgM; a situation in which ERK1/2 are not activated and U0126 is 
predicted to be exerting its effects through p38. SB202190 produced a similar decrease 
in mRNA in the presence of BCR cross-linking (when ERK1/2 are activated), 
demonstrating that although BCL6 protein expression is reduced the major effect of p38 
is to induce BCL6 mRNA transcription. 
Figure 4.3. p38 induces BCL6 expression. Expression of BCL6 mRNA in Ramos cells after treatment 
time with (a) 75 µM of the ERK inhibitor U0126 or with (b) 50 µM of the P38 Inhibitor SB202190 for different 
lengths of time (c) or after preincubation with 50 µM of the P38 inhibitor SB202190 for 30 minutes and then 
treatment with IgM for different lengths of time. BCL6 mRNA expression was analyzed by RT-qPCR and 
normalized to the level of HPRT
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4.2.2. Soluble CD40 ligand induces BCL6 through inducing p38 
 CD40/CD40L interaction is important for GC formation and B-cell survival,.(Foy 
et al., 1994; Nonoyama et al., 1993) These two processes would imply BCL6 
upregulated expression and contrarily previous reports showed that CD40 receptor 
stimulation with membrane bound CD40 ligand (mCD40) ligand leads to downregulation 
of BCL6 (Saito et al., 2007). Different groups using CD40 ligands from a variety of 
sources obtained either stimulation or inhibition of the NFKB pathway in Ramos cells 
(Wang et al., 2008; Zarnegar et al., 2004). Also, stimulation of specific Cd40 epitopes 
resulted in the activation of different signalling pathways and in diverse B cell responses 
(Sakata et al., 2000). Thus, it might be possible that different CD40 stimulus lead to 
produce different signalling outcomes. For this reason we investigated the effects of 
CD40 stimulation on BCL6 expression using CD40 ligands from two different sources. 
Ramos cells were treated with a commercial soluble CD40 ligand (Biovision; 
proteolytically cleaved 18 kDa soluble protein containing 149 aminoacid residues 
comprising the receptor binding TNF-like domain of CDE40L) or cultured on an mono-
layer mouse fibroblast cell line stable transfected with human CD40 ligand 
(mCD40L)(Wang et al., 2008; Zarnegar et al., 2004).  
CD40 stimulation by mCD40L has been reported to reduce BCL6 protein 
expression due to NF-ĸB induced IRF4 activity (Saito et al., 2007). mCD40L on MAPK 
proteins was investigated and showed that ERK1/2, p38 and JNK1/2 MAPK were all 
phosphorylated (Figure 4.4.e). The strong inhibitory effects of phosphorylated ERK1/2 
might, therefore, contribute to the effects of IRF4. Surprisingly, on using the alternative 
soluble CD40L (sCD40L) we found a strong induction of BCL6 protein (Figure 4.4.a), 
rather than the repression seen with mCD40L. This effect was observed over a 
concentration range of 0.1 to 20 µg/ml of sCD40L. sCD40L caused phosphorylation of 
p38 without activating ERK1/2, JNK1/2 or inducing IRF4. We conclude that p38 is an 
important inducer of BCL6, but as with cross-linking of the BCR by anti-IgM, its effects 
are strongly counter-acted by repressors – ERK1/2 and IRF4. In confirmation of this, the 
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addition of the p38 inhibitor, SB202190, to sCD40L completely abolished induction of 
BCL6 (Figure 4.4.b). 
a
BCL6
pP38
P38
pERK1/2
ERK1/2
pJNK1/2
IR4
0 10 16 24 0 10 16 24 0 10 16 24
JNK1/2
10 16 240 10 16 24 0
b
ABL
c d e
Time (h)
f
3 4 5 621
Figure 4.4. Soluble CD40 ligand induces BCL6 through inducing p38. Soluble CD40 ligand and membrane 
bound CD40 ligand differ in their effects on BCL6 expression. Ramos cells were treated with soluble CD40 
(sCD40) (a) or with Soluble CD40 after 30 minutes of preincubation with 10 µM of the P38 inhinbitor SB 202190 
(b) or cocultured with normal non transfected fibroblasts (NTL) (c) or with non transfected fibroblast after 30 
minutes of preincubation with the ERK inhibitor PD98059 (d) or with fibroblasts expressing CD40 ligand
(Mcd40)(e) for the indicated lengths of time. Whole cell lysates were analyzed by western blot using the 
indicated antibodies. ABL was used as  loading control for BCL6 and IR4. (f).EMSA to show the effect of 
sCD40L and mCD40L on NF-kB activation. A commercial probe obtained from Promega, known to bind the NF-
KB subunit p50, a processed product of the p105 precursor, that forms a transcriptionally active heterodimer
with the NF-κB subunit p65. Lane 1: no cell lysate. Lane 2: unestimulated Ramos cells; Lane 3: 4h with sCD40; 
Lane 4; 8h with sCD40; Lane 5: 4h with mCD40L; Lane 6: 8h with mCD40. The shifted band is indicated by the 
arrow.
sCD40 SB202190+sCD40 NTL
NTL
+PD98059 mCD40
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            mCD40L is expressed on the surface of the mouse fibroblast, L-cells. I reasoned 
that interactions of the B-cell line with adhesion molecules on the surface of fibroblasts 
may be important and, therefore, sought effects of this line alone on BCL6 (Figure 
4.4.c). There was a transient decrease in p38 phosphorylation (lane 2; figure 4.4.c), with 
induction of ERK1/2 phosphorylation, without either JNK1/2 or IRF4 induction. Overall 
there was a reduction in BCL6 expression, which was likely to be due to the effects of 
ERK1/2 as BCL6 expression was restored by the ERK1/2 inhibitor, PD98059 (Figure 
4.4.d). ERK1/2 phosphorylation is, therefore, caused, not only by IgM cross-linking (as 
previously reported (Niu et al., 1998), but also by interactions with fibroblast surface 
proteins. However, interactions between the B-cell line and the fibroblast does not 
induce IRF4, which appears to be a specific mCD40L effect.  
IRF4 is activated by the NF-kB pathway (Saito et al., 2007). In order to 
distinguish effects of mCD40L and sCD40L on NF-kB, NF-κB activation was measured 
following incubation with sCD40L or mCD40L using gel shift assays (Figure 4.4.f). Whilst 
both ligands increased NF-kB activation, this was greater with the mCD40L.Taken 
together, these results suggest that IRF4 is induced when NF-kB activity is above a 
certain threshold level. 
 Next to find out if the effects of sCD40L were transcriptional BCL6 mRNA was 
measured. sCD40L causes an increase in BCL6 mRNA expression (Figure 4.5.a). 
Ramos expresses BCL6 at high level under basal conditions and, therefore, a 2-fold 
induction represents a significant increase in mRNA. The fibroblast layer alone produced 
no significant change in BCL6 mRNA (Figure 4.5.b) and mCD40L reduced mRNA 
expression as anticipated (Lossos, 2007) from the induction of IRF4 (Figure 4.5.c). 
Therefore, the effect of sCD40L is transcriptional and largely operates through 
phosphorylation of p38. 
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Figure 4.5. CD40L effects on BCL6  transcription. Ramos cells were treated with (a) soluble CD40 (b) or 
cocultured with normal non transfected fibroblasts or (c) with fibroblasts expressing CD40 ligand for different 
lengths of time. BCL6/HPRT mRNA relative expression was analyzed by RT-qPCR. The fourth column in all 
panels represents the BCL6/HPRT mRNA ratio of the BCL6 non-expressing cell line 293T. 
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4.2.3. Expression of phosphorylated p38 in tonsil 
In order to find out the relationship between BCL6 and phosphorylated p38 in 
primary germinal centres immunocytochemistry of human tonsil (Figure 4.6) was 
performed with the help of the Department of Histopathology at the Hammersmith 
Hospital.  
Figure 4.6. Immunocytochemistry showing phosphorylated p38 and BCL6 expression in GC. (a)
Staining with anti-phospho p38(x10). Expression occurs mainly in the centrocytes. MZ stands for mantle 
zone and GC for germinal centre. (b) Double staining with anti-phospho p38 (red) and anti-CD20 (brown) 
(x10) (c) Higher power view of germinal centres stained with anti-phospho p38 (red) and surface CD20, a 
pan B marker, (brown) (x60). (d) Staining of the mantle zone with nuclear phospho p38 (red) and surface 
CD20 (brown). (e) double staining with anti-BCL6 (red) and anti phospho p38 (brown)(x10) (f) further high 
power view (x100) from the germinal centre/mantle border stained with anti-phospho p38 (brown) and anti-
BCL6 (red). Cells staining for both proteins are illustrated by black arrowheads. Photographs were taken by 
Professor Kikkeri Naresh
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 There are scattered phosphorylated p38 expressing cells present within germinal 
centres (Figure 4.6.a, 4.6.b and 4.6.c). In contrast, the majority of the cells of the mantle 
zone, a corone of variable thickness which surrondes the germinal centre and 
composed of small recirculating B lymphocytes, cells express phospho-38 MAPK 
protein. Cells that are morphologically centroblasts are negative and there are increased 
numbers of phosphorylated p38 expressing cells within the light zone of the germinal 
centre. Double staining with anti-BCL6 and anti-phosphorylated p38 (Figure 4.6.e, and 
4.6.f) shows that a minor population of BCL6 expressing cells (~10%) express 
phosphorylated p38. It is therefore possible to suggest that activation of the p38MAPK 
pathway in B lymphocytes within the mantle zone might be responsible for turning on 
BCL6 expression.  
 
4.2.4. Site of action of p38 target genes at the BCL6 promoter 
The p38MAPK signalling pathway is known to phosphorylate and activate a 
number of transcription factors. In order to determine which regions whitin the BCL6 
promoter might be influenced due to the p38MAPK luciferase reporter assays were 
carried out. Assays for transcriptional activity of the BCL6 promoter in BCL6 expressing 
cell lines are associated with specific difficulties. It has been recognised that 
transcriptional activity of the BCL6 promoter is lower in BCL6 expressing cell lines than 
in non-expressing cell lines (Arguni et al., 2006) due to the presence of the negative 
autoregulatory BCL6 binding site in exon 1(Wang et al., 2002). Therefore, both BCL6 
non-expressing HEK293T and the BCL6 expressing Burkitt's lymphoma cell line, DG75 
were used.  
In order to mimic p38 activity the compound anisomycin which is known to be a 
p38 activator but is also a protein synthesis inhibitor (Geiger et al., 2005; Hong et al., 
2007; Torocsik and Szeberenyi, 2000) was employed. HEK293T cells were a suitable 
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cell line for these experiments because anisomycin increased the levels of 
phosphorylated p38 MAPK (Figure 4.7.a).  
Luciferase reporter assays examining 5 kb of the BCL6 promoter region from the 
DNase I hypersensitive site 4.4 kb upstream of the transcription start site (HSS-4.4) to 
exon 1, which is about 500 bp downstream of the transcription start site were carried 
out. The activity due to the whole promoter was tested and the effects of deletions of 
either HSS-4.4 or exon 1 or both together were also examined.  
Constructs with exon 1 had 3-fold greater transcriptional activity than those 
lacking this region. Addition of anisomycin, a p38 activator (Figure 4.7.a), induced a 30% 
increase (**Paired tests; p= 0.0012) in luciferase in those constructs containing both the 
DNase I hypersensitive site and exon 1 (Figure 4.7.c).and, as anisomycin acts as well 
as a protein synthesis inhibitor, we concluded that this effect was mediated through p38 
activity and not due to a general reduction in protein synthesis. Although it was not 
statistically significant, inhibition of p38 with the inhibitor, SB202190, decreased the 
luciferase activity below basal levels, suggesting that there may be a small amount of 
resting p38 activity. Despite maintaining a high basal transcriptional activity, those 
constructs without the DNase I hypersensitive site, did not show a significant 
enhancement after addition of anisomycin. On the other hand, deletion of exon 1 
sequence from the 3' portion of the promoter construct (−4904 to +239) caused 
transcription to fall by >60%, making direct comparison with constructs retaining exon 1 
difficult. It was however possible to see that anisomycin had little effect on the 
transcriptional activity of those constructs lacking exon1. Finally constructs containing 
only the exon1 region had no detectable transcriptional activity.  
 These experiments are difficult to interpret for the reasons given, but one 
conclusion is that the p38 effect on BCL6 transcription seems to require both the DNase 
I hypersensitive site and the 5´region of the BCL6 exon1. A binding site for a known 
target of p38, C/EBPβ, within exon 1 very close to the known negative autoregulatory 
binding site for BCL6 was noted (Pasqualucci et al., 2003; Wang et al., 2002) (Figure 
……………………………………………………………………………………………  . 
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4.7.b). Binding sites for PU.1 and CTCF, two other putative p38 targets, are also located 
within the exon 1 region. As PU.1 and C/EBPβ are not expressed in 293T cells, we 
speculated that p38 may operate through an effect on CTCF, but this requires further 
work to substantiate.  
a
Figure 4.7. p38 efffect on BCL6 promoter activity. (a) 293T  cells were treated with 1µg/ml of anisomycin
for different lengths of time. Whole cell lysates were analyzed for pP38 expression. GAPDH was used as a 
loading control. (b) Schematic representation of the BCL6 gene and regulatory region (c) Luciferase assays 
to show the effects of anisomycin and a p38inhibitor on BCL6 transcription. 293T cells were transiently 
transfected with 4µg of different BCL6pGL3 reporter constructs (the constructs used are indicated on the left) 
and treated the day after with anisomycin for 2 hours (+ indicates treated with anisomycin whereas –
indicates untreated). Means +/- SEM are shown. Each experiment was carried out 6 to 10 times with the 
exception of the p38 inhibitor+full length construct (2 times) and the exon-1 construct +/- anisomycin (2 
times).** Indicates paired-test; p=0,0012.HSS: Hipersensitivity site.
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4.3. DISCUSSION 
 
In this study the effects of BCR and CD40 stimulation on the B-cell line Ramos, a 
germinal centre representative cell line were examined. Cross linking of the BCR 
receptor or stimulation with mCD40L activated various MAPKs, some of which 
repressed (ERK1/2) whilst others induced (p38) BCL6. In most experimental situations 
the repressive signals were stronger than the inductive. By contrast, sCD40L activated 
p38 but not ERK1/2 or JNK1/2, and this caused an increase in BCL6 expression. One 
explanation is that sCD40L and mCD40L may be causing different amounts of CD40 
cross-linking. Also the possibility that mCD40L and sCD40L have different kinetics of 
ligand-receptor association cannot be discounted. These hypotheses are supported by 
previous reports that have shown that different degrees of CD40 signalling can result in 
different biological outcomes. In macrophages strong CD40 signalling resulted in 
activation of p38 whilst weak signals led to ERK1/2 activation, and both have 
antagonistic effects (Mathur et al., 2004). 
Activation of the ERK1/2 pathway is not only produced by IgM cross linking, but 
also by culture with untransfected mouse fibroblasts cells, suggesting that the ERK1/2 
phosphorylation is not a specific BCR mediated effect as had been previously thought.  
Thus, the major B cell stimuli, BCR cross linking and CD40 stimulation, could 
both activate p38. However, both also strongly activated pathways repressing BCL6: 
BCR activated ERK1/2 and mCD40L activated IRF4. The overall effect of BCR 
signalling and mCD40L was to reduce BCL6 expression, whereas sCD40L activated 
p38, without inducing signals repressing BCL6. It is very likely that these different 
signalling pathways are therefore integrated to regulate BCL6 through the different 
phases of the germinal centre reaction.  
p38 was shown in this study to be expressed in almost all mantle zone B-cells. 
Although it is very likely that p38 is not sufficient for BCL6 expression, and might co-
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operate with other factors e.g. STAT5 (Scheeren et al., 2005), activation of the 
p38MAPK pathway might be essential for inducing BCL6 expression in B cells whitin the 
follicule. Interestingly, it has been shown that p38 expression is detected in DLBCL 
arising from follicular lymphomas (Elenitoba-Johnson et al., 2003), suggesting that an 
abnormal activation of this pathway might contribute to the transformation of these 
lymphomas. If this were to be the case, p38 might have a role in the treatment of 
patients with this type of lymphomas. 
Further work will elucidate which p38 targets are directly responsible for the 
effect on BCL6 expression. Preliminary results suggest, that p38 might require both the 
BCL6 distal promoter, which contains a recent identified hypersensitivity site 
(Papadopoulou et al., 2010) and the proximal region of the first non coding exon 1 to 
perform, its effect. It should be noticed that within the studied BCL6 exon 1 region, 
binding sites for several p38 putative targets were identified, including a binding site for 
the multivalent regulator CTCF.  
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CHAPTER 5. CTCF involvement in BCL6 regulation  
 
5.1.- INTRODUCTION. 
 
Chapters 3 and 4 of this thesis suggested that there is a relatively short region 
on the BCL6 first non-coding exon 1, spanning from +1 to +533, which is associated with 
both high level transcriptional activity in reporter assays and high transcription factors 
binding sites density, making it a likely region to be involved in the BCL6 regulation.  
Using a bioinformatic approach, a putative binding site for the multivalent 
CTCF regulator was found at this BCL6 gene region. CTCF is a highly conserved 
protein, which can potentially bind to thousands of sites in the genome. It is capable of 
interacting with various proteins that are known to be essential for genome regulation 
and organization (see general introduction). Besides its insulator function, CTCF has 
also been shown to act as both a transcriptional repressor and an activator. In the 
present study we aimed to investigate a potential role for CTCF as a BCL6 regulator and 
to establish the functional relevance of that regulation.  
 
5.2.- RESULTS 
 
5.2.1. A putative CTCF binding site on the BCL6 exon 1 
Whilst investigating potential p38 targets binding sites at the exon 1 of the 
BCL6 gene, a putative binding site for the CTCF transcriptional regulator was found. A 
“CTCF binding sites database”  (http://insulatordb.utmem.edu) (Bao et al., 2008) 
constructed from CTCF binding sites  identified by genome-wide screens, has been 
widely used to estimate the probability of CTCF binding to putative sites (Bao et al., 
……………………………………………………………………………………………  . 
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2008). We, therefore, analysed 5,6 kb of the BCL6 gene resulting in the prediction of a 
CTCF binding site in the BCL6 gene exon1 regulatory region, with a very high score 
(Matrix1: 18.0907; Matrix 2: 8.47517; Matrix3: 14.3321; Matrix 4 10.0761. Average: 
12.75) (Figure 5.1). 
 
Figure 5.1. Putative CTCF binding site on the BCL6 exon 1. (a) Analysis of putative CTCF binding sites 
on the BCL6 gene was carried out using a “CTCF binding site database” for characterization of vertebrate 
genomic insulators (Bao et al, 2008), which uses four different matrices to perform the analysis (b)
Schematic view of the BCL6 regulatory region on exon 1, where the predicted CTCF binding site is located. 
The human BCL6 transcription start site is indicted as +1 (Bernardin et al, 1997). 
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5.2.2. CTCF binds in vitro to the BCL6 exon1 regulatory region  
In order to investigate CTCF binding to the BCL6 exon-1 regulatory region, 
electrophoretic mobility shift assays (EMSA) were carried out. A 130 bp radio-labelled 
probe, containing the CTCF BS (Figure 5.2.a), was generated by PCR amplification.  
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Figure 5.2. EMSA to analyze in vitro binding of CTCF to BCL6 exon 1 (a) BCL6 exon 1 sequence that 
includes the CTCF binding site (orange) and the primers used for the EMSA (underlined) (b, c) 32P labelled 
PCR fragments of MYC-N (positive control, b) and BCL6 exon 1 (c) were used as probes. Nuclear extracts 
were obtained from mock transfected 293T or from 293T cells transfected with either a pEGFP-CTCF N 
terminal or a pEGFP-CTCF full length expression vectors. CTCF shift bands are shown by red arrows.  For 
supershift experiments an anti-CTCF monoclonal antibody was added. The supershift bands are indicated 
by a red star. To assess the specificity of the supershift, an anti-actin antibody was used.
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 This method has been previously used to generate DNA probes when 
investigating CTCF binding capacity (Chau et al., 2006; Filippova et al., 1996; Fitzpatrick 
et al., 2007; Renaud et al., 2005; Renaud et al., 2007; Vatolin et al., 2005; Vetchinova et 
al., 2006; Yoon et al., 2005). The resulting radio-labeled probe was then incubated with 
nuclear extracts obtained from HEK293T cells that had been previously transfected, 
either with a CTCF expressing vector (pEGFP-CTCF), or with the empty vector. Band-
shifts were optimized using a known CTCF binding site (MYC-N) (Ohlsson et al., 2001) 
as a positive control (Figure 5.2.b). Nuclear extracts obtained from cells transfected with 
CTCF, showed binding to the BCL6 probe compared to extract from mock-transfected 
cells or cells transfected with the CTCF N-terminal vector (Figure 5.2.c lanes 1 to 3). 
The binding specificity was shown by incubating the nuclear extracts with a specific anti-
CTCF antibody. A clear supershifted band was observed when this antibody was used 
(Figure 5.2.c lane 4) while no supershift was observed with an anti-actin antibody 
(Figure 5.2.c lane 5). CTCF, therefore, interacts in vitro with the predicted binding site at 
the BCL6 exon 1.  
 
5.2.3. Methylation of BCL6 exon 1 does not alter BCL6 binding.  
Although CTCF binding to the DNA has been shown to be methylation 
dependent in many cases (Fitzpatrick et al., 2007; Hark et al., 2000; Kanduri et al., 
2000; Kim et al., 2006; Renaud et al., 2007; Yoon et al., 2005), DNA methylation did not 
alter CTCF binding in several other examples (Hong et al., 2005; Kim et al., 2009; 
Renaud et al., 2007; Vatolin et al., 2005). Could the CTCF binding to the BCL6 gene be 
methylation sensitive or not? To address this question, additional electrophoretic 
mobility shift assays were performed using probes that were fully methylated due to the 
enzyme SssI methyl transferase, or unmethylated. (Figure 5.3.a) To verify that the SssI-
treated-probe was completely methylated several digestions employing CpG-
methylation sensitive restriction enzymes were carried out. Those enzymes are known 
to cut when the restriction site is non methylated, and consistently, only the non 
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methylated probe was cut by SmaI, HinP1I, (Hin6I) and PmlI (Eco71I) methylation-
sensitive enzymes (Figure 5.3.b).  
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Figure 5.3. CTCF binds BCL6 exon1 in a methylation insensitive manner. (a) Schematic 
illustration of the SssI-untreated (left) and treated (right) probes. CTCF BS is indicated in red. (b)
Illustration of the probe showing the relative positions of several methylation sensitive (red) and 
non sensitive (blue) restriction enzymes. To assess complete methylation control probe (lanes 1-
5) and SssI treated probe (6-10), were uncut or digested with the indicated restriction enzymes 
and run on an 8% polyacrilamide gel. (c) EMSA experiment using a control probe and a SssI-
treated probe.  Nuclear extracts were obtained from mock transfected 293T cells or from 293T 
cells transfected with the expression vector pEGFP-CTCF (lanes 2 to 6 and 8 to 12). The CTCF 
shift bands are shown by a red arrow. Unlabelled probe (cold) was used as a competitor. For 
supershift experiments an anti-CTCF monoclonal antibody was added. The supershift band is 
indicated by a red star. To assess the specificity of the supershift, an anti-actin antibody was 
used.
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 On the contrary, both probes were efficiently cut with the non-methylation 
dependent restriction enzyme Eco-RI. These results show that methylation of the probe 
after SssI treatment was close to 100%. 
We then made a comparison of CTCF binding capacity to both the control and 
the methylated probe. The methylation of the probe neither impeded nor reduced CTCF 
binding (Figure 5.3.c). Therefore, CTCF showed methylation insensitive binding to the 
BCL6 exon1 site. 
 
5.2.4. BCL6 and CTCF expression in different lymphoma cell lines 
In order to investigate a correlation between BCL6 and CTCF expression, 
western blots were carried out on a number of different lymphoma derived cell lines. 
BCL6 protein expression was clearly different among the different cell lines and was 
consistent with the expression pattern observed previously by other authors. No 
detectable differences were observed in CTCF protein expression in the different B cell 
lines (Figure 5.4.a). This was not surprising, since CTCF normally shows ubiquitous 
expression.   
If CTCF is regulating BCL6 expression, this effect might depend on CTCF 
binding to BCL6 gene in a cell type specific manner. Therefore, it might be possible to 
observe different patterns of CTCF occupancy in lymphoma cell lines with different 
BCL6 expression pattern. The BCL6 gene is very often disrupted by chromosomal 
translocations involving the BCL6 exon1 region (see introduction). Thus, in order to find 
a possible correlation between BCL6 protein expression profile and CTCF occupancy at 
the BCL6 locus,  BCL6 gene rearrangements were investigated in cell lines and also in 
patients included in this study by fluorescence in situ hybridization (FISH), utilizing a 
commercial probe widely used for diagnostic purposes (Figure 5.4.b).  
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Figure 5.4. BCL6 and CTCF expression in lymphoma cell lines. (a) Western blot showing 
CTCF and BCL6 protein expression in several lymphoma cell lines. Coomassie blue stain of the 
gel was used as loading control. Cell lines showed high (red), intermediate (blue) and 
undetectable (green) BCL6 protein expression. (b) A schematic illustration of the LSI BCL6 break 
apart probe used for FISH analysis. (c) Hybridising with the LSI BCL6 in a normal nucleus results 
in two fusion signals (red-green or yellow) (top panel). The same probe hybridised on a nucleus 
with BCL6 locus rearrangement results in one fusion signal (representing the normal allele), one 
green signal and one red signal. (d, e and f) FISH using the LSI BCL6 break apart probe of 
LY03, Toledo and MUTU III lymphoma cell lines. 
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              When BCL6 is not rearranged two yellow fusion signals are observed on a 
single nucleus, whilst those cells with a BCL6 translocation will normally show one red 
signal, one green and one yellow signal (Figures 5.4.b-c). None of the cell lines utilized 
on this study showed rearrangement of the BCL6 gene. It is noteworthy that several of 
the cell lines showed more than three yellow fusion signals, sometimes up to five  
(Figure 5.4.d-f), suggesting hyperploidy or amplification of the BCL6 gene. Lymphomas 
often show hyperploidy, but this result is intriguing because amplification of the BCL6 
gene was found in cell lines, such as MUTUIII or Toledo, where BCL6 protein 
expression was undetectable (see western in figure 5.4.a). 
 
5.2.5. CTCF interacts in vivo with the BCL6 exon 1 regulatory region  
Chromatin immunoprecipitation (ChIP) experiments were performed in order 
firstly to investigate the CTCF in vivo occupancy of the BCL6 exon 1 region by CTCF, 
and secondly to study whether this occupancy was modified in cell lines with different 
levels of BCL6 expression. 
ChIP assays were initially carried out in two cell lines: K562, a myeloid cell line 
which does not express BCL6, and Ramos, a germinal centre derived cell line 
expressing high levels of BCL6. The immunoprecipitation experiments were performed 
with and without CTCF-specific antibodies. In all experiments the well established -5.9 
Kb upstream region (H1 site) on the c-MYC gene (Gombert et al., 2003) was used as a 
negative control. To determine the reproducibility and efficiency of the technique the 
MYC-N CTCF BS was amplified simultaneously with the BCL6 target sequence and 
used as a positive control (Figure 5.5.a). ChIP analysis revealed occupancy of CTCF at 
the BCL6 exon 1 region. Strong in vivo binding was demonstrated in Ramos whilst the 
CTCF enrichment was much lower in K562 cells (Figure 5.5.a), suggesting that CTCF 
binds to the BCL6 exon-1 regulatory region preferentially in BCL6 expressing cells.  
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Additional ChIP assays were then carried out, utilizing a variety of cell lines 
with different levels of BCL6 expression. As anticipated from the results described 
above, CTCF binding in the BCL6 low expressing cell lines, was almost undetectable 
Figure 5.5. CTCF interacts in vivo with BCL6 (a) ChIP analysis on the BCL6 gene. Chromatin 
was prepared from K562 cells (undetectable BCL6 expression) and Ramos cells (high BCL6 
expression). Chromatin was immunoprecipitated with a mixture of different anti-CTCF antibodies 
and analyzed by real time PCR with the indicated primer sets. Fold enrichment was calculated as 
described in Material and Methods section. CTCF Myc-N and Myc-H1 target sites were used as 
positive and negative controls, respectively. Values are means and SD of duplicate 
determinations from three independent ChIP experiments. (b) ChIP examining the relative fold 
enrichment of the CTCF binding site on the BCL6 exon1 in LYO3, Toledo and MUTU III 
lymphoma cell lines. 
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(Figure 5.5.b). These results suggest that CTCF is preferentially bound to BCL6 exon1 
in cells where BCL6 is highly expressed.  
To further investigate whether CTCF binding to the BCL6 gene was specific to 
the exon1 site several amplicons at the BCL6 regulatory region were analyzed by ChIP 
in Ramos cells (Figure 5.6.a). A region spanning ≈1500 bp was explored using three 
different sets of primers. As shown in figure 5.6.b. high CTCF enrichment was observed 
only with the primers covering the predicted CTCF BS in exon 1.  
The variant histone H2A.Z has been reported to be a CTCF cofactor (Yusufzai 
et al., 2004) and to colocalize with CTCF genome wide (Barski et al., 2007). H2A.Z 
incorporation alters the stability of nucleosomes and is frequently detected in promoters 
of active genes or genes poised for activation (Sharma et al., 2010). We therefore asked 
whether H2A.Z binding was detected in the BCL6 exon 1 regulatory region in Ramos 
cells. ChIP analysis revealed specific accumulation of H2A.Z at CTCF binding site of 
BCL6 (Figure 5.6.c).  
All together these results show specific interaction of CTCF with the predicted 
site on BCL6 gene exon 1 regulatory region. 
 
5.2.6. CTCF effects on BCL6 promoter activity 
What could the function of CTCF at the BCL6 promoter be? Luciferase assays 
were carried out to determine whether CTCF had any effect on the activity of the BCL6 
promoter. The effects of enforced and reduced CTCF expression on the BCL6 promoter-
exon-1 activity were examined in both DG75, a BCL6 expressing cell line, and in K562, 
a BCL6 negative cell line. These cell lines were selected because they can be very 
efficiently transfected (see Figure 2.2 in Material and Methods section). CTCF was 
efficiently silenced using plamid encoding for a shRNA against CTCF (see below figure 
5.8 b and c). Overexpression of CTCF was achieved by transfecting both cell lines with 
a GFP-CTCF plamid (see figure 5.8.d).  
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Figure 5.6. Occupancy of the BCL6 exon1 by CTCF and H2A.Z (a) Scheme of the BCL6 
regulatory region, showing the relative position of several binding sites for different transcription 
factors that have been implicated in the BCL6 regulation (b) ChIP assays were performed on the 
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              To perform these reporter assays, four different pGL3 reporter constructs 
containing various BCL6 gene fragments were used (Figure 5.7). To investigate whether 
a recently discovered 5´upstream DNAse I hypersensitive site (Papadopoulou et al., 
2010) was influencing the CTCF effect two further constructs containing this 
hypersensitivite site, were employed. 
Reporter constructs were co-transfected with either a vector (pRS-CTCF) 
containing a CTCF-shRNA, which resulted in a significantly CTCF reduced expression 
or with CTCF expression vectors (pcDNA-CTCF or pEGFP-CTCF). Consistent with our 
earlier studies on non-expressing BCL6 cells, the basal activity of the reporter constructs 
that contained the proximal exon1 region, was significantly higher when compared to the 
ones that lacked that region in K652 cells. Reduced expression of CTCF resulted in a 
dramatic increase in the reporter activity of the exon 1-BCL6 constructs (figure 5.7.b). 
The rise in the reporter activity was not observed in those constructs that did not contain 
the CTCF BS. The DNAse I hypersensitivite site (HSS-4.4) seems to have little impact 
on the CTCF effects (figure 5.7.b).    
Transfections were also carried out in the BCL6 expressing cell line DG75. 
Compared to the K562 cells the plasmids containing the exon 1 region showed little 
basal reporter activity on the DG75 cells. This was not surprising, since the exon-1 
region also contains an important autoregulatory BCL6 binding site, that has previously 
been shown to reduce expression from the gene (Pasqualucci et al., 2003). 
Interestingly, CTCF silencing did not significantly modify the reporter activity in DG75 
cells, suggesting, that BCL6 binding to its own promoter has a stronger effect that the 
induced by the CTCF silencing (Figure 5.7.c). On the contrary, the reporter activity on 
the DG75 cells rose as a result of overexpressing CTCF using two different expressing 
vectors (Figure 5.7.d,e). This effect required the full length-CTCF protein, as 
cotransfections with individual CTCF domains (ZF or C-term domains) had no significant 
effect on the reporter gene activity.  
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Figure 5.7. CTCF effect on the transcriptional activity of the BCL6 promoter (a) Schematic 
representation of the BCL6 gene and regulatory region indicating the 5´hypersensitivity site (red 
box) and the CTCF binding site (orange) (b, c) Luciferase assays showing the effects of silencing 
CTCF expression on BCL6 promoter activity. K562 cells (b) or DG75 cells (c) were transiently 
cotransfected with either a pRS empty vector or a pRS-CTCF vector, and with different 
PGL3BCL6 reporter constructs (indicated on the left) and with a pRL null plasmid. SD values of 
duplicates from 2 to 5 independent experiments are indicated. (d, e) Luciferase assays showing 
the effects of CTCF ectopic expression on BCL6 promoter activity. DG75 cells were transiently 
cotransfected with either a pGL3 empty vector or with the pGL3/BCL6 indicated constructs and 
with a pRLnull plasmid and with (d) pEGFP empty vector, pEGFP-ZF, pEGFP-Ct, or pEGFP-
CTCF full length  constructs or (e) pcDNA or pcDNACTCF vectors. SD values from two different 
experiments are indicated. pRL-null was used to normalize for transfection efficiency. Luciferase
activity is shown as the increase in activation relative to the activity of the pGL3 vector alone.
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             Unfortunately, despite repeated efforts, it was no possible to over-express 
CTCF in K562 cells, since the cells rapidly stopped growing, presumably due to the 
CTCF negative effect on the cell proliferation as previously reported (Rasko et al., 2001; 
Torrano et al., 2005).  
 
5.2.7. CTCF effect on BCL6 expression 
The effects of transient CTCF reduction and enforced expression on BCL6 
mRNA and protein levels (figure 5.8.) were examined to determine further the CTCF 
regulatory effect on BCL6 expression,   
CTCF silencing was achieved 48 hours after transfection with the pRS-CTCF 
vector and this effect was maintained until, at least, 96 hours (Figures 5.8.a to c).  CTCF 
silencing in DG75 cells resulted in a small but reproducible down-regulation on both 
BCL6 mRNA (figure 5.8.a) and protein expression (Figure 5.8. b). As expected, after 
effectively silencing CTCF there was no effect on BCL6 protein expression in K562 cells 
(Figure 5.8.c).  
Ectopic expression of CTCF was observed as soon as 48 hours after 
transfection (Figure 5.8.d). The CTCF exogenous protein was easily differentiated from 
the endogenous one on a western blot, because the exogenous CTCF was fused to the 
EGFP protein, and therefore migrated more slowly than the endogenous one. Over-
expression of CTCF in DG75 cells showed no impact on BCL6 expression (Figure 
5.8.d).  
In summary, the effects of CTCF differ depending on whether BCL6 is 
expressed. It appears to restrain BCL6 transcriptional activity in cell lines that lack BCL6 
protein expression. However, in BCL6 expressing cell lines reduction in CTCF caused a 
small reduction in BCL6 mRNA expression.  
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5.2.8. CTCF effects on the cell cycle of BCL6 positive and negative cell 
lines 
CTCF has important roles on cell cycle regulation as well as apoptosis. 
Interestingly, regulation of cell proliferation and apoptosis is crucial in germinal centre 
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cells, although not completely understood. We therefore wished to determine whether 
CTCF might be involved in cell cycle regulation of germinal centre cells. For this reason 
we transiently transfected either a CTCF expression vector or a pRS-CTCF vector into 
DG75 and MUTU III cell lines which are, respectively, BCL6 expressing and non-
expressing lymphoma cell lines (Figure 5.9.). In both cell lines silencing of CTCF had 
very little effect on the cell cycle (Figure 5.9.a.). Conversely, enforced expression of 
CTCF induced significant cell cycle arrest and this effect was stronger in the BCL6 
negative cells (MUTUIII) than in the positive ones (DG75) (Figure 5.9.b). It is not clear 
from these experiments whether the BCL6 exon 1 CTCF binding site is required for 
these effects and further experiments are required to elucidate its exact role. 
 
5.3. DISCUSSION  
 
Based on the previous reporter assays results, a 300 bp region located on the 
5´region of exon-1 was shown to have important basal transcriptional activity and has a 
high concentration of transcription factor binding sites. Thus, this small region is 
probably required for an adequate BCL6 regulation.Upon investigation of potential 
transcriptional regulator binding sites in this area, a binding site for CTCF, a multivalent 
DNA binding factor was identified.  
EMSA experiments revealed that in vitro CTCF binding to the BCL6 exon 1 
region was specific and not methylation dependent. The latter result was expected as 
the predicted CTCF binding site had no CpG dinucleotides. However, since the CTCF 
BS was identified inside a CpG island (see chapter 6), the analysis of its possible 
methylation sensitivity binding was considered necessary. ChIP assays confirmed that 
CTCF interacts in vivo with the BCL6 regulatory region. Moreover, CTCF occupancy 
was associated with high BCL6 protein expression.  
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Figure 5.9. CTCF effect on the cell cycle in lymphoma cell lines. (a) CTCF knockdown. DG75 (upper 
panels) and MUTU III cells (lower panels) were cotransfected with GFPmax vector and with either a  pRS
vector (left panel) and a pRS CTCF plasmid (right panels). After 48 hours of transfection cells were separated 
using a FACS-SORTER ARIA II based on the GFP fluorescence expression. GFP positive cells were then 
allowed to recover for 24 hours and  stained with propidium iodide for cell cycle analysis. (b) CTCF 
overexpression. DG75 (upper panels) and MUTU III cells  (lower panels) were transfected with either a pEGFP
empty vector (left panels) or with a EGFP-CTCF plasmid (right panels). After 48 hours cells were separated 
using a FACS-SORTER ARIA II based on the GFP fluorescence expression. GFP positive cells were then 
allowed to recover for 24 hours and  stained with propidium iodide for cell cycle analysis
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              To provide insights into how CTCF was regulating BCL6 expression, we 
transiently transfected reporter gene constructs containing the CTCF binding site, with 
either CTCF expressing vectors or vectors encoding for a shRNA against CTCF into 
BCL6 non expressing K562 cells, or expressing DG75 cells. In line with my previous 
results, basal activity of those constructs composed of the 5´extreme of the BCL6 exon 
1 was significantly higher in BCL6 non-expressing cells than in BCL6 positive ones 
probably because of the exon1 BCL6 binding site that is known to serve as a potent 
negative autoregulatory domain. Surprisingly, CTCF silencing on K562 cells significantly 
increased the reporter activity of those constructs containg the CTCF BS. Although 
these results seem to contradict our ChIP results, the discrepancy might be explained by 
the existence of CTCF indirect effects that might be contributing to the inhibition of BCL6 
expression on those cells. Indeed, CTCF binding was almost undetectable in cell lines 
with BCL6 low expression supporting the idea that the BCL6 potential downregulation in 
these cell lines is probable mediated by CTCF indirect effects. It is also noteworthy that 
overcoming CTCF inhibitory effect is not sufficient for inducing BCL6 expression in K562 
cells. 
In contrast to K562 cells, silencing of CTCF in the BCL6 positive cell line, 
DG75, did not produce a significant change on the reporter activity. As discussed above, 
the BCL6 autoregulatory domain might have an overall effect on the reporter activity 
stronger than the induced by the CTCF silencing. Thus, the BCL6 interfering effect on 
the reporter assays make these two models, BCL6 positive and negative cell lines, not 
suitable for comparison. It is interesting that enforced expression of CTCF, using 
different CTCF expressing vectors, led to a reproducible increase in the reporter activity, 
suggesting that in BCL6 expressing cells CTCF might be acting as a transcriptional 
activator. In support to this conclusion, CTCF silencing led to a moderate but consistent 
reduction in both BCL6 mRNA and protein levels and also, ChIP assays showed that 
BCL6 expressing cells had considerable higher CTCF occupancy rates compared to 
those BCL6 negative cell lines. On the contrary, CTCF over-expression did not induce a 
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measurable change on BCL6 expression. This latter effect might be due to the strength 
of the endogenous CTCF effect, since these cells were shown to have high basal levels 
of CTCF protein. Indeed it has been suggested that CTCF alone has minimal effect on 
reporter gene expression (Phillips and Corces, 2009). 
Several additional hypotheses emerge from these experiments. CTCF may 
have a role in the regulation of BCL6 but whether the CTCF effect on BCL6 regulation 
differs in BCL6 positive and negative cell lines, as suggested by our preliminary reporter 
assays, requires further investigation. Another prediction is that CTCF could be 
recruiting different protein complexes in a cell-type specific manner that could potentially 
have opposing functions. Another possibility would be that CTCF induces different 
epigenetic modifications at the BCL6 regulatory region or/and maybe CTCF could be 
responsible for long- distance interactions inducing the formation of loops or hubs (see 
general introduction). Some of these possibilities will be addressed in the next chapter. 
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CHAPTER 6. Epigenetic modifications and the regulation of 
BCL6 gene 
 
6.1. INTRODUCTION 
 
In normal conditions BCL6 is highly expressed in B-cell within the germinal 
centre, suggesting that BCL6 expression relies on an exquisite and tight regulatory 
mechanism. In lymphomas BCL6 expression is variable. Constitutive over-expression of 
BCL6 can be accomplished by chromosomal translocations and promoter substitution 
whereas in other cases point mutations at the BCL6 binding site in exon 1 are 
responsible. However, there are cases in which abnormal expression of BCL6 cannot be 
explained by any of these mechanisms. This uncertainty opens a question, is there a 
role for the epigenetic modifications in the BCL6 regulation?. CTCF has been involved in 
the epigenetic regulation of several genes (Filippova, 2008; Klenova and Ohlsson, 2005; 
Recillas-Targa et al., 2006) and in the previous chapter a potential role of CTCF in the 
regulation of BCL6 was demonstrated, and the involvement of CTCF in such regulation 
of BCL6 was tested. 
Epigenetic modifications include DNA-methylation, histone post-translational 
modifications and chromatin remodelling (Esteller, 2008; Jones and Baylin, 2007). 
These modifications play crucial roles in the control of gene expression and nuclear 
architecture. Epigenetic modifications and their potential role in diagnosis and treatment 
of cancer are active areas of research (Esteller, 2008; Sharma et al., 2010). Since the 
epigenetic status of the BCL6 gene has not been investigated previously, in this study 
the epigenetic influence on BCL6 expression in lymphoma cells lines and in primary 
lymphoma cells was explored. 
. 
……………………………………………………………………………………………  . 
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6.2. RESULTS 
 
6.2.1. BCL6 expression is modulated by epigenetic modifications  
Could BCL6 expression be modulated through epigenetic mechanisms such 
as DNA methylation and histone deacetylation? To assess this possibility a variety of 
different BCL6 positive and negative cell lines were treated with 5-aza-2´-deoxycytidine 
(5-azadC), a methyltransferase inhibitor that impedes de novo methylation, as well as 
with Trichostatin A (TSA), a histone deacetylase (HDAC) inhibitor. As TSA treatment 
alone has been previously been shown not to be sufficient to up-regulate genes with 
methylated promoters (Rodriguez et al., 2008 and references therein), we decided to 
combine TSA with 5-aza-dC. BCL6 relative mRNA levels were measured by RT-PCR to 
study the effect of these drugs on BCL6 expression (Figure 6.1). 
Figure.6.1. Treatment with demethylating agents and HDAC inhibitor agents induces BCL6 
expression. RT-PCR analysis showing relative mRNA levels of BCL6 in cells untreated or treated with 5-
azadC for three days  or with 5-azadC for three days and TSA for three additional days as indicated. The 
experiments were performed in K562,Toledo, MUTU III cell lines with undetectable BCL6 expression
(a),and in DG75 and Ramos BCL6 expressing cell lines (b). Values are means of duplicate 
determinations.
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Treatment of different BCL6 negative cell lines with 5-azadC for three days 
resulted in a significantly increase on the BCL6 mRNA levels. Furthermore, BCL6 
mRNA expression was dramatically increased when TSA was added to the medium for 
three additional days (Figure 6.1.a). In contrast, the BCL6 mRNA levels after treatment 
with 5-azadC showed either non significant difference or even a decrease, on the two 
BCL6 positive cell lines evaluated (Figure 6.1.b). In conclusion, results with these 
different chromatin modifying agents indicates a role of DNA methylation and histone 
modification in BLC6 gene regulation. 
 
6.2.2. Methylation status of the BCL6 regulatory region  
The above results suggest a role for epigenetics in the regulation of BCL6 
gene expression. A search was carried out for possible CpG islands within the BCL6 
exon 1 region because the 5´ regulatory regions of genes are usually rich in CpG 
dinucleotides. The BCL6 gene sequence NG_007149.1. (NCBI website) was used. It 
should be noticed that the transcription start site was defined attending to the Bernardin 
et al work (Bernardin et al., 1997). 20 kb of the BCL6 regulatory region were searched in 
the Methyl Primer Express software (Applied Biosystems) and the parameters used to 
find CpG islands were set as follows: minimum length of the island: 300bp; maximum 
length of island: 2000bp; C+Gs/Total bases > 50%; CpG observed/CpG expected >0.6. 
Several intermediate-small CpG islands were found in the sequence, and 
interestingly, the BCL6 exon 1 region containing the CTCF BS, is located within the first 
predicted CpG island (Figure 6.2.a). We therefore speculated that CTCF might be 
regulating the methylation pattern of BCL6 gene regulation maybe controlling and 
impeding methylation progression, as it has been shown previously in other genes (De 
La Rosa-Velazquez et al., 2007; Renaud et al., 2005; Soto-Reyes and Recillas-Targa, 
2010). 
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Figure 6.2. Methylation status of BCL6 exon1 regulatory region (a) Schematic view of the BCL6 gene, 
BCL6 proximal regulatory region and CpG islands. The CTCF binding site on the BCL6 exon1 is indicated. (b) 
DNA methylation status of the  BCL6 gene was investigated by sequencing of bisulfite-modified genomic DNA 
of three cell lines with undetectable expression of BCL6 protein (b) K562 (c) MUTU III (d) Toledo, of three 
BCL6 expressing cell lines (e) LY03 (f) Ramos (g) DG75 and of (h-i) two diffuse large B cell lymphoma patient 
(DLBCL) samples (j-k) two follicular lymphoma lymphoma patientes (l) one mantle lymphoma (m) one acute 
lymphoblastic leukemia patient sample. (n) one Burkitt lymphoma patient. Unmethylated CpG dinucleotides
are indicated as open circles. 
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              For this purpose “Bisulfite modification Primers” (BSP) were designed using the 
Methyl Primer Express program, so that we could investigate the methylation status of 
the 10 CpG dinucleotides located upstream and the 7 downstream, of the CTCF binding 
site (Figure 6.2.a). Sodium bisulfite treated genomic DNA from three BCL6 expressing 
and three non-expressing cell lines were employed for PCR utilizing the BSP specific 
primers. The PCR product was then directly sequenced. Since in some cases the results 
of the direct sequencing were not clear enough, presumably due to the coexistence of 
methylated and non methylated sequences within a PCR product, we cloned the PCR 
products into the pGEM-T easy vector. Five to ten different clones of each cell line were 
thereafter sequenced. In all the cell lines evaluated the 17 CpG dinucleotides analyzed 
were unmethylated (Figure 6.2.b to f). 
To further investigate the methylation status of that region, sodium bisulfite 
treated genomic DNA from seven patients suffering from a variety of B neoplasms (2 
diffuse large B cell lymphoma (DLBCL); 2 follicular lymphoma (FL); 1 mantle lymphoma 
(ML); 1 Burkitt lymphoma (BL); 1 acute lymphoblastic leukaemia (ALL), were PCR 
amplified, cloned and sequenced. Again, none of the CpG dinucleotides studied were 
methylated in any of the patients (Figure 6.2.h to n). All together, these results indicate 
that differential methylation of the BCL6 exon1 regulatory region including the CTCF BS, 
is not associated with regulation of BCL6 expression.  
 
6.2.3. Histone marks present at BCL6 exon 1 region 
Histone functions are modulated through a variety of post-translational covalent 
modifications. The histone marks are truly epigenetic events that work by modifying the 
accessibility of chromatin or by recruiting different protein complexes involved in the 
regulation of the transcription (Sharma et al., 2010). The HDAC inhibitor TSA altered  
BCL6 expression (see Figure 6.1) suggesting a potential role for histone acetylation in 
regulating BCL6. For this reason, the presence of modified histones at exon1 in the 
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BCL6 positive cell line, Ramos, and in the non expressing BCL6 cell line, K562 was 
tested. (Figure 6.3.).  
 
Ramos cells showed a prominent enrichment of active chromatin marks, such as 
histone H3 lysine 4 dimethylated (H3K4me2) or histone H3 acetylated (H3ac) as well as 
variant histone H2A.Z, and those levels were much higher than those observed in the 
K562 cells (Figure 6.3.). Collectively these results show a clear association between 
CTCF binding, presence of active histone marks at BCL6 exon 1 regulatory region and 
BCL6 expression. It is therefore, tempting to speculate that the BCL6 exon 1 region, 
which seems to be an important regulatory region, might be modulated through changes 
in chromatin conformation. CTCF may be playing a crucial role in such BCL6 gene 
regulation. 
Figure.6.3. Binding of modified and variant histones to the BCL6 exon1 regulatory region. Chromatin 
was prepared from Ramos (a) and K562 cells (b). Protein-DNA complexes were immunoprecipitated with 
antibodies against CTCF, H2A.Z, H3K4me2 and H3ac, as indicated. ChIP analysis shows specific binding 
to the BCL6 exon1 region. 
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6.3. DISCUSSION 
 
BCL6 regulation is crucial for a normal adaptive immune response. 
Deregulated expression of BCL6 occurs in many lymphoproliferative diseases, but the 
exact mechanisms of BCL6 regulation are unknown.  
The aim of this section of the thesis was to determine whether BCL6 
expression was regulated by epigenetic modifications, such as DNA methylation and 
histone modifications. The rearrangement status of the BCL6 gene in several BCL6 
positive and negative cell lines was investigated, because those cell lines without 
translocations involving the BCL6 gene could be used for further studies. It was very 
interesting to discover that several copies of the BCL6 gene with no sign of 
rearrangement were found even in BCL6 non expressing cell lines. This result 
suggested that other regulating mechanism such as epigenetic modifications might be 
crucial for the regulation of this gene. 
It has been previously demonstrated that HDAC inhibitors are only capable of 
activating those genes with unmethylated promoters and that combination of both HDAC 
inhibitors and de-methylating agents act in a synergistic manner (Cameron et al., 1999; 
Meng et al., 2007; Saito et al., 2006) and maybe required for a complete gene 
reactivation. Therefore, as an initial approach we studied the effects of the de-
methylating agent 5-azadC and of the HDAC inhibitor TSA on BCL6 expression. An 
impressive increase in BCL6 mRNA levels was observed in different cell lines with 
undetectable BCL6 expression. This finding suggested that epigenetic modifications 
might be crucial for the regulation of this oncogene although the effects of 5-azadC on 
BCL6 expression could be indirect. The epigenetic pattern of the BCL6 gene has not 
previously been investigated but the methylation status of the BCL6 gene might be 
responsible for BCL6 regulation in normal and malignant germinal centre cells.  
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Moreover, controlling the methylation status of the promoter and regulatory 
regions of a gene appears to be a very appealing way of tightly regulating gene 
expression. It is known that CTCF is involved in the regulation of DNA methylation 
(Filippova, 2008; Recillas-Targa et al., 2006). This multivalent transcriptional regulator 
binds to the BCL6 exon 1 region, therefore, and to find out whether CTCF may have a 
role in the methylation status of the BCL6 gene further experiments were carried out. 
Thus, the first hypothesis was that CTCF might be acting as an insulator, blocking 
propagation of the methylation front. Although it is probably necessary to examine the 
DNA methylation status in a larger genomic area, we found lack of methylation of the 17 
CpG dinucleotides around the CTCF binding site (that is itself within a CpG island) 
regardless of the pattern of BCL6 expression. This result was not completely 
unexpected since, with some exceptions such us CpG islands within the promoters of 
imprinted genes or in some somatic tissue-specific genes, most CpG islands remain 
unmethylated during differentiation (Sharma et al., 2010).  
Also, islands with low even intermediate content of CpG dinucleotides, often 
found in the control regions of tissue specific genes, are not usually regulated through 
DNA methylation but by covalent histone modifications (Kondo et al., 2008; Meissner et 
al., 2008; Soto-Reyes and Recillas-Targa, 2010; Weber et al., 2007). Indeed, ChIP 
assays support this idea, since the enrichment of H3K4me2 and of H3Ac observed in 
the BCL6 expressing cell line Ramos was significantly higher than in the BCL6 negative 
cell line, K562. Along with these active chromatine marks we found a notable 
enrichment of CTCF in Ramos, together with the H2A.Z, a histone variant often co-
imunoprecipitated with CTCF and frequently detected in promoters of active genes 
(Sharma et al., 2010). In comparison, K562 enrichment of the H2A.Z was considerably 
lower. It is tempting to speculate that CTCF might be responsible for protecting the 
BCL6 exon 1 regulatory region against repressive covalent histone modifications. Such 
a mechanism has been recently described for the CTCF regulation of the p53 promoter 
(Soto-Reyes and Recillas-Targa, 2010). In addition, a similar mechanism related to the 
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loss of repressive histone modifications has also been proposed for the activation of the 
cancer-promoting gene CLDN3 in ovarian cancer (Kwon et al., 2010). In order to confirm 
this hypothesis ChIP assays in BCL6 expressing cells after effectively silencing CTCF 
should be performed. 
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CHAPTER 7 GENERAL DISCUSSION 
 
7.1. Biological importance of BCL6 
BCL6 is an important transcriptional repressor that is essential for the 
development and regulation of the immune system. It has well-established functions in 
B-cells (Dent et al., 1997; Ye et al., 1997) and has more recently been shown to have 
essential roles in follicular helper T-cell development (Yu et al.; Nurieva et al.; Johnston 
et al.). BCL6 expression, therefore, has to be tightly regulated in B- and T-cell lineages. 
In addition aberrant expression is associated with the development of B-cell lymphomas 
(Cattoretti et al., 2005)  
BCL6 expression is regulated at several levels. It is post-translationally 
regulated by phosphorylation and acetylation, and important cis-acting control 
mechanisms have been discovered. There is a negative autoregulatory mechanism that 
involves a BCL6 binding site in exon 1. Binding of BCL6 to this site in association with 
the co-repressor CtBP (Mendez et al., 2008) reduces BCL6 transcription. However, to 
allow full expression of BCL6 this mechanism must be suppressed. Our laboratory. has 
recently added to this story by suggesting that elements at a DNase I hypersensitive site 
4.4 kb upstream of the transcription start site (HSS-4.4) bind a protein complex also 
involving CtBP (Papadopoulou et al., 2010). A speculative model suggests that the 
transcription factor ZEB1 (binding at HSS-4.4) forms a repressive complex with BCL6 
(binding at exon 1) and CtBP to shut down BCL6 transcription and when this complex is 
disrupted (by reduction in ZEB1 expression) BCL6 transcription takes place. Other cis-
acting control sequences have also been identified: The repressive transcription factor 
IRF4 binds in intron 1 (Saito et al., 2007) and STAT5, which is an activating factor in 
primary cells (Scheeren et al., 2005) , binds in exon 1. Other factors have also been 
demonstrated to bind at the BCL6 promoter e.g. FoxO3a and PU.1, but their roles in 
lymphocytes have not been defined in detail. 
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Much remains to be discovered about the lineage and temporal control of 
BCL6 expression. Following the discovery by others that BCL6 is induced in CML 
lymphoid blast crisis cell lines (Deininger et al., 2000a; Fernandez de Mattos et al., 
2004), these cells were chosen to study the effects of BCR-ABL signalling pathways on 
BCL6 expression. 
Dissection of three major BCR-ABL pathways the Ras/Raf/MEK, the 
PI3K/AKT/mTOR and the JAK/STAT5 as described here, showed that BCL6 regulation 
is not due to a single transcription factor but to the cooperation of many different 
signalling pathways. In this study and in agreement with Scheeren et al (Scheeren et al., 
2005) STAT5, was also shown to upregulate BCL6 in BCR-ABL+ cells. However, STAT5 
can not be responsible for the upregulation of BCL6 due to Imatinib since STAT5 
becomes inactive in the presence of this drug. In this thesis it is shown that p38 MAPK, 
was responsible for driving BCL6 expression upon treatment with Imatinib.  
The fact that BCL6 is not expressed in BCR-ABL cells in basal conditions 
despite the constitutive activation of p38 MAPK and STAT5 shows that additional strong 
repressive pathways must be inhibiting BCL6 expression in these cells. We 
demonstrated that mTOR, is one of the repressive pathways in the Z119 cell line, since 
its repression by Rapamycin led to a transient but significant increase in BCL6 
expression. However, since we failed to achive the same effect in other cell lines, the 
conclusion is that there must be other repressive pathways implicated in the BCL6 
repression, which remain to be defined. A model for BCL6 regulation by BCR-ABL is 
depicted in Figure 7.1. 
 
7.2. BCL6 regulation by Imatinib 
The biological relevance of BCL6 upregulation in lymphoid BCR-ABL+ cells 
when treated with Imatinib is not clear. It has been shown that BCL6 upregulation in 
BV173 cells leads to downregulation of cyclin D2 (Deininger et al., 2001; Fernandez de 
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Mattos et al., 2004), which is known to be essential for proliferation. Therefore it is 
possible that BCR-ABL inhibits BCL6 expression to allow uncontrolled proliferation. 
BCL6 could also be involved in the apoptotic process induced by Imatinib in these cells. 
Accordingly, BCL6 has been reported to induce apoptosis in some cell types including a 
pro-B cell line (Albagli-Curiel, 2003).  
JAK 
PI3K
STAT5 
BCR-ABL
RAS
RAF
MEK1/2
JNKp38MAPK
ERK
BCL6
? ?
BCR-ABL
p38MAPK
Imatinib
FoxO3a
AKT 
mTOR
BCL6
?
FoxO3a
a
b
Figure 7.1. A proposed model for BCL6 regulation by BCR-ABL in lymphoid cells. (a) BCR-
ABL can activate many signaling pathways including Stat5, Akt and P38MAPK. In basal conditions 
the BCR-ABL downstream signalling pathways JAK/STAT5 and p38MAPK induce BCL6 
expression, and despite these strong positive signals, no BCL6 protein expression is detected, 
suggesting that additional strong repressive pathways must be inhibiting BCL6 expression in these 
cells (upper panel). Upon treatment with Imatinib (lower panel), BCR-ABL tyrosin kinase activity is 
inhibited and as a result the signalling pathways downstream BCR-ABL become inactive. 
P38MAPK remains active in these cells, supporting the idea of p38 being regulated by BCR-ABL 
dependent and independent mechanisms (Sanchez Arevalo Lobo et al, 2005). In BCR-ABL 
inactive cells (b) both the p38 MAPK and Fox03a pathways induce BCL6 expression. 
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             Also, BCR-ABL could be represssing BCL6 expression in order to block the 
differentiation process (Duy et al., 2007). In this regard it has been shown that pre-B 
cells require BCL6 expression to differentiate and for the immunoglobulin (Ig) light chain 
gene recombination (Duy et al., 2010). Moreover, abnormal low expression of BCL6 
combined with an increased expression of the protoncogene c-MYC was associated 
with a differentiation arrest in a number of acute lymphoblastic leukaemia cells, including 
the Ph+ lymphoid leukaemia (Duy et al., 2007). This, however, does not explain why 
mice lacking BCL6 have normal B cell development at the bone marrow stage. One 
possible explanation is that different redundant pathways are regulating the same 
processes. 
 
7.3. BCL6 and lymphomagenesis 
BCL6 is known to be essential for the generation of germinal centres (Cao et 
al., 1997). Germinal centres are areas within lymphoid nodes that are crucial for the 
generation of mature T cell dependent responses. Intense B proliferation together with 
somatic hypermutation are processes required for the production of high affinity 
antibodies, but these features also make a good environment for the generation of 
malignancy, and, in fact, over 50% of lymphomas have a germinal centre derivation.  
 Deregulated expression of BCL6 due to rearrangements, mutations of the 
negative autoregulatory BCL6 binding site in exon 1, and other aberrations, have been 
detected in a number of human lymphoproliferative processes with a germinal centre 
origin. 
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7.4. Biological Roles of p38 MAPK 
Here it has been shown for the first time that p38 MAPK induced BCL6 
expression. The p38 MAPK pathway, can be activated by genotoxic and environmental 
stresses or cytokines, and has been involved in a wide range of processes. Thus it is 
known to mediate cellular stress responses inducing apoptosis and cell growth arrest, 
but it also plays key roles in the proliferation, differentiation and even cell survival 
processes in a number of cell types (Dong et al., 2002; Nebreda and Porras, 2000; 
Raman et al., 2007; Wagner and Nebreda, 2009). It is also interesting that constitutive 
activation of p38 can promote tumorogenesis (Greenberg et al., 2002) and even favour 
metastatic spread of cancers (Ito et al., 2006).  
Interestingly there are some previous reports suggesting that p38 might also be 
regulating BCL6 in other cell types. Both p38 and BCL6 were upregulated in 
differentiating C2C12 myoblasts, a cell line which undergoes differentiation when 
cultured in serum-free medium (Kumagai et al., 1999; Nebreda and Porras, 2000) and 
both proteins were required to induce growth arrest and differentiation of those cells. 
Similarly, high concentrations of calcium induces differentiation in keratinocytes and, 
after calcium stimulation both BCL6 and p38 are activated (Efimova et al., 2002; 
Yoshida et al., 1996).  
 
7.5. p38 MAPK and germinal centres  
Transfection of a BCR-ABL p210 vector produced a significantly decrease in 
the BCL6 protein expression in Burkitt's lymphoma cell lines, which are representative of 
germinal centre B-cells. Thus, the same pathways that operate in CML lymphoid blast 
crisis cell lines might also be important for BCL6 regulation in germinal centre cells. Both 
STAT5 and p38 were shown to be enhancers of BCL6 in these cells. Although STAT5 
was previously shown to upregulate BCL6 in primary B tonsillar cells (Scheeren et al., 
2005), the p38 effect on the BCL6 regulation in germinal centre cells has not been 
……………………………………………………………………………………………  . 
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reported before.  
Interestingly, mice with homozygous disruptions of the locus of the MAPK 
kinase kinase, MEKK1, have a very similar phenotype to that of mice lacking BCL6. 
Thus, these animals have defects in germinal centre formation with abnormal T-
dependent antibody responses and also have an increased production of Th2 cytokines. 
The normal effects of MEKK1 were shown to be dependent on the activation of the JNK 
and p38 pathways (Gallagher et al., 2007). Therefore we speculate that the B-cell 
phenotype of MEKK1 deficient mice is due to reduced or absent induction of BCL6 by 
p38MAPK, and this remains to be proved in future work. 
 
7.6. p38 MAPK, BCL6 and germinal centre derived lymphomas  
Burkitt's lymphoma is an example of a germinal centre derived non-Hodgkin's 
lymphoma. It is highly proliferative and shows surface IgM expression. The 
immunoglobulin genes show somatic hypermutations and this process is on-going in at 
least one Burkitt's lymphoma cell line, Ramos (Sale and Neuberger, 1998). One of the 
defining characteristics of Burkitt’s lymphoma according to the WHO classification is the 
expression of BCL6, without chromosomal translocations involving the BCL6 locus. It is 
worth mentioning that constitutive activation of p38 in several Burkitt’s lymphoma cell 
lines has been previously demonstrated (Horie et al., 2007; Vockerodt et al., 2001). 
Work reported here suggested that p38 is important for the induction and/or 
maintenance of BCL6 expression in germinal centre cells. Although the over-expression 
of the c-MYC oncogene in Burkitt’s lymphoma is required and of undoubted importance 
in terms of proliferation and cell survival, inhibition of BCL6 using specific peptides to 
inhibit function, was able to produce apoptosis and cell cycle arrest in these cells 
(Capelson and Corces, 2004). It has also been demonstrated that p38 inhibition in 
Burkitt’s lymphoma cell lines is able to induce growth arrest (Horie et al., 2007), which 
may link to its role in BCL6 expression. 
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Expression of phosphorylated p38 MAPK is detected in diffuse large B-cell 
lymphoma (DLBCL) and it has been implicated in the transformation of another type of 
non-Hodgkin's lymphoma, follicular lymphoma, into DLBCL. Inhibition of the p38 
signalling pathway induced growth arrest and apoptosis of follicular transformed cells 
(Elenitoba-Johnson et al., 2003). Several Burkitt’s lymphoma cell lines show constitutive 
activation of p38 and inhibition of p38 induces growth arrest. Expression of 
phosphorylated p38 MAPK is detected in DLBCL and it has been implicated in the 
transformation of follicular lymphoma into diffuse large cell lymphoma. Inhibition of the 
p38 signalling pathway induced growth arrest and apoptosis of follicular transformed 
cells (Elenitoba-Johnson et al., 2003).  
As shown previously, abnormal regulation of BCL6 has also been implicated in 
the pathogenesis of DLBCL and although there is less evidence it might be implicated in 
the pathogenesis of follicular lymphoma (Gollub et al., 2009). Abrogation of BCL6 
function leads to the death of Burkitt’s lymphoma cell lines and, therefore, routes to 
inhibit p38 may critically reduce BCL6 expression contributing to lymphoma cell death. 
p38 inhibitors are under investigation for the treatment of several diseases 
(Coulthard et al., 2009; Munoz and Ammit, ; Navas et al., 2006; Yong et al., 2009). 
Furthermore, specific p38 inhibitors have been employed as anti-inflammatory targets in 
clinical trials with promising results (Kumar et al., 2003). These drugs might have 
application in Burkitt’s lymphomas and maybe in other BCL6 expressing lymphomas. 
BCL6 expression defines a specific subtype of DLBCL (Alizadeh et al., 2000; 
Polo et al., 2007). Early studies (Offit et al., 1994) showed that DLBCL with BCL6 
translocations had a better clinical outcome than those without. Relative BCL6 mRNA 
expression also proved to be a marker of good prognosis (Iqbal et al., 2007) and 
extension of this work to immunocytochemistry confirmed the usefulness of BCL6 for 
this purpose (Hans et al., 2004). The treatment of DLBCL has been dramatically 
improved recently by the addition of the anti-CD20 monoclonal antibody Rituximab to 
the CHOP (cyclophosphamide, daunorubicin, vincristine and prednisolone) 
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chemotherapy regime. However, there is currently uncertainty about whether this new 
combination alters the status of BCL6 translocations as a prognostic marker (Shustik et 
al., 2010). One large series of patients demonstrated that BCL6 expressing cells are 
relatively resistant (Winter et al., 2006) to the effects of Rituximab, whereas another 
(Rimsza et al., 2008) showed that BCL6 continues to be a marker of good prognosis 
when this antibody is included in the treatment. 
Whilst lymphoma cells coated with antibody will be removed and killed by the 
reticulo-endothelial system, signalling through CD20 has also been reported. Rituximab 
inhibits several pro-survival and anti-apoptotic pathways - AKT, NF-κB, ERK1/2, p38 - 
(Bonavida, 2007). Pathways that are modified by Rituximab have been directly or 
indirectly implicated in the regulation of BCL6 (Niu et al., 1998; Saito et al., 2007).  
Taken together, these results might suggest that CD20 signalling modifies 
BCL6 expression through p38 MAPK. Further work will investigate how CD20 signalling 
modifies BCL6 expression through p38 MAPK in B-cell lines and primary lymphoma 
cells and will define the role of p38 inhibitors in synergising with anti-CD20 monoclonal 
antibodies in the treatment of DLBCL. 
Rituximab is the first developed anti-CD20 antibody but more recently a group 
of antibodies binding to different CD20 epitopes has been developed. These class II 
antibodies, of which GA101 (Roche) is one, are believed to have enhanced ADCC and 
superior caspase-independent apoptosis induction in comparison to Rituximab. The 
signalling pathways involved in the GA101 effect have not yet been thoroughly 
analysed.  
 
7.7. BCR and CD40 signalling effects on BCL6 expression 
Both the B-cell antigen receptor (BCR) and CD40 play key roles in the 
regulation of germinal centre processes. The former is necessary for antigen/B cells 
specific interactions while the latter mediates interactions with the CD40 ligand 
expressed in T CD4+ cells (Hollenbaugh et al., 1992). Both receptors have been shown 
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to negatively regulate BCL6 expression.  The ERK1/2 pathway mediates IgM induced 
BCL6 protein degradation (Niu et al., 1998) and CD40 stimulation leads to BCL6 
transcriptional down-regulation through the NF-ĸB/IRF4 pathway (Lossos, 2007). 
However, it is also known that both receptors significantly activate the p38 pathway 
(Sutherland et al., 1996). We ought to find out the role of p38 MAPK on the BCL6 
regulation after stimulation of the BCR and CD40 receptors. In agreement with previous 
results we found that BCR cross-linking simultaneously activated pathways that 
repressed (ERK1/2) and induced (p38, STAT5) BCL6. However, we showed by utilizing 
inhibitors of single pathways that repressive signals were stronger than the inductive.  
BCL6 repressive pathways (ERK1/2 and IRF4) were also stronger than the activating 
pathways (p38 MAPK) when Burkitt's lymphoma cell lines were stimulated with 
membrane bound CD40 ligand (mCD40L). The only situation in which BCL6 was further 
up-regulated was on stimulation with sCD40 and this was mainly due to the activation of 
the p38 pathway since SB202190, a p38 MAPK inhibitor antagonised this effect. 
Remarkably, none of the known BCL6 inhibitory pathways including the NF-ĸB/IRF4 
pathway were activated by sCD40.  
Collectively, these results show that, despite p38 and ERK1/2 signalling 
pathways belonging to the same MAPK super-family, they have opposing effects on 
BCL6 expression. There are precedents for such dichotomy. In macrophages activation 
of p38 or ERK1/2 MAPK leads to antagonistic immune responses (Mathur et al., 2004). 
CD40/CD40L interaction is required for B-cell survival, antibody isotype 
switching and memory B cell formation (Aruffo et al., 1993; Foy et al., 1994). CD40 
stimulation is also important for germinal centre formation and more controversially 
prevents B cell terminal differentiation (Randall et al., 1998). An interesting aspect of this 
work is that qualitatively different CD40 stimuli defined by responses to sCD40L and 
mCD40L in my experiments, produce different signalling outcomes corresponding, 
speculatively, to the early and late phases of CD40 signalling (Basso et al., 2004). There 
are several previous findings that support this idea. First, it has been shown that strong 
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and weak CD40 signalling in macrophages activates p38 or ERK1/2 signalling pathways 
respectively and the outcome is the production of different spectrum of cytokines 
(Mathur et al., 2004). Second, stimulation of specific CD40 epitopes resulted in the 
activation of different signalling pathways and in diverse B cell responses (Sakata et al., 
2000). Third, different groups of researchers using CD40 ligands from a variety of 
sources obtained either stimulation or inhibition of the NF-ĸB pathway in Ramos cells 
(Cai et al., 2008; Zarnegar et al., 2004). Fourth, our hypothesis also has some bearing 
on observations by others that transient or prolonged B-cell/T-cell contact produce 
different effects on BCL6 expression, and as a result diverse cellular outcomes. 
Transient CD40 signalling may be compatible with continued residence within germinal 
centre whilst prolonged CD40 signalling could be associated with germinal centre exit 
(Cerchietti et al., 2008).  
Whether the different effects on BCL6 expression produced by mCD40L and 
sCD40L are due to different amounts or quality of CD40 cross-linking or, to differences 
in the kinetics of the ligand-receptor interaction remain to be determined. 
 
7.8. Non-lymphoid cell/B-cell interactions may also regulate BCL6 
CD40 signalling activates many signalling pathways including p38 and ERK1/2 
in different cell lines. Correspondingly interaction of CD40 with mCD40L not only 
induced p38 activation but also ERK1/2. However, we demonstrated that co-culture of 
Ramos with untransfected mouse fibroblasts cells also showed phosphorylation of this 
MAPK family member, and it cannot, therefore, be a specific CD40 mediated effect. 
Moreover, Ramos interaction with fibroblasts alone also produced a reduction of BCL6 
and this effect was mediated by the ERK1/2 pathway since it was abrogated by the 
PD98059 Inhibitor. Consequently ERK1/2 may be activated, in vivo, in germinal centre 
cells by cell contact mediated by receptor- ligand pairs that are not unique to lymphoid 
cells. For instance, integrin signalling which lowers the threshold for early activation cells 
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may also have a role in the later stages of germinal centre reaction (Batista et al., 2007).  
 
7.9. p38 targets and BCL6 
There are several p38 targets that could mediate the p38 transcriptional 
regulation of BCL6. The Ccaat enhancer box binding proteins (C/EBP) family members 
play key roles in terms of cell differentiation and proliferation and control genes involved 
in inflammatory and immune responses (Chen et al., 1997). My preliminary reporter 
assays results showed that a small region at the beginning of the first exon of BCL6 
might be important for the p38 transcriptional regulation. It is interesting that within the 
exon 1 region there is a binding site for the polyvalent transcriptional regulator CTCF .  
 
7.10. CTCF regulation of BCL6  
One consequence of my p38 work was that specific regions of the BCL6 
promoter, including exon 1, will be the subject of further work. A previously 
unrecognised CTCF binding site was discovered and CTCF is a genomic regulator 
implicated in a number of functions including insulator activity, transcriptional activation 
and repression, and regulation of the cell cycle and cell proliferation.  
CTCF functions are modulated through post-translational modifications. 
Phosphorylation of the CTCF C-terminal serine residues by CKII interferes with CTCF 
regulatory function (Klenova et al., 2001) and interestingly, this phosphorylation may be 
dependent on the p38 MAPK pathway (Sayed et al., 2000). Therefore, it is tempting to 
speculate that p38 might be regulating BCL6 expression by controlling CTCF regulatory 
function. It has been reported a CTCF functional role in insulin-stimulated cell 
proliferation through ERK and AKT signalling pathways (Gao et al., 2007). Furthermore, 
EGF induced activation of ERK cascades resulted in increased CTCF expression in 
corneal epithelial cells (Li and Lu, 2005). The NFkB pathway was involved in this CTCF 
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upregulation (Lu et al., 2010). Thus CTCF seems to be a downstream target protein of 
growth factor-induced pathways. However there are no reports on the possible 
regulation of CTCF by the p38 MAPK pathway. We will address this issue in the future 
(see below future work) 
In this study, CTCF was shown to bind in vitro to BCL6 exon 1 and occupancy 
of this site in vivo was selectively detected in BCL6 expressing cells. This suggested 
that CTCF might be involved in the transcriptional up-regulation of BCL6, and 
accordingly several reporter assays using constructs consisting of the CTCF BS and 
performed in BCL6 expressing cells showed a consistent increase in the reporter activity 
when those cells were transfected with two different CTCF expressing vectors. Also, 
CTCF silencing in germinal centre BCL6 expressing cell lines led to a moderate but very 
reproducible reduction on the BCL6 protein expression. Although no significant effect 
was observed in the reporter activity of the constructs containing the CTCF BS after 
CTCF silencing in DG75 cells, the basal activity of this constructs is low probably due to 
the very potent negative autoregulatory BCL6 domain. In fact, it is known that the BCL6 
positive expressing cell lines might not be adequate models for studding the reporter 
activity of this region.  
CTCF enforced expression in the BCL6 negative cell line K562 led to cell arrest  
within less than 24 hours, and thus, it was not possible to study the effect of the CTCF 
over-expression on the reporter activity of the BCL6. However, it was possible to silence 
effectively  CTCF in K562 cells which caused a large increase in the reporter activity of 
these constructs. Although this result seems to contradict our previous findings, the 
discrepancy might be explained by CTCF having opposing effects in different cell types. 
CTCF might be acting through direct and indirect effects which might be regulated in a 
cell type dependent way. Speculatively CTCF could be recruiting different protein 
complexes in BCL6 positive and negative cell lines. However, this latter possibility is 
less probable since ChIP assays revealed no significant occupancy by CTCF in BCL6 
negative cell lines. An alternative explanation could be that different post-translational 
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modifications might be responsible for the antagonistic functions and, in fact, there are 
precedents for such a dichotomy. Two different CTCF forms with opposite roles in 
breast normal and cancer cells can be identified attending to their poly(ADP-ribosyl)ation 
status (Docquier et al., 2009). 
Finally, specific mutations of CTCF have been shown to interfere with CTCF 
function in certain tumors (see introduction). Point mutations of the CTCF binding site at 
the H19 ICR locus interfered with CTCF binding and function (Pant et al., 2004). 
Surprisingly, no other specific mutations on the other CTCF´s targets binding sites have 
been reported yet. Our preliminary results suggest that such mechanism might be 
operating in the BCL6 gene, since different point mutations on the CTCF BS were found 
in several BCL6 non-expressing cell lines. Further studies should be conducted to study 
the potential repercussions of such mutations in terms of interference with CTCF binding 
and with BCL6 expression.  
 
7.11. Epigenetics and BCL6 
Epigenetic changes are heritable variants in gene expression that are not due 
to any alteration in the DNA sequence. They include DNA methylation, histone 
modifications and chromatin remodelling (Esteller, 2008; Jones and Baylin, 2007). One 
of the most well known mechanisms of silencing DNA is through DNA methylation. The 
methylation pattern of the whole genome in certain tumours has been extensively 
investigated by several groups. Generally, in cancer, it is frequent to observe a 
predominant hypomethylation pattern of the genome with a few genes being aberrantly 
hypermethylated. Investigating the methylation status of specific genes can in some 
circunstances lead to their use as biomarkers (Nakayama et al., 2004).  The methylation 
status of different tumor suppressor genes has been examined by a number of research 
groups. However, the potential role of the different epigenetic modifications of 
oncogenes in differentiation and in cancer is less well understood. In particular the 
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epigenetic influence in the BCL6 gene regulation in normal conditions and in 
lymphomagenesis has not been thoroughly investigated.  
FISH studies revealed that some BCL6-non-expressing lymphoma cell lines 
showed three or more copies of the BCL6 gene with no sign of rearrangement. It could 
be possible that, despite there being extra copies of the BCL6 gene, the BCL6 
expression is silenced in those cases through epigenetic mechanisms. Moreover, 
different epigenetic modifications might explain the variability on the BCL6 expression 
found in different lymphoma samples, regardless sharing a common genotype. In this 
study the epigenetic influence on BCL6 expression was explored. 
The BCL6 gene contains several CpG islands in the region from the promoter 
to the first intron. and CTCF is essential for the regulation of CpG methylation of a 
number of genes. (see introduction). While this Thesis was in progress, several CTCF 
binding sites within the BCL6 intron 1 were described (Lai et al., 2010). At these sites, 
CTCF binds in a methylation dependent manner, with higher methylation (and less 
CTCF binding) being found in cell lines in which the BCL6 locus was transcriptionally 
active. Accordingly, administration of a methyl transferase inhbitor increased CTCF 
binding in BCL6 the Burkitt cell line Raji, whereas silencing of CTCF caused an increase 
in BCL6 mRNA in a plasma cell line (Lai et al., 2010). 
CTCF binding to the described CTCF BS within the BCL6 exon-1 is not 
dependent on methylation, despite being at a CpG island. Moreover, and in agreement 
with previous studies (Ramachandrareddy et al., 2010), no methylation was observed at 
that region, despite having different levels of BCL6 protein expression. Also, in contrast 
to the intronic sites, CTCF binding at the exon1A site is highest in BCL6 expressing cell 
lines. The exon1A CTCF site is close (250 bp) downstream of the major transcription 
start site in a region that has previously been implicated in the regulation of BCL6 
(Arguni et al., 2006; Papadopoulou et al., 2010). It is likely that a complex, repressing 
BCL6 transcription, involving BCL6 itself and CtBP assembles at exon1A based on a 
BCL6 binding site. We speculated that the repressive complex involved the two-handed 
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zinc finger transcription factor ZEB1, which also requires CtBP as a co-repressor, 
binding to a DNase I hypersensitive site 4.4 kb upstream of the transcription start site. 
The location of the exon1A CTCF site suggests that it may be important in the regulation 
of BCL6, and data presented here demonstrates that CTCF binding is associated with 
high level expression of BCL6. Silencing of CTCF in BCL6 positive DG75 lymphoma 
cells (this work), but apparently not the plasma cell line NCI-H929 (Lai et al., 2010), is 
associated with reduction in BCL6. Speculatively dismissal of CTCF from its exon1A 
binding site may be one of the early events switching off the BCL6 locus and allowing 
assembly of the repressive complex. A similar model has been previously shown within 
the p53 locus (Soto-Reyes and Recillas-Targa, 2010). We have found association of 
CTCF with active histone marks in the BCL6 expressing cell line Ramos. Others have 
found RNApolII enrichment near the CTCF binding site at exon1 (Lai et al., 2010). Lack 
of CTCF could lead to reduced binding of RNA polymerase II, active histone marks and 
of the variant histone H2A.Z near the BCL6 transcription start site eventually and to lead 
to the incorporation of repressive histone marks, We will addressed all these issues in 
the future (see next section). A proposed model for BCL6 regulation by CTCF at exon1 
based in our current results is depicted in (Figure 7.2).  
There are many other possible mechanisms whereby CTCF may cause 
epigenetic changes to alter BCL6 expression. Poly(ADP-ribosyl)ation modulates CTCF 
functions (Klenova and Ohlsson, 2005; Yu et al., 2004) and this post-translational 
modification might be interfering with CTCF binding to the BCL6 exon 1, leading to an 
epigenetic silencing of BCL6. This mechanism has been previously described (Soto-
Reyes and Recillas-Targa, 2010; Witcher and Emerson, 2009). Alternatively, CTCF 
binding to the BCL6 regulatory region might be required to protect against 
heterochromatin spreading, and binding to DNA might be dependent on poly(ADP-
ribosyl)ation as shown for the p16 (INK4a) gene (Witcher and Emerson, 2009). It is 
interesting that a PARP-1 binding site has been found by our group, relatively close to 
the CTCF binding site (Ambrose et al., 2007).   
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7.12. Summary and future work 
1. BCL6 has been shown to be upregulated in lymphoid blast crisis cells upon 
treatment with Imatinib. Although it has been suggested that BCR-ABL represses BCL6 
expression in order to block the differentiation process (Duy et al., 2007), the biological 
relevance of BCL6 upregulation in those cells after treatment with Imatinib is yet not 
clear and requires further investigation. Combination of Imatinib with specific peptide 
inhibitors against BCL6 might provide new insights in the biological relevance of BCL6 
modulation in those cells. 
 
2. It has been impossible using a variety of growth factors and other signals to 
induce BCL6 in cultured B cells and one reason for this may be that signals repressing 
and inducing BCL6 are produced by the same stimuli: the repressive ones being 
dominant. There might only be restricted circumstances in vivo in which positive signals 
predominate to cause BCL6 activation. A minority of germinal centre B-cells (~10%) 
Figure 7.2. A proposed model of BCL6 regulation by CTCF. The CTCF binding site is 
included within a CpG island of the BCL6 exon 1. However, DNA methylation of this region is not 
directly involved in BCL6 silencing in lymphoma cells (upper panels). CTCF and H2A.Z bind to 
BCL6 exon 1, favouring the incorporation of active histone modificatios. BCL6 silencing is 
associated to lack of CTCF, H2A.Z and active histone marks binding (lower panels). 
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(Figure 5.7) expresses phosphorylated p38 MAPK and it may be possible that this 
population represents cells in which BCL6 expression is being switched on. Others 
(Basso et al., 2004) have shown that a minority of germinal centre cells express 
activated NF-κB, and a similar argument has been made that this is the population in 
which BCL6 is being down-regulated prior to exit from the germinal centre 
Collectively these results reveal, for the first time, that the p38 pathway has an 
important role in the regulation of BCL6 in germinal centre cells. It was demonstrated 
that BCL6 regulation is due to cooperation between different signalling pathways and 
the findings suggest that the relative impact of the negative pathways is stronger than 
the positive ones. We have reported that sCD40L seems to activate only p38 and 
induces BCL6 expression.  
p38 inhibitors are under investigation for the treatment of several diseases 
(Guo et al., 2000). Furthermore, specific p38 inhibitors have been employed as anti-
inflammatory targets in clinical trials with promising results (Mihara et al., 2008). Our 
results suggest that these drugs might have applications in Burkitt’s lymphomas and 
maybe in other BCL6 expressing lymphomas.  
 
3. The important transcriptional regulator, CTCF was also shown to have a role 
in the regulation of BCL6, although a precise mechanism of action has not been defined. 
One appealing hypothesis is that CTCF might be locally organizing chromatin at the 
BCL6 exon1 and may be required to protect the BCL6 transcriptional start site against 
repressive histone marks. ChIP assays for repressive histone marks in basal conditions 
in Ramos cells as well as ChIP assays for active and repressive histone marks and for 
the RNAPol II in Ramos cells upon silencing of CTCF will be performed in order to verify 
this hypothesis. Also, as our major interest is to validate our findings utilising primary 
lymphoma cells. CTCF occupancy in primary cells from patients with BCL6 expressing 
lymphomas and myeloma (BCL6 negative) will be analyzed. 
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TSA combined with 5-azadC led to increased BCL6 expression in the BCL6 non-
expressing cell lines Toledo and K562. The effects of TSA alone will now be tested. If 
TSA is effective as a single agent, it is possible that TSA administration will cause 
increased acetylation of histone H3, leading to CTCF binding at BCL6 exon1. 
Altogether, these results might help to validate our hypothetical model of BCL6 
regulation by CTCF shown in Figure 7.2. 
Finally, this work has shown that both p38 MAPK and CTCF modulate BCL6 
expression through BCL6 exon-1. As CTCF function can be modulated through MAPK-
mediated phosphorylation, it might be possible that CTCF regulation of BCL6 depends 
on the p38 MAPK signalling pathway. Future challenge will be to validate this hypothesis 
and to further investigate this possibility differential CTCF phosphorylation in a variety of 
B-cell lines after treatment with p38 inhibitors will be analyzed. Also CTCF occupancy of 
BCL6 exon 1 and the pattern oh histone marks after treatment with p38 inhibitors will be 
explored. 
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a b s t r a c t
Bcl-6 is essential for germinal centre development and normal antibody responses, and has major roles
in controlling B-cell proliferation and differentiation. Bcl-6 expression is tightly controlled, but neither
the nature of all the regulatory signals nor their interactions are known. Bcl-6 expression is induced
in Bcr-Abl expressing lymphoid cell lines by the tyrosine kinase inhibitor, imatinib. We show that p38
MAPK mediates induction of Bcl-6 following inhibition of Bcr-Abl by imatinib. Next we analyze p38
function in agerminal centreB-cell line, Ramos. p38 is phosphorylatedunderbasal conditions, and studies
with p38 inhibitors show that it induces Bcl-6 expression. Membrane bound CD40 ligand activates p38
but also other MAPK pathways that strongly repress Bcl-6 and the overall effect is reduction in Bcl-ranscription
APK
6 expression. Surprisingly soluble CD40 ligand induces Bcl-6 by activating p38 without activating the
repressive pathways. Hence different types of CD40 signalling are associated with varying effects on
Bcl-6 expression. Transcription reporter assays demonstrate p38 responsive sequences at about 4.5 kb
from the transcription start site. Immunocytochemistry of tonsil sections show phosphorylated p38 in
a minor population of germinal centre B-cells. We demonstrate for the ﬁrst time that p38 induces Bcl-6
ed prtranscription, but increas
are not activated.
. Introduction
Bcl-6 is a zinc ﬁnger transcription factor, whose expression is
equired for normal germinal centre formation (Dent et al., 1997;
e et al., 1997) and, therefore, for normal high afﬁnity antibody
esponses to T-dependent antigens. Bcl-6 protein expression is
ightly regulated and it is not found in naïve B-cells or plasma cells
Cattoretti et al., 1995).
Bcl-6 is constitutively expressed through involvement in chro-
osomal translocations in 20–30% of human diffuse large B-cellymphoma (Ofﬁt et al., 1994; Ye et al., 1995, 1993), and is
xpressed (largelywithout structural changes to the locus) in follic-
lar lymphoma, Burkitt’s lymphomaand lymphocyte-predominant
odgkin’s lymphoma. Bcl-6 allows B-cell proliferation (Reljic et al.,
∗ Corresponding author at: MRC Toxicology Unit, University of Leicester, Hodgkin
uilding, Room 404, Lancaster Road, Leicester LE1 9HN, UK. Tel.: +44 116 252 5589;
ax: +44 116 252 5616.
E-mail address: sw227@le.ac.uk (S.D. Wagner).
161-5890/$ – see front matter © 2009 Elsevier Ltd. All rights reserved.
oi:10.1016/j.molimm.2009.02.003otein expression occurs only when the strong pathways repressing Bcl-6
© 2009 Elsevier Ltd. All rights reserved.
2000; Shvarts et al., 2002) and prevents terminal differentiation to
plasma cells (Diehl et al., 2008; Reljic et al., 2000; Tunyaplin et al.,
2004).
Understanding the regulation of Bcl-6 expression has been the
focus of work by several groups ﬁrstly, because this protein is fun-
damental to germinal centre development, and, secondly, because
disruption of Bcl-6 function may be therapeutically useful in some
non-Hodgkin’s lymphomas and certain autoimmune diseases. A
B-cell within the germinal centre receives signals from growth fac-
tors, from antigen presented by the follicular dendritic cells and
from cognate interactions with T-cells. The Bcl-6 proximal pro-
moter region contains several consensus STAT sites, and in B-cell
lymphoma cell lines STAT5 has a repressive effect on Bcl-6 tran-
scription (Walker et al., 2007), whereas in primary tonsillar B-cells
its effect is to induce Bcl-6 transcription (Scheeren et al., 2005).B-cell receptor (BCR) and CD40 signalling both activate mitogen
activated protein kinases (MAPK). MAPK are serine/threonine pro-
tein kinases and comprise many families of which the best studied
are extra-cellular signal related kinases 1 and 2 (Erk1/2), the Jun-N-
terminal kinases (Jnks) and the p38 kinases. In turn the MAPKs are
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ctivated by MAP kinase kinases (MKKs), with Erk1/2, Jnk and p38
ach being predominantly regulated by different MKKs (Raman et
l., 2007). BCR cross-linking the of the germinal centre representa-
ive cell line, Ramos, causes activation of p44 Erk1 and p42 Erk2,
hich then phosphorylate Bcl-6, leading to its nuclear export and
egradationby theubiquitin/proteasomepathway (Niuet al., 1998).
More recently, CD40 stimulation (by the T-cell surface antigen
D40 ligand ectopically expressed on the surface of a ﬁbroblast cell
ine) has also been shown to reduce Bcl-6 expression, in cell lines
nd puriﬁed tonsillar centroblasts, through NF-B activation and
nduction of IRF4 (Saito et al., 2007). Thus, it appears that both
CR engagement and CD40 signalling cause a reduction in Bcl-6
xpression, possibly associated with the production of a high afﬁn-
ty antibody at the end of the germinal centre reaction. Therefore,
hilst several signals altering Bcl-6 expression are known, their
elative importance is not understood.
Chronicmyeloid leukaemia (CML) cells bear a reciprocal translo-
ation between chromosomes 9 and 22 that creates a non-receptor
yrosine kinase fusion protein, Bcr-Abl. It has been previously
hown that Bcl-6 is induced when Bcr-Abl is inhibited with
he tyrosine kinase inhibitor, imatinib (Deininger et al., 2000)
n lymphoid blast crisis cell lines. This occurs before apopto-
is takes place, and is not likely to be secondary to cell death.
he main signalling pathways controlled by Bcr-Abl are Jak/Stat,
af/Mek/Erk and PI3K/Akt and, therefore, the CML cell lines are
conditional system for analyzing the regulation of Bcl-6 by
hese molecules (Steelman et al., 2004). Preliminary work sug-
ests that Bcl-6 is a functionally important survival factor in
cr-Abl driven acute lymphoblastic leukaemia crisis (Duy et al.,
008).
Here,wedeﬁne the regulationofBcl-6byMAPKpathwaysﬁrstly,
tilising CML lymphoid blast crisis cell lines and secondly in the
erminal centre representative cell line, Ramos. We show that p38
s an important inducer of Bcl-6 in both systems but that MAPK
roteins can both induce and repress Bcl-6 with the overall effect
epending on the precise stimulus used to activate this signalling
athway.
. Materials and methods
.1. Cell lines and culture
The Bcr-Abl-positive cell lines (BV173, Nalm-1, Z119, Z-33, TOM-
and K562), acute myeloid leukaemia cell line (MV4;11) and the
-cell lines DG75 and Ramos were grown in RPMI-1640 (Lonza,
asel, Switzerland) supplementedwith 10% fetal calf serum (Lonza,
asel, Switzerland), 2% l-glutamine and 5% penicillin/streptomycin
Invitrogen, Paisley, UK).
Informed consent was obtained for the use of a sample of
rozen mononuclear cells from a patient with lymphoid blast cri-
is of CML from the Hospital Marques de Valdecilla, Department
f Haematology, Santander, Spain. Cell viability was assessed by
rypan blue staining. 107 cells were cultured in 1ml of FCS-free-
edium (Iscove’s Modiﬁed Dulbecco’s medium (Sigma, St. Louis,
O, USA), 1%penicillin-streptomycin-l-glutamine and serum sub-
titute (BIT: StemCell Technologies, Vancouver, BC, Canada) and
ept in culture overnight (Hamilton et al., 2006).
As a source of CD40 stimulation either soluble CD40 ligand
sCD40L) (Biovision, Mountain View, CA, USA; 0.1–20ng/ml) or
o-culture with a mouse ﬁbroblast cell line stably transfected
ith human CD40 ligand (mCD40L) were used. Non-transfected
broblast cells (NTL) were used as controls. The cell layers were
0–90% conﬂuent and irradiated (30Gy) before use. 107 Ramos
ells were cultured in 5ml of complete medium when using
CD40L.logy 46 (2009) 1727–1735
2.2. Treatment with inhibitors and stimulators
The Bcr-Abl-positive cell lines, Z119 and BV173, and the germi-
nal centre B-cell lines, Ramos and DG75, and primary cells were
incubated with inhibitors of the Erk1/2 pathway (using the Mek1/2
inhibitorsU0126orPD98059 (Calbiochem,Nottingham,UK))orp38
pathway (SB 202190; Calbiochem, Nottingham, UK). Where indi-
cated, imatinib (0.5–5M; Novartis; Pharma, Basel, Switzerland)
was included in the cell suspension. Stock solutions of the inhibitors
were prepared with DMSO. The ﬁnal concentration of DMSO in
all the experiments was below 0.8%. For cross-linking surface IgM
we used goat anti-human IgM (Southern Biotech, Birmingham, AL,
USA; 2020-01).
2.3. Bcl-6 reporter gene assay
Fragments of Bcl-6 genomic DNA (base position as measured
from the transcription start site (Bernardin et al., 1997): −4904
to +533; −4904 to +239; −4128 to +533; −4128 to +239 and
+239 to +533) were obtained by PCR and subcloned into the
pGL3 basic reporter vector (Promega, Madison, WI, USA). The pRL
luciferase control vector was purchased from Promega, Madison,
WI, USA.
HEK293T cells were transfected with the pRL transfection con-
trol vector (Promega, Madison, WI, USA) and with either the
pGL3 basic vector or with equimolar concentrations of differ-
ent Bcl6pGL3 constructs, using Lipofectamine2000 (Invitrogen,
Paisley, UK). To assess the effect of phospho-p38 on the Bcl6 pro-
moter, 1g/ml of anisomycin (Sigma, St. Louis, MO, USA) was
added to the medium 2h before lysing the cells. Supernatants
were assayed using the Dual-Glo Luciferase Reporter System fol-
lowing the manufacturer’s instructions (Promega, Madison, WI,
USA).
2.4. Western blot analysis and antibodies
Cells (2–10×106 cells) were washed once in cold PBS and resus-
pended in RIPA lysis buffer (1% nonidet P-40, 100mM Nacl, 20mM
Tris–HCl (pH: 7.4) with 10mM NaF and complete protease and
phosphatase inhibitors (Sigma, St. Louis, MO, USA). Lysates were
incubatedon ice for 30minandcentrifuged for 20min (12,000 rpm)
at 4 ◦C. 40–100g of protein were separated on 7.5–10% SDS-
polyacrylamide gels followed by transfer onto a PVDF membrane
(Immobilon-P,Millpore, Bedford,MA). Themembranewas blocked,
either in 5% skimmed milk or 5% BSA, in Tris-buffered saline and
then incubated sequentially with the primary and the secondary
antibodies. Speciﬁc bands were visualized using the enhanced
chemiluminescence system (ECL, GE Healthcare, Chalfont St. Giles,
UK). To control for protein loading, the blots were restained
with either anti-GAPDH (Cell Signalling Technology, Danvers, MA,
USA, #2118, 1:2000) or anti-abl (Santa Cruz Biotechnology, Santa
Cruz, CA, USA). We used commercial lysates: Jnk (sc-24769) and
p38 (sc-2217) as controls for anti-phospho-Jnk and anti-phospho-
p38.
The following antibodies were obtained from Cell Signalling
Technology, Danvers, MA, USA: HRP-conjugated anti mouse
IgG, HRP-conjugated anti-rabbit IgG, anti-phospho-c-Abl (Tyr412)
#2865, 1:500; anti-phospho-STAT5 (Tyr694) #9351, 1:500; anti-
phospho-p38 #9215, 1:1000; anti-p38, 1:1000; anti-phospho-JNK,
#4668; 1:1000; anti-Jnk, 1:1000; anti-phospho-Erk1/2, #9101;
1:1000; anti-Erk1/2, #9102; 1:1000 and anti-IRF4, 1:1000. Other
antibodies were anti-4G10 used ay 1:1000 (Upstate Biotechnology,
Lake Placid, NY, USA); anti-Bcl-6 (N-3) (Santa Cruz Biotechnology,
Santa Cruz, CA, USA, sc-858, 1:100) and anti-STAT5 (Santa Cruz
Biotechnology, sc-835, 1:100).
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.5. Real-time PCR (Taqman)
Total RNA was isolated with a RNeasy kit (Qiagen, Crawley, UK)
nd treated with DNase I (Invitrogen, Paisley, UK). RNA (2g) was
everse transcribed using an Omniscript kit (Qiagen, Crawley, UK),
nd the cDNA was used in real-time semi-quantitative PCR anal-
sis. Primer and probe mixtures were purchased from Applied
iosystems, Foster City, CA, USA: HPRT-1 (hs99999909 m1) and
cl-6 (Hs00153368 m1). Ampliﬁcations were performed on an ABI
rism7700 SequenceDetector (Applied Biosystems, Foster City, CA,
SA) for 10min at 95 ◦C, 2min at 50 ◦C, followed by 40 cycles of
5 seconds at 95 ◦C and 1min at 60 ◦C. All measurements were per-
ormed in triplicate. Each sample was analyzed for Bcl6 and HPRT
xpression and values were expressed as Bcl-6:HPRT-1 ratios.
.6. Electrophoretic mobility shift assay
Nuclear proteins were extracted (Schreiber et al., 1989) from ten
o twenty million cells. Cells were washed in PBS and resuspended
n buffer A (10mMHEPES pH7.9, 1.5mMMgCl2, 10mMKCl, 0.5mM
TT and 5l of 10%NP40). After centrifuging the nucleiwere resus-
ended in buffer C (20mM HEPES pH 7.9, 25% glycerol, 0.42M NaCl,
.5mM MgCl2, 0.2M EDTA and 0.5mM DTT). Protease and phos-
ig. 1. Imatinib induces Bcl-6 transcription and protein expression in Bcr-Abl expressing
ifferent concentrations of imatinib for 24h in lymphoid Bcr-Abl cell lines (BV173, Nalm-
yrosine kinase inhibitor, imatinib (lane 1, 0M; lane 2, 0.5M; lane 3, 1M; lane 4, 2M
CR for Bcl-6 mRNA was carried out on BV173 cells after treatment with 1M of imatinib
ig. 2. Imatinib induces Bcl-6 in primary CML cells and cell lines through a p38 mecha
matinib plus a p38 inhibitor (SB202190) for 8 and 16h. Loading control is GAPDH. To con
cr-Abl. (b) Westerns of phosphorylated and total Bcr-Abl, Stat5, p38, Erk1/2, Jnk1/2 and
matinib. (c) Western of Bcl6 expression in BV173 cells after treatment with 10M of SB2
ndicated in lane 2. (d) Western showing the effect of SB202190 on Bcl-6 expression in BVlogy 46 (2009) 1727–1735 1729
phatase inhibitors (Sigma, St. Louis, MO, USA) were included in
all solutions. Each binding and binding competition assay mixture
(10l) contained 0.05pmol of the 32P-labelled probe and unla-
belled competitor DNA at either 1, 5 or 10pmol, respectively, in
5mM MgCl2, 50mM Tris–HCl, 2.5mM EDTA, 2.5mM DTT, 20% glyc-
erol and 250mM NaCl. Cell lysate and radiolabelled probe were
incubated at room temperature for 30min. Mixtures were run on a
4% native acrylamide gel.
2.7. DNase hypersensitive site assays
Nuclei preparation, DNase I digestion, DNAextraction, and
Southern blot analysis were performed as previously described
(Vyas et al., 1992). Details of single-copy probes used for Southern
blot analysis are available on request.
3. Results3.1. p38 MAPK induces Bcl-6 in CML lymphoid blast crisis cell lines
One of the effects of the tyrosine kinase inhibitor imatinib is to
increase expression of Bcl-6 mRNA in Bcr-Abl lymphoid blast crisis
lymphoid cell lines. (a) Westerns showing Bcl-6 expression after treatment with
1, Z119, Z-33 and TOM-1) and myeloid Bcr-Abl cell lines (K562 and MV4;11) by the
and lane 5, 5M). Loading controls were carried out for each cell line. (b) Real-time
for different lengths of time.
nism. (a) Primary lymphoid blast crisis cells were treated with imatinib alone, or
ﬁrm the effectiveness of imatinib we also analyzed expression of phosphorylated
Akt in BV173 cells in the absence of imatinib and after 6h incubation with 1M
02190 for different lengths of time. The effect of 4h culture with 1M imatinib is
173 treated with 1M imatinib. Loading control is GAPDH.
1 munology 46 (2009) 1727–1735
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Fig. 4. Differential effects of Mek1/2 inhibitors, U0126 and PD98059, on p38 phos-
phorylation. (a) Westerns showing the combined effect of anti-IgM and increasing
concentrations of SB202190. The effect of anti-IgM alone is shown in lane 2. Loading
control is Abl. (b) Western showing the effect of anti-IgM and increasing concen-
trations of the Mek1/2 inhibitor U0126. The effects of anti-IgM alone are shown in
lane 2. Loading control is Abl. (c) Ramos cells were either untreated, treated with730 A. Batlle et al. / Molecular Im
ell lines (Deininger et al., 2000; Fernandez de Mattos et al., 2004).
e carried out further testing of Bcr-Abl lymphoid cell lines: all
howed induction of Bcl-6 protein expression on treatment with
matinib (Fig. 1a), and this was largely due to increases in Bcl-6
ranscription (Fig. 1b). The Bcr-Abl myeloid cell lines tested showed
o induction of Bcl-6. Primary cells from a patient with lymphoid
last crisis (without Abl kinase domain mutations in the leukaemic
ells) were treated with imatinib and also demonstrated increased
cl-6 expression (Fig. 2a).
Imatinib abolishes phosphorylation of Bcr-Abl and thereby pre-
ents phosphorylation of target proteins. We found that imatinib
educed phosphorylation of STAT5 and AKT, but that p38 was rel-
tively resistant to the effects of this drug (Fig. 2b). We reasoned
hat, because it was persistently phosphorylated in the presence of
matinib, p38 was a candidate protein inducing Bcl-6 expression.
tilising Z119 we found that a speciﬁc inhibitor of p38, SB202190,
educed Bcl-6 expression (Fig. 2c). When Z119 was treated with
matinib together with SB202190 for varying lengths of time, Bcl-
expression was again reduced (Fig. 2d). This effect was also
bserved in BV173 (not shown) and primary lymphoid blast crisis
ells. We conclude that p38 acts to induce Bcl-6 expression under
oth basal conditions and in the presence of imatinib.
.2. Multiple MAPKs, including p38, are induced by anti-IgM in
amos
Bcl-6 has important roles in normal germinal centre B-cells and
he germinal centre derived non-Hodgkin’s lymphomas.We sought
o ﬁnd out the effects of p38 on basal Bcl-6 expression in the human
urkitt lymphoma cell line, Ramos (Niu et al., 1998; Saito et al.,
007). We found that SB202190 reduces Bcl-6 expression (Fig. 3a).
e also obtained this result with another Burkitt cell line, DG75
not shown). (As previously reported (Oster et al., 2008;Wang et al.,
000) SB202190 increased p38 phosphorylation, probably because,
hilst p38 activity is inhibited, phosphorylation by proteins in the
APK signalling cascade continues.)
B-cell receptor signalling reduces Bcl-6 expression largely by
ost-translational mechanisms acting through Erk1/2 (Niu et al.,
998). However, we found that BCR signalling increased p38 phos-
horylation as well as Erk1/2 phosphorylation (Fig. 3b), suggesting
hat this stimulus activates pathways that both induce and repress
cl-6.Whenused togetherwith anti-IgM, the speciﬁc p38 inhibitor,
B202190, reduced Bcl-6 expression further (Fig. 4a). Others have
ound that MEK1/2 inhibition by PD98059 prevents the reduction
f Bcl-6 expression caused by anti-IgM (Niu et al., 1998), but sur-
risingly we found that U0126 causes only a minor reversal of the
ffect of IgM (Fig. 4b). Indeed, at the highest concentration of U0126
75M) Bcl-6 expression was reduced to that found with anti-IgM
lone.
ig. 3. Activated p38 induces Bcl-6 in Ramos cell line, but its effects are overcome
y repressive Erk1/2. (a) Westerns for Bcl-6 expression in cells treated with varying
oncentrations of SB202190. SB202190 caused an increase in phosphorylated p38
as previously reported (Oster et al., 2008; Wang et al., 2000)), but this form of the
olecule is inactive. Loading control is Abl. (b) Westerns showing the effects of IgM
ross-linking (10g/ml) for different lengths of time on Bcl-6 expression. Loading
ontrol is Abl.anti-IgM alone or treated with U0126 10M (left hand panel) or PD98059 50M
(right hand panel) for 30min followed by the addition of anti-IgM (10M) for 6h.
Whole cell lysates were then analyzed by westerns using antibodies as indicated to
the right of the panels. Loading control is Abl.
In order to pursue the cause of this discrepancywedirectly com-
pared U0126 and PD98059 (Fig. 4c). As anticipated both inhibitors
abrogated Erk1/2 phosphorylation, but they differed in their effects
on p38: whereas U0126 abolished anti-IgM-induced p38 phos-
phorylation, PD98059 had no effects. U0126 is a potent Mek1/2
inhibitor but, at higher concentrations, inhibits other pathways
including p38 (Favata et al., 1998). Therefore, Bcl-6 expression
integrates the effects of positive and negative factors. Erk1/2 is a
powerful negative regulator and, in this system, appears to over-
whelm the effects of p38, which we identify as a positive regulator.
3.3. Expression of phosphorylated p38 in tonsil
In order to ﬁndout the relationship betweenBcl-6 andphospho-
rylated p38 we carried out immunocytochemistry of human tonsil
(Fig. 5). There were scattered phosphorylated p38 expressing cells
within germinal centres (Fig. 3a) and the majority of mantle zone
(MZ) cells expressed this protein. In order to conﬁrm that germinal
centre B-cells express phosphorylated p38 we carried out double
staining with antibodies directed against the surface protein CD20
andanti-phosphorylatedp38 (Fig. 5b–d).Double stainingwithanti-
Bcl-6 and anti-phosphorylated p38 (Fig. 5e and f) shows that a
minority of Bcl-6 expressing cells (5–10%) express phosphorylated
p38.
3.4. Soluble CD40 ligand induces Bcl-6 through inducing p38
CD40 stimulation by membrane bound CD40 ligand (mCD40L)
has been reported to reduce Bcl-6 protein expression due to NF-B
induced IRF4 activity (Saito et al., 2007).Wemeasured the effects of
mCD40L on MAPK proteins and found that Erk1/2, p38 and Jnk1/2
were all phosphorylated (Fig. 6e). The strong inhibitory effects of
phosphorylated Erk1/2 on Bcl-6 might, therefore, contribute to the
effects of IRF4. We also tested soluble CD40 ligand (sCD40L) for its
effects on Bcl-6 protein expression and surprisingly found a strong
A. Batlle et al. / Molecular Immunology 46 (2009) 1727–1735 1731
Fig. 5. Immunocytochemistry showing phosphorylated p38 expression in normal human tonsil germinal centres. (a) Stainingwith anti-phospho p38 (×10). Expression occurs
mainly in centrocytes and not centroblasts. MZ is mantle zone and GC is germinal centre. (b) Double staining with anti-phospho p38 (red) and anti-CD20 (brown) (×10). (c)
Higher power view of germinal centre cells stained with anti-phospho-p38 (red) and surface CD20 (brown) (×60). (d) Staining of the mantle zone with nuclear phospho-p38
(red) and surface CD20 (brown)(×60). (e) Double-staining with anti-Bcl-6 (red) and anti-phospho p38 (brown) (×10). (f) Further high power view (×100) from the germinal
centre/mantle zone border stained with anti-phospho-p38 (brown) and anti-Bcl-6 (red). Cells staining for both proteins are indicated by black arrowheads. The majority of
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egend, the reader is referred to the web version of the article).
nduction (Fig. 6a). This effect was observed over a concentration
ange of 0.1–20g/ml of sCD40L. sCD40L caused phosphoryla-
ion of p38 without activating Erk1/2, Jnk1/2 or inducing IRF4. We
onclude that p38 is an important inducer of Bcl-6, but as with
ross-linkingof theBCRbyanti-IgM, its effects are strongly counter-
cted by repressors—Erk1/2 and IRF4. In conﬁrmation of this the
ddition of SB202190 to sCD40L completely abolished induction of
cl-6 (Fig. 6b).
ig. 6. Soluble CD40 ligand and membrane bound CD40 ligand differ in their effects on
nalyzed by Western blot using antibodies indicated to the right of the panels. (a) Cells tr
ells were co-cultured with the untransfected mouse ﬁbroblast layer. (d) Ramos cells we
ntransfected mouse ﬁbroblasts for different lengths of time as indicated. (e) Ramos cell
he effect of sCD40L and mCD40L on NF-B activation. Lane 1, no cell lysate; lane 2, unst
ith mCD40L and lane 6, 8h with mCD40L. The shifted band is indicated by the arrowheaeen in the mantle zone (For interpretation of the references to color in this ﬁgure
mCD40L is expressed on the surface of the mouse ﬁbroblast
line, L-cells. We reasoned that interactions of the B-cell line with
adhesion molecules on the surface of ﬁbroblasts may be impor-
tant and we, therefore, sought effects of this line alone on Bcl-6
(Fig. 6c). There was a transient decrease in p38 phosphorylation
(lane2, Fig. 6c),with inductionof Erk1/2phosphorylation andwith-
out either Jnk1/2 or IRF4 induction. Overall therewas a reduction in
Bcl-6 expression,whichwas restored by PD98059 (Fig. 6d).We con-
Bcl-6 expression Ramos cells were treated for 0, 10, 16 and 24h. Cell lysates were
eated with sCD40L. (b) Cells were co-cultured with the p38 inhibitor, SB202190. (c)
re treated for 30min with the Erk1/2 inhibitor PD98059 and then co-cultured with
s were co-cultured with ﬁbroblasts expressing mCD40L. (f) Gel shift assay to show
imulated Ramos cells; lane 3, 4h with sCD40L; lane 4, 8h with sCD40L; lane 5, 4h
d to the right.
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the 5 portion of the construct (−4128 to +533) retained transcrip-
tional activity, but the addition of anisomycin no longer produced
signiﬁcant enhancement. Deletion of exon 1 sequence from the 3′
portion of the promoter construct (−4904 to +239) caused tran-
scription to fall by>60%.Comparisonwith the constructspossessing
Fig. 8. p38 drives transcription through sequences in the Bcl-6 promoter region. (a)
Western showing time course of p38 phosphorylation in response to anisomycin in
HEK293T cells. (b) Luciferase assays to show the effects of anisomycin and a p38ig. 7. Manipulation of p38 activity causes changes to Bcl-6 expression (a–d) are rea
oints as indicated. Means± SEM are shown. The right-hand column of each grap
egative control. (a) Effect of the p38 inhibitor, SB202190, on expression of Bcl-6 m
ffect of BCR cross-linking by anti-IgM on Bcl-6 transcription. (d) Culture of Ramos
lude that Erk1/2 phosphorylation is caused by interactions with
broblast surface proteins but there is no induction of IRF4, which
s speciﬁcally due to mCD40L (Fig. 6e). sCD40L, therefore, causes
peciﬁc activation of p38 with no detectable phosphorylation of
rk1/2 or Jnk1/2.
IRF4 is activated by the NF-B pathway (Saito et al., 2007).
e measured NF-B activation following incubation with sCD40L
r mCD40L using gel shift assays (Fig. 4f). Whilst both ligands
ncreased NF-B activation this was greater with mCD40L demon-
trating that under the experimental conditions IRF4 is induced
hen NF-B activity is above a threshold level.
.5. Effects on Bcl-6 transcription
Next we sought effects on Bcl-6 transcription. The p38 inhibitor
B202190 produced a reduction in Bcl-6 mRNA (Fig. 7a). sCD40L
auses a 2-fold increase in Bcl-6 mRNA expression (Fig. 7b). The
broblast layer alone produced no signiﬁcant change in Bcl-6
RNA (compatible with a post-translational effect of phosphory-
ated Erk1/2 (Niu et al., 1998) (Fig. 7c) and mCD40L reduced mRNA
xpression as anticipated from the induction of IRF4 (Saito et al.,
007) (Fig. 7d). We conclude that p38 acts at the level of Bcl-6
ranscription.
.6. Site of action of p38 target genes at the Bcl-6 promoter
p38 acts to phosphorylate and activate a number of transcrip-
ion factors. In order to ﬁnd the site of action of p38 we carried out
uciferase reporter assays. Bcl-6 promoter assays in Bcl-6 express-
ng cell lines are complicated by a negative autoregulatory effect
Wang et al., 2002), which suppresses transcriptional activity, and
e, therefore, followed others (Saito et al., 2007) in using 293T
uman embryonic kidney cells (HEK293T). HEK293T cells express
ow levels of phosphorylated p38, and this can be increased by ani-
omycin (Fig. 8a). We measured luciferase activity due to about
.5 kb (positions −4904 to +533 relative to the transcription start
ite) of the Bcl-6 promoter comprising sequence 4.5 kb upstream
f the transcription start site to exon 1 (Fig. 8b). There was strong
ranscriptional activity due to the full-length construct and thiswase PCR measurements of Bcl-6 mRNA in Ramos normalised to HPRT at different time
esents the measurement of Bcl-6 mRNA in HEK293T cells. This was included as a
b) Effect of sCD40L. There is an increase of 2-fold over basal expression of Bcl-6. (c)
broblasts expressing CD40L (mCD40L).
enhanced a further 25% by anisomycin (paired t-test; p=0.0012).
Inhibition of p38 by SB202190 reduced luciferase activity below
basal levels (not statistically signiﬁcant), suggesting that there may
be a small amount of resting p38 activity. Deletion of 300bp from
′inhibitor on transcription from a 5.5 kb section of the Bcl-6 promoter ‘+’ indicates
that the transfected cells were exposed to anisomycin and ‘−’ indicates absence of
anisomycin. The constructs used are indicated to the left. Means± SEM are shown.
Each experiment was carried out 6 to 10 times with the exception of the p38
inhibitor + full-length construct (2 times) and the exon1 construct± anisomycin (2
times).
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Fig. 9. Proposedmodel for the regulationof Bcl-6 expression as theoutcomeofweak
positive and strong negative signals. Bcl-6 expression in germinal centre B-cells is
regulated by BCR and CD40 signalling. The strong inhibitory pathways are shown as
heavy lines and the weak activating signals as dotted lines. BCR cross-linking acti-
vates inhibitory Erk1/2 signalling (heavy lines) acting post-transcriptionally (Niu et
al., 1998) aswell as p38 (dotted lines) and the overall effect is Bcl-6 down-regulation.
CD40 stimulation also drives pathways inhibiting Bcl-6 transcription by IRF4 (Saito
et al., 2007) (heavy lines) and increasing transcription by p38 (dotted lines). The
overall effect depends on the quality of the signal: physiological signals equivalent
to membrane bound CD40 ligand inhibit Bcl-6 expression and lead to germinal cen-
tre exit, but signals similar to those delivered by soluble CD40 ligand cause increased
Bcl-6 expression, and continued residence within the germinal centre. Stromal cell
contactsmay also down-regulate Bcl-6 through Erk1/2 activation. Interleukins causeA. Batlle et al. / Molecular Im
ull transcriptional activity is, therefore, difﬁcult and we cannot
xclude a small anisomycin effect. Finally, exon 1 alone had virtu-
lly no transcriptional activity. We conclude that exon 1 with other
equences in this 5.5 kb region is required for full transcriptional
ctivity, and that p38 responsiveness is abolished by deletion of
he distal promoter region.
. Discussion
Germinal centres are sites of intense B-cell proliferation asso-
iated with somatic hypermutation and isotype-switching. These
rocesses are necessary for the production of high afﬁnity anti-
odies but may also contribute to lymphomagenesis. Absent or
ysregulated germinal centre reactions can result in immunodeﬁ-
iency (Aruffo et al., 1993; Revy et al., 2000) or autoimmunity. There
s a wealth of evidence that Bcl-6 is required for normal germinal
entre function (Dent et al., 1998; Ye et al., 1997) and its overex-
ression in mice is sufﬁcient for the development of lymphomas
Cattoretti et al., 2005).Mutations of cis-acting Bcl-6 regulatory ele-
ents are associated with human DLBCL (Pasqualucci et al., 2003;
aito et al., 2007; Wang et al., 2002). Failure or over-activity of the
ignalling pathways regulating Bcl-6 can, therefore, have profound
ffects on germinal centre function and lymphomagenesis.
Bcl-6 is induced by imatinib in Bcr-Abl cell lines (Deininger et al.,
000). Utilising this as amodel system,we showed that inductionof
cl-6 is a general effect in Bcr-Abl lymphoid cell lines (and primary
ymphoid blast crisis cells) but not Bcr-Abl myeloid cell lines. In one
cr-Abl lymphoid cell line, BV173, the transcription factor FoxO3a
irectly induces Bcl-6 (Fernandez de Mattos et al., 2004) but the
APK pathways have not been analyzed. We showed that p38, like
oxO3a, is a mediator of the Bcl-6 response to Bcr-Abl Inhibition by
matinib.
We next transferred our analysis to the B-cell line Ramos,
hich has been used before, as a germinal centre representa-
ive, to characterise Bcl-6 regulation (Niu et al., 1998; Saito et
l., 2007) and somatic hypermutation (Sale and Neuberger, 1998).
e investigated responses to important B-cell signalling pathways
ediated by BCR cross-linking and CD40 stimulation. We found
hat BCR cross-linking and mCD40L activated MAPKs, some of
hich repressed (Erk1/2) whilst others induced (p38) Bcl-6, and
hat the repressive signals were stronger than the inductive (Fig. 9).
y contrast sCD40L activated p38 MAPK but not Erk1/2 or Jnk.
CD40 signalling is required for germinal centre formation, spe-
iﬁc antibody production and memory B-cell development (Aruffo
t al., 1993; Foy et al., 1994;Nonoyama et al., 1993;Ochs et al., 1994)
nd activates p38 (Craxton et al., 1998; Sutherland et al., 1996).
ecent work shows that NF-B signalling, caused by CD40 stimu-
ation, mediates down-regulation of Bcl-6 (Saito et al., 2007) and,
y inference, exit from the germinal centre. Thus, apparently oppo-
ite roles can be assigned to CD40 signalling in the germinal centre.
CD40L, which repressed Bcl-6, clearly causes NF-B activation
ut sCD40L, which increased Bcl-6 expression does not activate
his pathway to the same degree in Ramos cells. Gene expression
nd immunoﬂuorescence studies show that CD40 signalling does
ot occur in most germinal centre cells but is found in a subset of
entrocytes (Basso et al., 2004). We found that phosphorylated p38
as expressed in a minority of tonsillar germinal centre B-cells. We
peculate that signals, either repressing or inducing Bcl-6 are only
ctive transiently and in small germinal centre populations. p38 is
xpressed in almost all mantle zone B-cells, and it is, therefore, not
ufﬁcient for Bcl-6 expression, but is likely to co-operatewith other
actors.
Mechanistically, sCD40L and mCD40L may cause different
mounts of CD40 cross-linking or there may be differences in
he kinetics of the ligand–receptor interaction that are crucialSTAT5activationand increaseBcl-6 transcription (Scheerenet al., 2005). This scheme
is not complete: neither the transcriptional effects of FoxO3a (Fernandez de Mattos
et al., 2004) or the post-transcriptional effects of Bcl-6 acetylation (Bereschenko et
al., 2002) are included.
for the outcome of signalling. Others have also found that dif-
ferent CD40 signalling strengths can produce different outcomes.
In macrophages strong CD40 signalling produced p38 activation
whereas weak signals caused Erk1/2 phosphorylation, and each
produced unique and biologically opposing effects (Mathur et al.,
2004). Soluble CD40 ligand has been suggested to be produced and
have biological roles in primarymouse B-cell development (Kilmon
et al., 2007; Wykes et al., 1998).
Using mCD40L we obtained activation of Erk1/2 but culture of
Ramos with untransfected mouse ﬁbroblast cells also produced
phosphorylation of this MAPK family member. Phosphorylation
of Erk1/2 cannot, therefore, be a speciﬁc CD40 effect. Previously,
BCR cross-linking has been shown to activate Erk1/2, leading to
ubiquitin-mediated Bcl-6 degradation (Niu et al., 1998). However,
in vivo Erk1/2 may be activated in germinal centre B-cells by cell
contact mediated by receptor–ligand pairs that are not unique to
B-cells. For example, integrin signalling which lowers the thresh-
old for early activation of B-cells (Batista et al., 2007; Carrasco et al.,
2004) may also have a role in the later stages of a germinal centre
reaction.
Finally mice bearing homozygous disruptions of the locus of the
MAPK kinase kinase, Mekk1, have a B-cell autonomous defect in
germinal centre formation and T-dependent antibody responses
(Gallagher et al., 2007). These animals have defective activation
of Jnk and p38. We speculate that the B-cell phenotype of Mekk1
deﬁcient mice is due to reduced or absent induction of Bcl-6 by
p38. It is interesting that Mekk1 deﬁcient animals (Gallagher et al.,
2007) have increased production of TH2 cytokines similar to Bcl-6
deﬁcient mice (Dent et al., 1998, 1997; Ye et al., 1997).
The major B-cell stimuli – BCR cross-linking and CD40 ligand –
both activate p38. However, both also strongly activate pathways
repressing Bcl-6: BCR activates Erk1/2 and mCD40L activates IRF4.
The overall effect of BCR signalling and mCD40L signalling is to
reduce Bcl-6 expression and they are likely to have roles in B-cell
exit from a germinal centre. sCD40 ligand activates p38, without
inducing signals repressing Bcl-6, and may mimic signals required
1 muno
f
d
f
(
i
a
a
t
B
i
(
v
t
r
u
p
g
w
l
t
d
r
A
t
T
g
l
c
R
A
B
B
B
B
C
C
C
C
C
D
D734 A. Batlle et al. / Molecular Im
or maintaining B-cell residence in a germinal centre. There is little
ata on p38 expression in primary lymphomas, but DLBCL arising
rom follicular lymphoma appear to express phosphorylated p38
Elenitoba-Johnson et al., 2003).
p38 inhibitors have been employed as anti-inﬂammatory agents
n clinical trials. Bcl-6 is a validated drug target (Chattopadhyay et
l., 2006; Polo et al., 2004) in human diffuse large B-cell lymphoma
nd our work suggests that p38 inhibitors may have applications in
his and other Bcl-6 expressing non-Hodgkin’s lymphoma, such as
urkitt lymphoma.
In summary we show that p38 induces Bcl-6, probably act-
ng in concert with STAT5 and other transcription factors in vivo
Scheeren et al., 2005) (Fig. 9). It has been impossible using a
ariety of growth factor and other signals to induce Bcl-6 in cul-
ured B-cells and a contributory reason for this may be that signals
epressing and inducing Bcl-6 are produced by the same stim-
li. There may only be restricted circumstances in vivo in which
ositive signals predominate and cause Bcl-6 activation, as is sug-
ested by immunocytochemistry of tonsil germinal centres in
hich a minority of Bcl-6 expressing cells co-express phosphory-
ated p38.
Future work will elucidate the in vivo signalling requirements
hat correspond to sCD40L in our experimental system, and also
eﬁne the protein complexes assembled at the CD40 receptor in
esponse to sCD40L and mCD40L.
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